Gamma-synuclein, a novel player in the control of body lipid metabolism by Millership, Steven James
  
 
!-synuclein, a novel player in the  
control of body lipid metabolism 
 
Steven J Millership 
 
 
Submitted for the award of Doctor of 
Philosophy, January 2012 
 
 
 
! ""!
Abstract 
Synucleins are a family of homologous, predominantly neuronal proteins known for 
their involvement in neurodegeneration. In neurons !-synuclein promotes the 
assembly of soluble-NSF-attachment receptor (SNARE) complexes required for 
fusion of synaptic vesicles with the plasma membrane during neurotransmitter 
release. "-synuclein is highly expressed in human white adipose tissue (WAT) and 
this expression is increased in obesity. Here we show that "-synuclein is nutritionally 
regulated in murine adipocytes and that "-synuclein deficiency protects mice from 
high fat diet (HFD)-induced obesity and associated metabolic complications. When 
compared to HFD-fed wild type mice, HFD-fed "-synuclein deficient mice display 
increased lipolysis, lipid oxidation and energy expenditure, and reduced adipocyte 
hypertrophy. "-synuclein null adipocytes express more ATGL, a key lipolytic enzyme, 
and contain fewer SNARE complexes of a type involved in lipid droplet fusion. Thus, 
"-synuclein may co-ordinately affect both lipid droplet formation and lipid hydrolysis. 
We also find that "-synuclein deficiency causes alterations in lipid classes and fatty 
acid patterns in the adult murine brain. Together our data suggest that "-synuclein is a 
novel regulator of lipid handling in both CNS neurons and adipocytes, with this 
adipocyte function becoming particularly important in conditions of nutrient excess.  
 
 
 
 
‘We are unanimous in our belief that obesity is a hazard to health and a detriment to 
well being. It is common enough to constitute one of the most important public health 
problems of our time.’ 
 
J.C. Waterlow, 1976 
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1. Introduction 
The misbalance in body metabolism manifested in conditions like obesity is an 
important risk factor for the development of many common debilitating disorders, 
including type II diabetes mellitus (T2DM) and cardiovascular diseases. Thus, 
understanding of the cellular processes that cause dysfunction of metabolism-
regulating body systems is of utmost importance. Everyday fluctuations in both 
nutrient consumption and physical activity require a tightly controlled mechanism for 
energy intake and expenditure in order to preserve the metabolic health of the 
organism. Failure of such mechanism can lead to states of obesity or lipodystrophy. 
 
1.1. Obesity 
The prevalence of obesity, which can be defined as a body mass index (BMI) over 
30kg/m2, is increasing across a large part of the world and is regarded as a major 
health issue. Obesity lies in the centre of a web of related disorders, namely T2DM, 
cardiovascular disease, cancer and various other metabolic complications. The strain 
on the economics and workload of the healthcare system is ever increasing, due to 
direct costs involved in the diagnosis and treatment of disease related to obesity. 
Revealing certain mechanisms in the development of obesity will undoubtedly relieve 
this burden. To achieve this goal it is essential to identify and understand the networks 
in place that control energy balance and tissue fuel utilization. 
 
Although a number of genetic and environmental factors influence the onset of 
obesity, the overall cause is a calorific imbalance. In the Western world especially, a 
tendency towards high daily calorific intake, often mixed with reduced physical 
exercise, is a prime example of this imbalance. These environmental factors are in 
addition to the complexities in the metabolic pathways involved in such a 
multifactoral disease. Studies on obese human subjects and findings from animal 
models of obesity are slowly expanding our knowledge on potential underlying 
mechanisms. Here the clear genetic influence on the onset of obesity and its related 
disorders is made obvious, with human subpopulations, and different genetic 
! $!
backgrounds of inbred mouse strains, affected differently by changes in diet, and in 
the progression of obesity and diabetic states. 
 
1.2. Adipose tissue 
It is only in the last decade that the perception of adipose tissue as an inert storage 
tissue has changed to that of a multifunctional secretary organ with a central role in 
lipid and glucose metabolism. Through para- and endocrine functions, adipocytes are 
able to influence energy metabolism both in neighboring adipocytes, as well as CNS 
neurons, hepatocytes, pancreatic !-cells and skeletal myocytes. The two major types 
of adipose tissue, brown (BAT) and white (WAT), vary in intracellular organization 
and gene expression profiles, and serve different purposes within the mammalian 
body. 
 
1.2.1. BAT 
Brown adipocytes found within brown adipose tissue (BAT) are multilocular, with 
small lipid droplets dispersed throughout the cell. These lipids are used as fast-access 
oxidative fuel by the abundance of mitochondria (the reason for the brown appearance 
of these adipocytes) found in these cells, where uncoupling protein 1 (UCP-1) acts to 
uncouple respiration from ATP synthesis at the mitochondrial inner membrane, 
producing heat (reviewed in (Rousset et al., 2004)). This common heat generating 
property of BAT is required for non-shivering and diet-induced thermogenesis, vital 
in new-born babies and hibernating animals (reviewed in (Griggio, 1988; Rothwell 
and Stock, 1979)). 
 
1.2.2. WAT 
WAT consists of a number of cell types, including mature white adipocytes (which 
make up around a third of the total WAT cell number) as well as preadipocytes, 
macrophages, stromal cells and vascular cells. WAT is localized in distinct depots 
around the body, both subcutaneously and within the peritoneum (visceral). These 
! %!
two major depot-types appear to have slightly different properties with respect to gene 
expression profiles and role in disease. For example, there are observed differences in 
expression of both secreted and non-secreted proteins from these depots (Dusserre et 
al., 2000). Pre-adipocytes isolated from subcutaneous fat depots also differentiate 
faster and are more responsive to the effects of thiazolidinediones (TZD), a class of 
peroxisome proliferator-activated receptors (PPAR) agonists used for the treatment of 
T2DM (Adams et al., 1997). Overall, visceral adiposity appears to play a larger role 
in downstream metabolic complications than subcutaneous adiposity, possibly due to 
draining of excess lipids and inflammatory mediators from visceral WAT directly into 
the portal vein to the liver (Fox et al., 2007). This may also be due to a more 
pronounced lipolytic effect of catecholamines in visceral depots due to differences at 
both the receptor and post-receptor levels (Arner et al., 1990; Fisher et al., 2001; 
Hellmer et al., 1992; Reynisdottir et al., 1997). It has also been demonstrated that the 
effect of insulin is lower in visceral WAT compared to subcutaneous WAT, owing to 
differences at both the insulin receptor level and post-receptor signaling (Bolinder et 
al., 1983; Wu et al., 2001; Zierath et al., 1998). 
 
Although beyond the scope of this work, it is important to understand that WAT also 
plays an important role in carbohydrate metabolism, exemplified by the phenotype of 
adipose-specific knockout of GLUT4 in mice. GLUT4 is a glucose transporter protein 
with an important role in insulin-mediated glucose uptake from the bloodstream, for 
which translocation of GLUT4 to the cell surface is a crucial process (Bryant et al., 
2002). GLUT4 null mutant mice display peripheral insulin resistance and glucose 
intolerance without any alteration in adiposity (Abel et al., 2001). Although the exact 
molecular mechanism for this phenotype is unclear, it does point to adipocyte glucose 
uptake as an important part of whole-body carbohydrate metabolism.   
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1.3. Adipogenesis: adipocyte hypertrophy and hyperplasia  
The process of adipogenesis occurs via two processes, increase of the size of pre-
existing mature adipocytes (hypertrophy) and proliferation with subsequent terminal 
differentiation of preadipocytes (hyperplasia). These preadipocytes derive from 
multipotent stem cells of mesodermal origin. The differentiation of preadipocytes is 
controlled by the activity of various hormones, cytokines and transcription factors 
(Farmer, 2006) and the ability of these precursor cells to become fully differentiated 
adipocytes decreases with age (Karagiannides et al., 2001). Circulating insulin 
appears to stimulate preadipocyte differentiation, with factors released from 
hypertrophied adipocytes such as insulin-like growth factor 1 (IGF-1) also shown to 
play a role in this process via paracrine effect (Avram et al., 2007). Non-esterified 
fatty acids (NEFA) released by hypertrophic adipocytes have also been demonstrated 
to induce differentiation of preadipocytes (Amri et al., 1994). Early in vivo animal 
experiments indicated that hypertrophy occurs prior to hyperplasia, and that this 
hyperplasia is associated with a more severe and less reversible state of metabolic 
dysfunction (Bjorntorp et al., 1982; Hirsch et al., 1989). 
Stimulation of preadipocyte differentiation triggers expression of a number of key 
adipocyte transcription factors, most notably of the PPAR, CCAAT-enhancer binding 
protein (C/EBP) and sterol regulatory element-binding protein (SREBP) families. 
This transcriptional cascade starts with early expression of C/EBP! and C/EBP", 
followed by C/EBP#, which in turn activates PPAR$. The latter two, as well as 
SREBP-1c, are central transcriptional players in differentiating adipocytes, activating 
a number of key adipogenic genes involved in NEFA influx and storage (Kim and 
Spiegelman, 1996; Vidal-Puig et al., 1996). Ultimately, this lipogenic program results 
in establishing the gene expression profile characterizing the phenotype of fully 
differentiated white adipocytes. Adipocyte differentiation can be studied in vitro using 
primary preadipocytes, or immortalized cell lines such as 3T3-L1 and 3T3-F22A 
fibroblasts. Here, the differentiation program discussed above can be initiated by 
treatment of cells with a cocktail of pro-differentiation agents (insulin, 
dexamethasone, Isobutylmethylxanthine (IBMX)), which stimulates the expression of 
adipocyte specific transcripts, changes in cell morphology and the formation of 
numerous lipid droplets. 
! '!
1.4. NEFA storage and release in the white adipocyte 
 
WAT is the most important organ in the body for the storage and release of energy 
from lipids, depositing NEFA originating either from the diet or de novo synthesis, as 
triacylglycerols (TAG). In times of energy surplus, WAT sequesters excess lipids into 
specialised intracellular structures known as lipid droplets (LD). TAG, along with 
cholesterol esters are stored in the LD core, which is surrounded by a phospholipid 
monolayer. Equally important is the ability of WAT to hydrolyse stored TAG by the 
process of lipolysis to release NEFA into the bloodstream as a vital oxidative fuel for 
other organs in times of energy demand. The LD is coated with a series of proteins 
involved in both the storage and release of these lipids. The processes of TAG 
synthesis and hydrolysis are not restricted to the postprandial and fasted states, 
respectively; both these anabolic and catabolic pathways undergo constant cycling, 
resulting in rapid turnover of neutral TAG stores (Newsholme, 1978; Vaughan, 1962; 
Hammond and Johnston, 1987). Moreover, small alterations in TAG synthesis and 
hydrolysis can have a significant effect on fat mass in a relatively short space of time 
(Langin and Arner, 2006). Adipose tissue as a whole is highly innervated by the 
sympathetic nervous system and highly vascularised, meaning that adipose tissue is 
able to respond rapidly to acute changes in dietary intake via both hormonal and 
neuronal control, to alter the storage and release of TAG accordingly. 
 
1.4.1. NEFA storage 
The role of WAT is to act as a buffering system for circulating free fatty acids. 
Circulating TAG is hydrolyzed via the action of lipoprotein lipase (LPL) from very 
low-density lipoproteins (VLDL) and chylomicrons in the capillary endothelial 
lumen, liberating NEFA, which are subsequently taken up by the adipocyte by both 
passive and active mechanisms (Abumrad et al., 1998; Hamilton and Kamp, 1999; 
Scow and Blanchette-Mackie, 1985). Fatty acid translocase (FAT/CD36) (Abumrad et 
al., 1993), fatty acid transport protein (FATP) (Schaffer and Lodish, 1994) and 
calveolin-1 (Trigatti et al., 1999) have all been linked with transport of NEFA 
transport across the plasma membrane, although further proteins may yet to be 
identified (Kampf et al., 2007). Here they are esterified using a glycerol backbone, 
using both glycerol-3-phophate (produced in glycolysis) and acyl coenzyme A 
! (!
(produced during adipocyte NEFA uptake), into TAG to reduce their cytotoxic effect. 
A summary of these processes can be found in Fig. 1.1. This process requires a series 
of acylation reactions catalysed by three different acyltransferases at the surface of the 
endoplasmic reticulum, the site of neutral lipid synthesis. Incorporation of TAG into 
the LD has been suggested to occur through fusion, which appears to be dependent on 
cytoskeletal elements and soluble N-ethylmaleimide–sensitive factor attachment 
protein receptor (SNARE) fusion machinery (Bostrom et al., 2007; Bostrom et al., 
2005; Olofsson et al., 2009). SNARE proteins are vital components of protein 
complexes involved in membrane fusion (reviewed in (Jahn and Scheller, 2006)) and 
may play a role in the control of fusion between neutral TAG packaged within 
amphipathic lipoproteins and the LD phospholipid monolayer.  
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Fig. 1.1. Overview of lipogenesis. Fatty acids (FA) obtained from lipoproteins 
through the action of lipoprotein lipase (LPL) are esterified into triacylglycerols 
(TAG) in the endoplasmic reticulum (ER) and stored in the lipid droplet. Excess 
glucose is oxidized to acetyl-CoA by glycolysis, and converted to acyl-CoA, which is 
also esterified into TAG. ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase. 
Adapted from (Vazquez-Vela et al., 2008).! 
! *!
1.4.2. NEFA release and the major lipolytic pathways 
Catecholamines and insulin are two of the most potent mediators of lipolysis. The 
classic pathway by which adipocyte TAG is hydrolysed is in response to 
catecholamine-mediated stimulation of !-adrenergic receptors on the adipocyte cell 
surface (!1 and !2 being the most active isoforms in human adipocytes and !3 in 
rodent adipocytes). This in turn activates adenylate cyclase via stimulatory G-proteins 
(G#s) consequently raising intracellular cAMP levels, activating cAMP-dependent 
protein kinase (PKA). Stimulated PKA has two key target proteins in this pathway, 
the major LD-associating lipoprotein, perilipin A, and the rate-limiting enzyme 
involved in catecholamine-stimulated lipolysis, hormone-sensitive lipase (HSL). This 
mechanism is discussed in detail below with an overview found in Fig. 1.2.  
 
1.4.2.1. Perilipins and the PAT family 
In addition to various cellular lipases, a number of LD-associated proteins modulate 
lipid metabolism in adipocytes. Members of a group of proteins known as the PAT 
family (perilipins, adipophilin, tail-interacting protein of 47kDa (TIP47)) all play 
roles in the efficient storage of TAG within the adipocyte LD (reviewed in (Bickel et 
al., 2009; Wolins et al., 2005)). Out of all members of the PAT family proteins, 
perilipins appear to have the most significant effect on adipocyte lipid storage. A 
single perilipin transcript gives rise to three distinct isoforms by alternative splicing, 
with perilipin A the most abundant form in WAT (Greenberg et al., 1993). Perilipin A 
has a dual role as a LD scaffold protein, under basal conditions it functions to protect 
TAG within the LD from hydrolysis by cellular lipases, whereas its 
hyperphosphorolation at up to six serine residues is required for maximally stimulated 
lipolysis (Brasaemle et al., 2000b; Martinez-Botas et al., 2000; Souza et al., 2002; 
Tansey et al., 2003; Tansey et al., 2001). In this latter state, perilipin A is required for 
translocation of a major lipase HSL from the cytosol to the LD (Miyoshi et al., 2006; 
Sztalryd et al., 2003) where it interacts physically with perilipin A (Shen et al., 2009).  
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1.4.2.2. Hormone sensitive lipase (HSL) 
For decades after the discovery of HSL in the 1960s (Bjorntorp and Furman, 1962; 
Rizack, 1964), this enzyme was considered the sole player in adipocyte TAG 
hydrolysis. Key PKA phosphorylation sites (S563, S659, S660 in rodents, 
corresponding to S552, S649 S650 in humans (Anthonsen et al., 1998; Contreras et 
al., 1998)) are responsible for increases in intrinsic enzyme activity and its 
translocation from a predominantly cytosolic localization to the LD (Brasaemle et al., 
2000a; Clifford et al., 2000; Egan et al., 1992; Hirsch and Rosen, 1984; Shen et al., 
1998; Su et al., 2003). This translocation is crucial to the access of HSL to stored 
TAG. As well as the classical activation of HSL by PKA, a number of other protein 
kinases have been shown to phosphorylate adipocyte HSL at key serine residues, 
independent of PKA activation, including AMP-dependent protein kinase (AMPK), 
glycogen synthase kinase 4 (GSK) and extracellular signal-related kinase (ERK) with 
both pro- and anti-lipolytic effects (Daval et al., 2005; Garton and Yeaman, 1990; 
Greenberg et al., 2001; Olsson et al., 1986). Accordingly, HSL null mutant mice have 
blunted catecholamine-stimulated lipolysis (CSL), but with no changes in basal 
lipolysis (Haemmerle et al., 2002; Harada et al., 2003; Mulder et al., 2003; Osuga et 
al., 2000). 
 
1.4.2.3. Adipose triglyceride lipase (ATGL)  
Although HSL has broad substrate specificity, with an affinity for TAG and both 
cholesterol and retinyl esters, it is most active against diacylglycerols (DAG) (Langin 
et al., 2000). The first hydrolysis reaction to liberate the first fatty acid is in fact 
performed by another key lipase in this pathway, adipose triglyceride lipase (ATGL). 
Its discovery in 2004 ended growing doubts that HSL was not the sole adipocyte TAG 
hydrolase (Jenkins et al., 2004; Villena et al., 2004; Zimmermann et al., 2004). These 
doubts had stemmed from two particular findings, firstly the disparity between 
increases in PKA-mediated HSL activity and overall adipocyte lipolysis, and secondly 
the observed DAG accumulation (and therefore sufficient TAG hydrolysis) in HSL 
null mutant mice (Haemmerle et al., 2002). In the absence of HSL, ATGL accounts 
for the majority of TAG hydrolase activity in WAT (Zimmermann et al., 2004). 
ATGL displays specific activity against TAG, and seems to play an important role in 
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basal lipolysis (Langin et al., 2005; Miyoshi et al., 2008; Ryden et al., 2007). 
Although not a direct target of PKA (Zimmermann et al., 2004), nor does it interact 
with perilipin A itself (Granneman et al., 2007), ATGL is also activated by !-
adrenergic stimulation (Miyoshi et al., 2007). Here its coactivator, comparative gene 
identification 58 (CGI-58), which is normally bound to unphosphorylated perilipin A 
at the LD, is released from phosphorylated perilipin A following stimulation, binds to 
ATGL at the LD surface, and increases its activity (Granneman et al., 2007; Lass et 
al., 2006; Subramanian et al., 2004). Accordingly, ATGL null mutant mice were 
shown to display reduced CSL (Haemmerle et al., 2006). The potent TAG hydrolase 
activity of ATGL and its important role in energy homeostasis is demonstrated both in 
vitro and in vivo. Overexpression or knockdown of ATGL in 3T3-L1 adipocytes alters 
TAG hydrolase activity and subsequent cell lipolysis, whilst ATGL null mutant mice 
display ectopic deposition of TAG in non-adipose tissues including the heart, which 
results in their premature death (Haemmerle et al., 2006; Kershaw et al., 2006; 
Villena et al., 2004). Similar pathology is seen in patients with autosomal recessive 
mutations in either the ATGL or CGI-58 gene, with accumulation of neutral lipids in 
multiple tissues manifesting in severe myopathy and ichthyosis respectively 
(Schweiger et al., 2009).  
 
1.4.2.4. Final stages of TAG hydrolysis 
After hydrolysis of TAG and DAG by ATGL and HSL respectively, a third lipase in 
this chain, monoglyceride lipase (MGL), which is not under hormonal control, is 
required for hydrolysis of the third and final fatty acid from the glycerol backbone 
(Fredrikson et al., 1986). Glycerol released from the complete hydrolysis of TAG 
leaves the cell via facilitated diffusion through the aquaporin 7 receptor (Hibuse et al., 
2005) while NEFA is able to cross the plasma membrane into the bloodstream via 
both passive diffusion or facilitated transport as discussed in section 1.4.1.  
 
1.4.2.5. aP2/fatty-acid binding protein 4 (FABP-4) 
Fatty-acid binding protein 4 (FABP-4), commonly known as aP2, is part of a large 
family of lipid-binding proteins and is a key NEFA carrier in adipocytes. aP2 has high 
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affinity for NEFA and is involved in their solubilisation and flux from lipases to cell 
membranes (Matarese and Bernlohr, 1988). aP2 physically interacts with HSL (Shen 
et al., 1999) in the cytosol upon PKA-mediated lipolysis, and this aP2/HSL complex 
migrates to the LD. Here, aP2 is important for the catalytic activity of HSL, and 
liberated NEFA is shuttled solely by aP2 from LD to the plasma membrane during the 
process of NEFA efflux (Jenkins-Kruchten et al., 2003). This role in NEFA efflux is 
supported by studies on aP2 null mutant mice, which demonstrated increases in 
intracellular NEFA levels as well as reduced lipolysis (Baar et al., 2005; Coe et al., 
1999; Scheja et al., 1999). 
 
1.4.3. Other pro-lipolytic molecules involved in the regulation of lipolysis 
 
1.4.3.1. Natriuretic peptides 
As well as extracellular stimulation by catecholamines, circulating natriuretic peptides 
also play a role in the lipolytic response of adipocytes (reviewed in (Lafontan et al., 
2005)). This occurs via a similar yet independent pathway to that of catecholamine-
mediated stimulation, involving cGMP and cGMP-dependent protein kinase (PKG) 
downstream of a natriuretic peptide type A receptor with intrinsic guanylyl cyclase 
activity, a pathway specific to primate adipocytes (Sengenes et al., 2002). The end 
result of this natriuretic peptide activation is also phosphorylation of HSL, and 
subsequent increases in lipolysis in vitro and in vivo (Sengenes et al., 2000; Sengenes 
et al., 2003).  
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Fig. 1.2. Lipolytic machinery of the adipocyte. #2-ad, #2-adrenergic receptor; !-ad, 
!-adrenergic receptor; AC, adenylyl cyclase; Akt/PKB, protein kinase B; ATGL, 
adipose triglyceride lipase; GC, guanylyl cyclase; CGI-58, comparative gene 
identification 58; Gi, inhibitory GTP-binding protein; Gs, stimulatory GTP-binding 
protein; HSL, hormone-sensitive lipase; NPr-A, natriuretic peptide receptor A; PeriA, 
perilipin A; Pi, phosphate group; PI3K, phosphatidylinositol-3-phosphate kinase; 
PKA, protein kinase A; PKG, protein kinase G; IR, insulin receptor; IRS, insulin 
receptor substrate. 
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1.4.3.2. Tumour necrosis factor-! 
Tumour necrosis factor-# (TNF-#) is a pro-inflammatory cytokine released by 
hypertrophic mature adipocytes and WAT resident macrophages, whose numbers 
increase in obesity (Weisberg et al., 2003). TNF-# has been shown to affect lipid 
metabolism via an ERK-dependent pathway in 3T3-L1 cells and human adipocytes 
(Ryden et al., 2002; Souza et al., 2003; Zhang et al., 2002), and has also been linked 
with effects on insulin signaling (Fujishiro et al., 2003), perilipin expression (Ryden 
et al., 2002; Souza et al., 2003) and lipase (HSL and ATGL) expression during an 
adipocyte ‘dedifferentiation’ process (Bezaire et al., 2009; Kim et al., 2006; Kralisch 
et al., 2005; Sumida et al., 1990). The effect of this cytokine on lipid metabolism in 
states of obesity and insulin resistance is discussed further in chapter 1.6.3. 
 
1.4.4. Anti-lipolytic pathways 
Adipocyte lipolysis is also under inhibitory control by various circulating 
catecholamines, hormones and factors. Probably the most potent is insulin, which acts 
via phosphorylation of the insulin receptor and its attached insulin receptor substrate 
(IRS). This in turn activates the phosphatidylinositol-3-phosphate kinase (PI3K) 
pathway, resulting in increased activity of a phosphodiesterase, PDE-3B, reducing 
intracellular cAMP levels. In addition to this cAMP degradation, there may be 
additional anti-lipolytic mechanisms of insulin, including direct inhibition of 
adenylate cyclase (Illiano and Cuatrecasas, 1972), internalization of !-adrenergic 
receptors (Engfeldt et al., 1988) and activation of phosphatases that dephosphorylate 
HSL (Stralfors and Honnor, 1989). Other molecules shown to possess anti-lipolytic 
activity include nicotinic acid (Carlson, 1963), adenosine (Dole, 1961), neuropeptide 
Y and peptide YY (Bradley et al., 2005; Valet et al., 1990). 
  
As mentioned above, catecholamines are able to stimulate lipolysis through a 
mechanism involving cAMP/PKA downstream of !-adrenoreceptors. Conversely in 
human adipocytes, catecholamines can also exert a strong anti-lipolytic effect via 
stimulation of #2-adrenergic receptors, with G#i activity reducing intracellular cAMP 
levels. In fact, #2-adrenergic receptors are more abundant than !-adrenoreceptors on 
human subcutaneous fat cells and also have a higher affinity for major catecholamines 
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such as adrenaline and noradrenaline, suggesting that this pathway plays in important 
role in control of lipolysis in humans (Lafontan and Berlan, 1995). These findings 
have since been supported by work demonstrating adrenaline-mediated lipolytic 
control in human subcutaneous WAT via !2-adrenoceptors, as well as their role in the 
blunted catecholamine-stimulated lipolysis observed in obese patients, an effect 
which is discussed in the next section (Mauriege et al., 1991; Stich et al., 2000; Stich 
et al., 1999). 
 
1.4.5. Blunted catecholamine-stimulated lipolysis in obesity 
In states of obesity, it becomes apparent that catecholamine-stimulated lipolysis 
(CSL) is less efficient (Blaak et al., 1994; Connacher et al., 1991; Horowitz and 
Klein, 2000; Webber et al., 1994). This has been linked with decreased abundance 
and function of !-adrenergic receptors (Reynisdottir et al., 1994) possibly combined 
with an increased effect of #2-adrenergic receptors, which have an opposing effect 
(Stich et al., 2000). Decreased activity and expression of HSL have also been reported 
(Large et al., 1999). It has also been speculated that WAT depots in obese individuals 
are less suited to receive an adequate blood supply and/or neuronal input. Whether 
this blunted CSL is itself is a key defect responsible for onset of obesity, or a 
consequence of the obese state is a topic of much discussion. Some findings suggest a 
strong genetic component for predisposition of this defect, with impaired CSL a 
feature of adipocytes from immediate relatives of obese patients and also from 
adolescent patients with childhood onset obesity (Bougneres et al., 1997; Enoksson et 
al., 2000; Hellstrom et al., 1996). Moreover, polymorphisms and alterations in 
expression of genes encoding !2-adrenoreceptors (Jocken et al., 2007a; Large et al., 
1997), HSL (Hoffstedt et al., 2001) and perilipin A (Mottagui-Tabar et al., 2003) are 
associated with obesity and diminished CSL.  
 
On the other hand, it is also possible that these changes in the lipolytic machinery are 
a compensatory mechanism to reduce NEFA efflux from adipocytes in order to avoid 
high levels of circulating NEFA in the bloodstream, which is linked to insulin 
resistance. In obese patients, fasting plasma insulin concentrations are inversely 
correlated to NEFA output from adipose tissue (Karpe and Tan, 2005) as are protein 
expression of HSL and ATGL (Jocken et al., 2007b; Large et al., 1999). If this 
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compensatory mechanism is the case, it would seem that this ‘protective’ function 
would also prevent efficient ‘switching’ of adipose tissue function from TAG storage 
to hydrolysis where necessary.   
 
1.5. Adipocyte secretion of ‘adipokines’ 
It is only relatively recently in the work on adipose tissue that research has 
demonstrated it to not simply be an inert storage tissue for excess lipids, but that it 
also functions as a major signaling organ, secreting a multitude of so called 
‘adipocytokines’ or simply ‘adipokines’ (reviewed in (Rosen and Spiegelman, 2006; 
Trujillo and Scherer, 2006)). These factors play a role in the local responses of WAT 
via auto-/paracrine effects, as well as an endocrine effect on overall body energy 
metabolism by modulating food intake, energy expenditure and substrate utilization, 
mainly via the CNS and other metabolic tissues. These adipokines include peptide 
hormones (e.g. leptin, adiponectin, resistin), cytokines (interleukin 6 (IL-6), TNF-#) 
and enzymes (plasminogen activated inhibitor 1, LPL). 
 
1.5.1. Leptin 
Probably the adipokine that has attracted the most attention since its discovery is 
leptin, the product of the Ob gene associated with genetically obese (ob/ob) mice 
(Zhang et al., 1994). Adipocyte leptin expression increases with adipocyte 
hypertrophy (Considine et al., 1996), and is responsive to insulin, (Saladin et al., 
1995), but is not directly affected by food intake itself. Leptin is seen as a signaling 
molecule able to convey long-term body fat mass status to the CNS (Schwartz et al., 
2000). Circulating leptin acts on key leptin-responsive neurons in the hypothalamus to 
control downstream effectors of satiety and energy expenditure, via inhibition of 
AMP-activated protein kinase (AMPK) signaling (Long and Zierath, 2006) 
demonstrating that WAT is able to affect the overall energy balance and nutritional 
status of the organism.  In peripheral tissues, leptin increases lipid utilization in WAT, 
liver and skeletal muscle, and has been shown to inhibit pancreatic insulin release as 
well as having an anti-apoptotic effect in pancreatic !-cells (Okuya et al., 2001; 
Poitout et al., 1998; Shimabukuro et al., 1998). Obese humans have increased levels 
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of circulating leptin, but without sufficient control of satiety and energy expenditure 
control. This led to the belief of a state of hypothamic leptin resistance, which appears 
to play an important role in the pathophysiology of obesity and its related disorders 
(Munzberg and Myers, 2005). 
 
1.5.2. Adiponectin 
Another key adipokine, adiponectin, is able to modulate insulin sensitivity by 
inhibiting hepatic glucose production, enhancing glucose uptake in muscle, and 
increasing NEFA oxidation in both liver and muscle via increased AMPK activity 
(Goldstein and Scalia, 2004; Kadowaki and Yamauchi, 2005). Adiponectin synthesis 
is decreased in states of obesity and insulin resistance (Hajer et al., 2007; Lindsay et 
al., 2002). As with leptin, adiponectin acts peripherally to increase energy expenditure 
in skeletal muscle, which in turn reduces lipid deposition in non-adipose tissues. 
However in the severe obese and insulin resistant state, it seems that the effect of both 
these adipokines is reduced, possibly due to a combination of the reduced levels of 
circulating adiponectin in obesity as well as a reduced sensitivity to leptin. A 
summary of the effects of leptin and adiponectin, as well as a few other major 
adipokines is summarized in Table 1.1 below. 
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Adipokine Overall effect 
on food 
intake 
Effects on lipid metabolism Levels 
found in 
obesity 
Leptin Anorexigenic Reduction of body lipid stores due to 
effects on CNS (via AMPK signaling) and 
enhanced lipid utilization in peripheral 
tissues (liver, WAT, skeletal muscle)  
Increased 
Adiponectin No effect Reduction of lipid stores due to enhanced 
utilization in liver and skeletal muscle (via 
AMPK signaling) 
Reduced 
Resistin Anorexigenic Increases adipocyte lipolysis in vivo, 
decreased NEFA uptake/metabolism in 
vitro 
Increased 
TNF-! Anorexigenic Increases adipocyte lipolysis and inhibits 
muscle AMPK signaling 
Increased 
IL-6 Anorexigenic Stimulation of adipocyte lipolysis and also 
lipid oxidation (via AMPK) 
Increased 
 
Table. 1.1. Summary of the major effects of key adipokines secreted from WAT. 
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1.6. Theories on how obesity leads to insulin resistance 
The expansion of adipose tissue in obesity is associated with metabolic disorders 
affecting multiple tissues. Given the pandemic of obesity it is critical to understand 
this link between increased adipose mass and metabolic disturbances in order to 
identify potential novel therapies. Inhibiting adipose tissue expansion alone is likely 
to worsen metabolic disease, as evidenced by human syndromes of lipodystrophy, 
where inappropriately decreased adipose mass causes severe insulin resistance. The 
insulin resistant state is a key risk factor for the development of cardiovascular 
disease and T2DM. Although studies have shown that obesity is the single most 
important predictor of T2DM (Hu et al., 2001), multiple genetic factors play a role in 
this pathogenesis. Discussed below are some major hypotheses that currently exist, 
proposing how obesity and WAT dysfunction lead to states of insulin resistance and 
metabolic disease. 
 
1.6.1. ‘WAT expansion’ hypothesis and downstream lipotoxicity 
As mentioned above, considering that states of severe obesity, but also lipodystrophy, 
are linked to downstream metabolic complications, it seems likely that lipotoxicity is 
due, at least in part, to the situation where body WAT has reached an upper limit of 
potential TAG storage. Lipotoxicity is a mechanism whereby failure to appropriately 
store lipids in adipose tissue leads to their accumulation in other tissues and the 
circulation causing hepatic steatosis, insulin resistance and cardiovascular disease.  
Adipose tissue dysfunction and/or exceeded adipose storage capacity is believed to 
lead to lipotoxicity in common obesity and therefore a major challenge is to identify 
pathways via which adiposity can be reduced without concomitant increases in 
circulating lipids, lipotoxicity and metabolic disease. This phenomenon is perhaps 
best demonstrated in mice completely lacking adipose tissue (A-ZIP/F-1 mice), which 
causes extreme metabolic dysfunction including severe insulin resistance in these 
animals (Moitra et al., 1998). It may be that it is more important to efficiently expand 
WAT and therefore increase adiposity, and to sequester lipids in this tissue in order to 
reduce levels of circulating NEFA and ectopic NEFA/TAG deposition. Further 
evidence for this theory is that insulin resistance appears to correlate with circulating 
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NEFA and uptake into non-adipose tissues, rather than just excess body fat per se. For 
example, reduction of circulating NEFA in obese patients using the anti-lipolytic drug 
acipimox, improves peripheral insulin resistance (Santomauro et al., 1999). 
Furthermore, deficiency of fatty acid binding proteins in either adipocytes or 
macrophages (therefore reducing NEFA efflux) also improves insulin sensitivity in 
mice (Furuhashi et al., 2008). Further evidence for the importance of efficient 
expansion of WAT comes from the use of TDZs in the treatment of T2DM and non-
alcoholic fatty liver disease, where this class of drugs actually increases WAT mass 
whilst improving insulin sensitivity (Nichols and Gomez-Caminero, 2007). Similar 
findings have also been made in mouse models of genetic obesity. Mice that harbour a 
dominant negative mutation in the PPAR$ gene, when crossed onto the ob/ob 
background (PPAR$ P465L ob/ob mice, aka PLO mice) have less adiposity than 
ob/ob mice but with a more severe insulin resistant phenotype (Gray et al., 2006). 
Similarly, mice with adipose specific overexpression of adiponectin (ADN-adTG/TG 
mice) on ob/ob background have seemingly limitless WAT expansion, are 50% larger 
than ob/ob alone, but have smaller adipocytes, are completely insulin sensitive with 
no ectopic lipid deposition (Kim et al., 2007). 
 
1.6.2. NEFA impairment of skeletal muscle insulin signaling 
Regardless of the upper limit of WAT expansion, an increased adipose tissue mass in 
obesity undoubtedly delivers more NEFA into the circulation, resulting in an 
increased plasma NEFA concentration when compared with lean subjects. This has 
been linked to peripheral insulin resistance in humans and animals, with concomitant 
reduction in glucose uptake into skeletal muscle. Elevated NEFA uptake into skeletal 
muscle has been shown to affect insulin signaling in skeletal myocytes at upstream 
parts of the pathway such as tyrosine phosphorylation of insulin receptor and insulin 
receptor substrate (IRS) proteins (Kraegen et al., 2001) as well as promoting 
inhibitory serine phosphorylation by various protein kinases such as protein kinase C% 
(Griffin et al., 1999) and p70 S6 kinase (Tremblay and Marette, 2001). Consistent 
with this role for these serine kinases mediating deleterious effects of NEFA, 
accumulation of intracellular lipid metabolites (e.g. fatty acyl-CoA and DAG) can 
also activate protein kinase C (PKC). This kinase has been shown to phosphorylate 
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IRS and inhibit insulin signaling in rodent skeletal muscle (Griffin et al., 1999; Yu et 
al., 2002). Furthermore, gene disruption of either protein kinase C% or p70 S6 kinase 
1 in mice gives resistance to high fat diet-induced defects in insulin-stimulated 
glucose uptake in skeletal muscle (Kim et al., 2004; Um et al., 2004). 
 
The onset of T2DM is most likely due to a combination of insulin resistance and 
reduced secretory function of insulin itself. To meet demands for increased insulin 
production, the mass of pancreatic !-cells enlarges. Acute increases in circulating 
NEFA cause temporary increases in insulin secretion but chronically (i.e. in obesity) 
they inhibit insulin secretion possibly due to an endoplasmic stress response resulting 
in apoptosis of !-cells (Zhao et al., 2006). Generally, although increases in weight 
correlate negatively with insulin sensitivity, it appears that there is a lag time between 
insulin resistance and the onset of T2DM, a period where circulating glucose levels 
are maintained by compensatory increases in !-cell insulin secretion. However this 
hypersecretion is unsustainable and results in !-cell dysfunction and apoptosis, 
perpetuating a state of worsening insulin resistance, hyperinsulinaemia and 
hyperglycaemia (Rhodes, 2005).  
 
1.6.3. A less beneficial array of adipokine secretion from larger adipocytes 
As mentioned previously, circulating adipokines secreted from adipocytes are an 
important modulator of energy metabolism and whole-body insulin sensitivity. 
Adipocytes alter their adipokine production profile upon nutritional overload. At first, 
increased adiposity appears to be compensated for, however eventually, hypertrophic 
adipocytes fail to properly secrete a normal balance of adipokines. Moreover they 
have been shown to secrete pro-inflammatory proteins such as monocyte 
chemoattractant protein 1 (MCP-1) and TNF-#, which modulate an inflammatory 
response in WAT. The resultant macrophage infiltration (and the low-grade 
inflammatory state) is a typical phenomenon associated with obesity (Weisberg et al., 
2003), with levels of macrophage infiltration shown to correlate with levels of insulin 
resistance (Otto and Lane, 2005). Cytokines secreted from macrophages and 
hypertrophic adipocytes affect lipid metabolism, for example the pro-lipolytic effect 
of TNF-# via the ERK pathway (Ryden et al., 2002; Souza et al., 2003; Zhang et al., 
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2002). The resulting increases in circulating NEFA further aggravate the insulin 
resistant state. IL-6, another pro-inflammatory cytokine secreted from WAT (Fontana 
et al., 2007) is increased in obese and diabetic patients (Bastard et al., 2000; Vozarova 
et al., 2001). Similar to TNF-#, IL-6 is pro-lipolytic (Path et al., 2001; Petersen et al., 
2005) and can induce insulin resistance (Lagathu et al., 2003; Rotter et al., 2003). 
NEFA release from hypertrophic adipocytes also have a paracrine effect in WAT 
whereby these NEFA are able to bind to toll-like receptors on macrophages, 
activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&B) 
pathway and augment TNF-# production (Suganami et al., 2007; Suganami et al., 
2005).   
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1.7. Synucleins 
The synucleins (#-, !- and $-synuclein) are a family of highly homologous and 
vertebrate-specific proteins, with elusive function and predominantly neuronal 
expression. Synucleins are probably best known for their involvement in various 
neurodegenerative conditions, termed ‘synucleinopathies’ (Goedert and Spillantini, 
1998; Spillantini and Goedert, 2000), the most notable of these being the role of #-
synuclein in the aetiology and pathogenesis of both familial and sporadic Parkinson’s 
disease (PD) (reviewed in (Cookson and van der Brug, 2008; Ruiperez et al., 2010; 
Venda et al., 2010)). Because of this link, #-synuclein is the most studied member of 
this family. 
 
1.7.1. !-synuclein 
 
1.7.1.1. !-synuclein gene and protein structure 
#-synuclein was first identified as a 143 amino acid protein of approximately 17 kDa 
localized in neuronal presynaptic terminals of the electric ray, Torpedo californica 
(Maroteaux et al., 1988). This group subsequently isolated from a rat brain cDNA 
library a highly homologous cDNA clone encoding 140 amino acid rat #-synuclein. 
The newly identified protein was found to contain a number of imperfect repeats 
based around a ‘KTKEGV’ motif throughout the first 100 amino acids, as well as an 
acidic C-terminus. These N-terminal repeats share similarity to the class A2 lipid-
binding domains of apolipoproteins and modulate interactions of synucleins with lipid 
membranes (George et al., 1995). Upon lipid binding, the structure of synucleins 
shifts from a natively unfolded state to adoption of partial #-helical structure 
(Davidson et al., 1998; Eliezer et al., 2001; Perrin et al., 2000). Identification of the 
highly similar (~95% identity of amino acid sequence) human orthologue came a few 
years later, originally as the precursor protein of a non-amyloid beta component 
peptide (NAC) from the amyloid preparation of Alzheimer’s disease brains (Ueda et 
al., 1993). Subsequent gene mapping showed the human SNCA gene to be located on 
chromosome 4 (4q21.3-22) containing 6 exons (Jakes et al., 1994; Spillantini et al., 
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1995). The expressed #-synuclein protein is found in various neuronal populations in 
the CNS, where it is concentrated at presynaptic terminals (George et al., 1995). A 
summary of some of the key features of synuclein proteins can be found in Fig. 1.3. 
 
1.7.1.2. Proposed function for !-synuclein 
As is the case for all three synucleins, the exact role of #-synuclein is not fully 
understood. The large proportion of research has been in the area of dopamine 
metabolism, with early work suggesting an interaction between #-synuclein and 
tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis, both in vitro 
and in vivo (Perez et al., 2002). Another study demonstrated interaction of #-
synuclein with the dopamine transporter (DAT), again both in vitro and in vivo, with 
resulting alterations in dopamine handling (Lee et al., 2001). Generally, emphasis has 
been put on the potential role of #-synuclein, and indeed !- and $-synuclein, in 
regulating synaptic function and plasticity, possibly through the suggested chaperone-
like activity of synucleins (Ahn et al., 2006; Lee et al., 2004; Park et al., 2002; Souza 
et al., 2000).  
Over the past ten years a number of different groups have produced and studied #-
synuclein null mutant mice, mainly concentrating on the nigrostriatal pathway, but 
with conflicting results. #-synuclein null mutant (#-synuclein-/-) mice are viable and 
fertile, but have been shown to display subtle alterations in dopamine metabolism, 
such as reduced striatal dopamine levels and attenuation of dopamine-dependent 
locomotor response to amphetamine (Abeliovich et al., 2000). These findings were 
however not seen in other studies, but rather various groups showed other alterations 
in mutant mice, including a reduction of dopaminergic neurons in the substantia nigra 
pars compacta, and impairments in synaptic response to prolonged electrical 
stimulation (Cabin et al., 2002; Robertson et al., 2004; Schluter et al., 2003). 
Interestingly, #-synuclein-/- mice have been shown to have enhanced resistance to the 
selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) with certain regimes and genetic backgrounds (Dauer et al., 2002; Drolet et 
al., 2004; Fornai et al., 2005; Robertson et al., 2004) although mice carrying a 
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spontaneous deletion of a region including the SNCA locus were as sensitive to 
MPTP as wild type mice (Schluter et al., 2003). 
Recently, Burre and colleagues demonstrated that in neuronal synapses, #-synuclein 
is involved in regulation of synaptic vesicle fusion with the cell membrane by 
promoting the assembly of SNARE complexes from its subunits, namely vesicular 
SNARE protein vesicle-associated membrane protein 2 (VAMP-2/synaptobrevin) and 
two target membrane-associated SNARE (tSNARE) proteins, syntaxin-1 and 
synaptosomal-associated protein 25 (SNAP-25) (Burre et al., 2010). These complexes 
play a pivotal role in synaptic vesicle docking and fusion pore formation at the plasma 
membrane, for example during neurotransmitter release (reviewed in (Rizo and 
Rosenmund, 2008; Sudhof and Rothman, 2009). The function of #-synuclein as a 
promoter of SNARE complex assembly was suggested to be particularly important 
during periods of increased synaptic activity (Burre et al., 2010).  
 
 
 
Fig. 1.3. Overview of some key functional domains of the synuclein family. 
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1.7.1.3. !-synuclein and neurodegeneration 
Links between #-synuclein and PD were first established in 1997 when a genetic 
defect causing familial, early onset form of the disease was located in the encoding 
(SNCA) gene and #-synuclein protein was found to be the main constituent of 
histopathological inclusions in the brains of PD sufferers. Firstly, an autosomal 
dominant mutation in the SNCA gene was discovered in a large Italian kindred and 
three other (non-related) Greek families. This mutation (A53T) was thought to disrupt 
the normal structure of #-synuclein and render the protein more susceptible to 
aggregation (Polymeropoulos et al., 1997). Since these findings, further discoveries 
have demonstrated more links with alterations to the SNCA gene sequence and forms 
of familial PD, including two further autosomal-dominant mutations A30P (Kruger et 
al., 1998) and E46K (Zarranz et al., 2004), gene duplications and triplications 
(Chartier-Harlin et al., 2004; Ibanez et al., 2004; Singleton et al., 2004) and 
polymorphisms in the SNCA promoter (Pals et al., 2004). 
A secondly major link between #-synuclein and PD was made with the discovery that 
#-synuclein is a key component of Lewy bodies, the pathological hallmark of both 
sporadic and familial Parkinson’s disease (Spillantini et al., 1997). Accumulation and 
aggregation of #-synuclein has since been found in a number of neurodegenerative 
disorders including dementia with Lewy bodies (DLB) (Galvin et al., 1999; 
Spillantini et al., 1998b), multiple system atrophy (Spillantini et al., 1998a; Tu et al., 
1998) and Hallervorden-Spatz syndrome (Galvin et al., 2000). Purified #-synuclein 
aggregates rapidly in vitro, and forms fibrils similar to the fibrils found in deposits 
typical for synucleinopathies, including Lewy Bodies. A number of factors affect the 
aggregation of #-synuclein including concentration of the protein itself as well as 
other various physiological parameters (reviewed in (Dev et al., 2003)). This 
aggregation appears to be initiated by a seeding mechanism (Uversky et al., 2002) and 
is exacerbated by A30P and A53T mutated #-synuclein (Conway et al., 1998). A 
major question regarding these disorders is the possible varying toxicity of 
aggregatory intermediates and final products, as well as the identification of toxic 
mechanisms (Cookson and van der Brug, 2008; Volles and Lansbury, 2003). A key 
topic of discussion is whether these proteinacious inclusions are cytotoxic themselves 
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or the result of a form of compensatory protective mechanism to reduce levels of 
toxic intermediates and sequester dysfunctional protein to a particular part of the cell. 
 
1.7.2. "-synuclein 
 
1.7.2.1 "-synuclein gene and protein structure  
Along with the identification of #-synuclein from human brain came the purification 
and sequencing of a 134 amino acid protein with 61% identity to #-synuclein that was 
named !-synuclein (Jakes et al., 1994). !-synuclein is the human orthologue of 
bovine phosphoneuroprotein 14 (PNP14) and like #-synuclein was also found to be 
predominantly expressed in the brain, and enriched in presynaptic terminals (Jakes et 
al., 1994). The gene encoding !-synuclein, SNCB, maps to chromosome 5q35 and has 
6 exons (Spillantini et al., 1995). !-synuclein lacks a string of 11 central hydrophobic 
residues found in #- and $-synuclein which appears to mediate structural differences 
between the three proteins (Fig. 1.3). !-synuclein exhibits a lower predisposition 
towards helical structure in this altered region and is the assumed reason for its 
negligible propensity to aggregate, with the NAC region of #-synuclein thought to be 
important for its aggregation (Sung and Eliezer, 2007). In vitro, !-synuclein was 
shown to inhibit the aggregation of #-synuclein (Park and Lansbury, 2003; Uversky 
et al., 2002). Moreover, transgenic overexpression of !-synuclein, which does not 
cause neurological dysfunction, was able to ameliorate #-synuclein neurotoxicity 
when the two proteins are co-expressed in bigenic mice (Fan et al., 2006; Hashimoto 
et al., 2001). 
 
1.7.2.2. "-synuclein and neurodegeneration 
Although #-synuclein is the major component of Lewy bodies as well as other 
pathological inclusions typical for that of the synucleinopathies, the presence of !-
synuclein in these aggregates is yet to be reported. However, in cases of Alzheimer’s 
disease (AD) and Lewy Body disease there do appear to be significant changes in the 
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levels of expression of !-synuclein (Rockenstein et al., 2001). There is also evidence 
that !-synuclein can be found within pathological lesions of other neurodegenerative 
conditions such as Pick’s Disease (Mori et al., 2002), in the axonal spheroids typical 
for Hallervorden-Spatz syndrome (Galvin et al., 2000), as well as in Ubiquitin 
Carboxyl-terminal Hydrolase-L1 (UCH-L1) deficient gad mice (Wang et al., 2004). 
To date, there have been no reported links between mutations to the SNCB gene and 
PD (Lincoln et al., 1999a), although two point mutations (V70M and P123H) have 
been found possibly predisposing to DLB. 
 
1.7.2.3. Modelling loss of "-synuclein in vivo 
As with #-synuclein-/- mice, !-synuclein-/- mice are viable and fertile with no obvious 
neurological phenotype ((Chandra et al., 2004), and our unpublished observations). 
Because the high similarity of #- and !-synuclein might potentially lead to functional 
redundancy in single null mice, #-/!-synuclein null mutant mice have been created. 
These double mutant mice did not exhibit any discernable phenotype although a 
statistically significant reduction in striatal dopamine levels was found, suggesting a 
certain degree of functional redundancy between #- and !-synuclein ((Chandra et al., 
2004), and our unpublished observations). 
 
1.7.3. #-synuclein 
 
1.7.3.1. #-synuclein gene and protein structure  
The most recently identified and probably the least studied member of the synuclein 
family is $-synuclein, which was cloned in three independent laboratories, including 
our own, a little over ten years ago (Buchman et al., 1998b; Ji et al., 1997; Lavedan et 
al., 1998b). The human $-synuclein gene maps to chromosome 10q23 and contains 5 
exons encoding a protein of 127 amino acids (Ninkina et al., 1998). Comparison of 
amino acid sequences shows that human $-synuclein shares 56% and 54% similarity 
with human #- and !-synuclein respectively (Lavedan et al., 1998b) with the highest 
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degree of similarity within the first 85 amino acid residues, containing six 'KTKEGV' 
repeats and the region similar to the NAC region found in #-synuclein. However $-
synuclein differs considerably at the C-terminus from the other two family members 
(Buchman et al., 1998b; Ji et al., 1997; Lavedan et al., 1998b). It appears that this 
diversion in C-terminal sequence confers some key differences in structure from the 
other two synucleins. This is thought to mediate functional variations between the 
three proteins, with differences in $-synuclein function expected to result from 
different protein-protein interactions mediated by its C-terminus (Sung and Eliezer, 
2006). $-synuclein adopts a similar free state residual secondary structure to #-
synuclein (Sung and Eliezer, 2007), which is consistent with the ability of $-synuclein 
to aggregate and form fibrils in vitro as does #-synuclein, although aggregates of #-
synuclein form much more readily (Biere et al., 2000; Serpell et al., 2000). The 
reduced tendency of $-synuclein to form aggregates may be due to its higher 
propensity to form secondary structure (#-helices) in the amyloid-forming region that 
is critical for the fibrillization of #-synuclein (Marsh et al., 2006). In its extended 
mode, the structure of $-synuclein resembles !-synuclein (Sung and Eliezer, 2007) 
which can be linked to the ability of both proteins to impede the in vitro aggregation 
of #-synuclein, although !-synuclein blocks this process much more efficiently than 
$-synuclein (Park and Lansbury, 2003; Uversky et al., 2002). 
 
1.7.3.2. #-synuclein expression and function  
$-synuclein is found predominantly distributed throughout the cell body and axons of 
motor and sensory neurons of the peripheral nervous system (PNS) where it is 
expressed from the earliest stages of neural development (Buchman et al., 1998b).  
Expression of $-synuclein can also be found in certain populations of neurons 
localised in other regions of the central nervous system (CNS), including the cerebral 
cortex, olfactory bulb, thalamus, hypothalamus, substantia nigra pars compacta 
(SNpc) and locus coeruleus (Lavedan et al., 1998b; Li et al., 2002). Initial work found 
that $-synuclein could influence the neurofilament network, by exposure of 
neurofilaments to Ca2+-dependent proteases (Buchman et al., 1998a). However 
determining a specific cellular role for $-synuclein has remained elusive, partly due to 
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the fact that $-synuclein knockout ($-synuclein-/-) mice are viable, fertile, and have no 
evident phenotypical abnormalities (Ninkina et al., 2003, and discussed later). 
Interestingly, hypothalamic expression of $-synuclein was recently shown to be 
responsive to both fasting and leptin administration in mice (Jovanovic et al., 2010; 
Tung et al., 2008). The hypothalamus is a heterogeneous region of the brain 
containing a number of anatomically distinct nuclei, each expressing their own 
individual sets of various neuronal populations. Within the CNS, the hypothalamus is 
recognised to receive and integrate neural, metabolic and humoral signals from the 
periphery and provides a major link between the nervous system and endocrine 
system to finely regulate downstream metabolic homeostatic responses as well as 
other activities of the autonomic nervous system. Two key regions of the 
hypothalamus, the arcuate nucleus (ARC) and the paraventricular nucleus (PVN) both 
include leptin receptor expressing-neurons which are critical for energy homeostasis 
and are considered key neurons through which leptin exerts its effects (Cone, 2005). 
Hypothalamic $-synuclein expression in both the PVN and ARC was substantially 
downregulated in mice fasted for 48 hours but restored to nearly ad libitum fed levels 
by leptin treatment (Jovanovic et al., 2010; Tung et al., 2008). 
 
1.7.3.3. #-synuclein and cancer 
$-synuclein was found to be a differentially expressed gene in advanced human breast 
cancer, which led to it being termed breast cancer-specific gene 1 (BCSG1) (Ji et al., 
1997). It has since been documented that its upregulation occurs during the 
development of invasive and metastatic carcinomas of the breast, ovary and pancreas 
amongst others, and that this level of expression correlates strongly with the stage of 
cancer progression (Bruening et al., 2000; Cao et al., 2005; Guo et al., 2007). This 
increased expression has been suggested to be caused by demethylation of the CpG 
island on the SNCG gene (Gupta et al., 2003a; Liu et al., 2005; Liu et al., 2007; Lu et 
al., 2001), and may lead to the potential inhibition of mitotic checkpoints (Inaba et al., 
2005), possibly via binding and subsequent degradation of the mitotic checkpoint 
protein BubR1 (Gupta et al., 2003b). In addition to this, it has been demonstrated that 
$-synuclein is able to block c-Jun N-terminal kinase (JNK) signalling (Pan et al., 
2002), a pathway which commonly induces apoptosis. 
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1.7.3.4. #-synuclein and neurodegeneration 
As is the case for !-synuclein, the presence of $-synuclein in pathological lesions 
typical for synucleinopathies is yet to be seen. However, in cases of Alzheimer’s 
disease (AD) and Lewy Body disease (Galvin et al., 1999; Mukaetova-Ladinska et al., 
2008; Rockenstein et al., 2001), glaucoma (Surgucheva et al., 2002) and Gaucher 
disease (Myerowitz et al., 2004) there are changes in the levels of expression of $-
synuclein as well as its abnormal distribution. $-synuclein has also been be found in 
axonal spheroids typical for Hallervorden-Spatz syndrome (Galvin et al., 2000) as 
well as in Ubiquitin Carboxyl-terminal Hydrolase-L1 (UCH-L1) deficient gad mice 
(Wang et al., 2004). 
Unlike the specific mutations found in the SNCA gene coding for #-synuclein that 
cause an early onset, hereditary form of PD, no mutations or polymorphisms in the 
SNCG gene have been found to be associated with familial PD (Flowers et al., 1999; 
Kruger et al., 2001; Lavedan et al., 1998a; Lincoln et al., 1999b). In addition to this, 
unlike #-synuclein, an acute overexpression of $-synuclein does not induce apoptosis 
in neuronal cultures (Saha et al., 2000). However $-synuclein has been implicated in 
some neurodegenerative conditions in the optic system. Its expression and distribution 
are altered in retinal ganglion cells and their axons in the optic nerve in human cases 
and mouse models of glaucoma (Buckingham et al., 2008; Soto et al., 2008; 
Surgucheva et al., 2002). It is therefore still possible that the accumulation and even 
aggregation of $-synuclein may occur in these conditions. Indeed, our laboratory has 
recently produced a transgenic mouse line with pan neuronal overexpression of $-
synuclein under control of the Thy-1 promoter. These mice display progressive motor 
deficits from six months onwards and die prematurely. On closer inspection, there is 
prominent neuronal pathology, most notably in the spinal cord, with accumulation and 
aggregation of $-synuclein within the axon and cell body (Ninkina et al., 2009). 
 
1.7.3.5. Modelling loss of #-synuclein in vivo 
As with both #- and !-synuclein-/- mice, $-synuclein-/- mice are viable, fertile, and do 
not display any obvious neurological phenotype. Moreover, neurons of the dorsal root 
ganglion and trigeminal ganglion, regions where $-synuclein is most highly expressed 
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do not display any developmental or functional defects (Ninkina et al., 2003; 
Papachroni et al., 2005; Robertson et al., 2004). Behavioural analysis of these animals 
did not reveal any motor deficits nor were there any evidence of cell loss in the SNpc 
or VTA even in aged animals (Al-Wandi et al., 2010). Similar to #-synuclein-/- mice, 
$-synuclein-/- mice have enhanced resistance to MPTP (Robertson et al., 2004) 
suggesting potential functional overlap between #- and $-synuclein, which is indeed 
supported by the fact that similar groups are genes are altered in single #- and $-
synuclein-/- mice (Kuhn et al., 2007). 
 
1.7.4. Synucleins and lipids 
 
1.7.4.1. Lipid interaction and multimerisation of synucleins 
In vitro #-synuclein interacts with phospholipid vesicles and in cultured Hela cells is 
enriched at lipid rafts, where it exhibits preferential interaction for certain 
phospholipid species (Fortin et al., 2004; Jo et al., 2000; Kubo et al., 2005; 
Ramakrishnan et al., 2003). #-synuclein can also associate with lipid droplets and 
protect internal TAG stores from hydrolysis in lipid-loaded cells (Cole et al., 2002). 
The binding of #-synuclein to neutral and charged membranes appears to occur by 
different mechanisms (Shvadchak et al., 2011). This study showed that binding of #-
synuclein to neutral bilayers increases with membrane curvature and rigidity and 
decreases in the presence of cholesterol. Furthermore, it was demonstrated that the 
association of #-synuclein with negatively charged membranes is much stronger 
overall, and is much less sensitive to membrane curvature and cholesterol content. In 
both neutral and charged membranes, the presence of unsaturated lipids was shown to 
increase binding of #-synuclein (Shvadchak et al., 2011). 
Links between synucleins and polyunsaturated fatty acids (PUFA) have also been 
documented, including direct in vitro interaction of #-synuclein with PUFA (Karube 
et al., 2008; Sharon et al., 2001). PUFA also promote multimerisation of #-synuclein 
(Perrin et al., 2001; Sharon et al., 2003a) as well as !-, and $-synuclein (Perrin et al., 
2001). The presence of lipid-associated oligomers of #-synuclein in the brain is 
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believed to play a role in the development of neuronal dysfunction observed in 
Parkinson's disease and other synucleinopathies (Fink, 2006; Uversky, 2007). In vitro 
work has shown that oligomerisation of #-synuclein is dependent both on fatty acid 
length and saturation, and that these oligomers are cytotoxic to neuronal cells in 
culture (Assayag et al., 2007). Certain lipid species increase this multimerisation, for 
example in yeast cells, the aggregation of !-synuclein is enhanced in yeast mutants 
that produce high levels of acidic phospholipids (Soper et al., 2011). Similarly, 
docosahexaenoic acid (DHA) promotes aggregation of #-synuclein in vitro, 
producing fibrils that are morphologically different from oligomers formed in the 
absence of DHA. Moreover, #-synuclein oligomers generated in a dopaminergic cell 
line were more cytotoxic when formed in the presence of this PUFA (De Franceschi 
et al., 2011). #-synuclein interaction with PUFA also affects the properties of PUFA 
themselves, reducing their micellular size (Broersen et al., 2006). This study also 
demonstrated that in the presense of PUFA, namely arachidonic acid (ARA) and 
DHA, and not saturated fatty acids, #-synuclein undergoes conformational changes 
adopting #-helical structure (Broersen et al., 2006). Of importance to normal lipid 
metabolism and in cases of possible dysfunction, DHA accounts for over half of all 
esterified fatty acids in plasma membrane phospholipids in neurons, and the levels of 
this fatty acid are elevated in Parkinson's disease patients (Lukiw and Bazan, 2008; 
Sharon et al., 2003b). Interestingly, in the brains of rats fed high n-3 PUFA diets (e.g. 
eicosapentaenoic acid and DHA), the expression of both #- and $-synuclein was 
increased approximately 2-fold (Kitajka et al., 2002). 
  
1.7.4.2. Effects of synucleins on lipid metabolism in the brain 
In the brains of #-synuclein null mutant mice, there are changes in intracellular lipid 
metabolism as well as an increase in whole-brain neutral lipid content (Barcelo-
Coblijn et al., 2007; Ellis et al., 2005). Alterations in fatty acid handling can also be 
found in the brains of these #-synuclein deficient mice. Here there is a reduced 
incorporation of ARA into phospholipids with a compensatory rise in incorporation of 
DHA (Golovko et al., 2007). This was attributed to a role for this protein in substrate 
presentation to acyl-CoA synthetase (ACS), an important enzyme in the fatty acid 
reacylation pathway, with reduced ACS (ACS-6 isoform) activity demonstrated in 
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mutant mice (Golovko et al., 2009; Golovko et al., 2006). #-synuclein deficient mice 
were also shown to have lower levels of free PUFA in brain, with the same group 
observing increased free PUFA levels in cultured neurons with overexpression of #-
synuclein (Sharon et al., 2003b). 
Various groups have demonstrated direct interaction and inhibition of phospholipase 
D (PLD) by #-synuclein in vitro (Ahn et al., 2002; Jenco et al., 1998) and in vivo 
(Gorbatyuk et al., 2010). PLD is an enzyme believed to participate in vesicle 
trafficking, membrane signaling and both endo- and exocytosis, and its activity is 
responsive to various hormones, factors, neurotransmitters and reactive lipids 
(Liscovitch et al., 2000). Specifically, PLD hydrolyses phosphatidylcholine at the cell 
membrane, producing phosphatidic acid and choline, and phosphatidic acid has been 
shown to mediate a number of processes controlling vesicular transport (Ktistakis et 
al., 1995; Tsai et al., 1989). In addition to #-synuclein, !- and $-synuclein were also 
able to inhibit PLD in vitro (Jenco et al., 1998; Payton et al., 2004). However a 
different group, who found no evidence of PLD inhibition by #-synuclein in either 
cell-free assays or several cell lines, has disputed these findings (Rappley et al., 
2009). 
 
1.7.5. Expression of #-synuclein in white adipose tissue 
As mentioned previously, there is no clear cellular role for $-synuclein, and ablation 
of $-synuclein causes only minor changes in the nervous system (Ninkina et al., 2003; 
Papachroni et al., 2005; Robertson et al., 2004). Whilst working on a mouse model of 
mammary gland tumourigenesis in our laboratory, we unexpectedly discovered that 
not only is $-synuclein expressed in certain types of mouse mammary tumours but 
also in the normal adjacent mammary tissue. Moreover, expression levels appeared to 
correlate with the number of stromal adipocytes. This prompted us to check the 
expression in various body fat pad depots using Northern blotting, quantitative RT-
PCR and Western blotting, which all confirmed that epididymal and subcutaneous 
white adipose tissue depots express high levels of $-synuclein (Fig. 1.4, 1.5, 1.6). 
Northern blot hybridisation with a highly specific 3’ UTR probe revealed the same 
size (~0.8 kb) $-synuclein transcripts in mouse neural tissues and WAT depots (Fig. 
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1.4). Transcript levels were very low in adult brown adipose tissue, however levels in 
WAT were higher than in the adult mouse central nervous system regions and only 
slightly lower than in the peripheral sensory ganglia, a tissue with the highest level of 
$-synuclein expression in the mouse nervous system (Buchman et al., 1998b; Ninkina 
et al., 2003) (Fig. 1.5). Western blotting with antibodies against mouse $-synuclein 
(Buchman et al., 1998b) confirmed the presence of $-synuclein protein in 
subcutaneous and epididymal WAT (Fig. 1.6). 
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Fig. 1.4. Northern blot analysis of $-synuclein mRNA in mouse tissues. mRNA 
isolated from wild type adult mouse brown adipose tissue (BAT), subcutaneous white 
adipose (WAT) as well as neuronal tissues where $-synuclein is known to be 
expressed. A specific hybridisation probe derived from the 3’-UTR of mouse $-
synuclein mRNA was used for detection of a 0.8 kb transcript in each tissue. Equal 
loading was confirmed by ethidium bromide (EtBr) staining of ribosomal RNA bands 
on the membrane before hybridisation. 
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Fig. 1.5. Quantitative RT-PCR analysis of $-synuclein mRNA in neuronal and 
adipose tissues of adult wild type mice. RNA was extracted from the spinal cord 
(SpC) and dorsal root ganglia (DRG) as well as subcutaneous (SC), epididymal (ED) 
and brown (BAT) adipose tissue. Results are shown as mean±SEM of fold change 
normalized to the average level of $-synuclein mRNA in the spinal cord (n=4).  
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Fig. 1.6. Analysis of $-synuclein expression in various mouse tissues using 
Western blotting. Total proteins were extracted from tissue taken from adult wild 
type mice, and detected using an affinity purified anti-mouse $-synuclein (SK23) 
antibody (Buchman et al., 1998b). Performed in collaboration with Hiroshi Sakaue 
(Kobe University, Japan).  
 
Other groups have previously reported high levels of $-synuclein expression in 
adipose tissue of both humans and pigs (Frandsen et al., 2009; Oort et al., 2008). 
Moreover, expression of $-synuclein is increased in adipose tissue of obese humans 
and decreased during caloric restriction (Oort et al., 2008). Therefore, we began 
studying $-synuclein expression in murine WAT, as outlined in the aims section 
below. 
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1.8. Aims 
In an attempt to understand the role of $-synuclein in WAT, and its possible 
involvement in the development of obesity, we planned to investigate the following: 
 
1. To determine whether in mice fed a high fat diet, $-synuclein expression is 
nutritionally regulated in WAT, similar to the expression changes seen in 
obese humans.  
 
2. To test whether $-synuclein deficiency affects progression of high fat diet-
induced obesity in a mouse model. In order to achieve this aim we challenged 
$-synuclein null mutant mice with a high fat diet known to cause diet-induced 
obesity in wild type mice. 
 
3. To describe any alterations in lipid metabolism within WAT resulting from 
loss of $-synuclein, and therefore begin to understand a possible role for $-
synuclein in this tissue.  
 
4. To elucidate the involvement of $-synuclein in molecular mechanisms 
concerned with lipid handling in adipocytes. 
 
5. To describe any changes in lipid composition in the brain of $-synuclein 
null mutant mice. 
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Chapter 2 - Experimental Procedures 
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2. Experimental Procedures 
 
2.1. Solutions 
DNA loading dye 
Tris-borate     89 mM 
EDTA      2 mM 
Glycerol     20% (v/v) 
Bromophenol blue    0.02% (w/v) 
 
Diaminobenzidine solution (Sigma-Aldrich) 
 3,3’-diaminobenzidine   3.3 mM 
Urea hydrogen peroxide   7.0 mM 
Tris      60 mM  
 
Enzyme dilution buffer pH 7.0 
KPO4 pH 7.0     0.1 M 
EDTA      1 mM 
DTT      1 mM 
BSA      0.002% (w/v) 
 
Garbus solution pH 7.4 
 KCl      2 M 
 KPO4      0.5 M 
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Hypertonic sucrose buffer 
Tris-HCl pH 7.5    50 mM 
Sucrose     0.25 M 
EDTA      1 mM 
DTT      1 mM 
 
Immunoprecipitation (IP) buffer 
Tris-HCl pH 7.5     50 mM 
NaCl      150 mM 
Triton X-100     1 % (v/v) 
Protease Inhibitors (Complete mini from Roche) 
 
Krebs-Ringer Media (KRM) pH 7.4 
NaCl      0.12 M 
KCl      4.5 mM 
MgCl2      0.5 mM  
NaH2PO4     1.5 mM 
Na2HPO4     0.7 mM 
D-Glucose     10 mM 
*  *  *  *  * 
HEPES     25 mM 
NaHCO3     15 mM 
BSA (fraction V)    1% (w/v) 
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CaCl2      2.5 mM 
Adenosine     200 nM 
Collagenase I (Sigma-Aldrich)  1 mg/ml 
 
Phosphate buffered saline: Dulbecco A (pH 7.3±0.2) (Oxoid) 
NaCl      0.1 M     
KCl      2.6 mM 
Sodium phosphate dibasic   6.5 mM 
(HNa2O4P.2H2O) 
Potassium phosphate monobasic  1.2 mM 
(N2KO4P) 
 
SDS-PAGE loading buffer 
Tris-HCl pH 6.8    100 mM 
Glycerol     20% (v/v) 
SDS      4% (w/v) 
Bromophenol blue    0.02% (w/v) 
!-mercaptoethanol    200 mM 
 
SDS-PAGE running buffer (pH 8.5) 
Tris      25 mM 
Glycine     192 mM 
SDS      0.1% (w/v) 
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TBE buffer (pH 8.3) (Sigma-Aldrich) 
Tris-borate     89 mM 
EDTA      2 mM 
 
TBS-T (pH 8.0) (Sigma-Aldrich) 
Tris      50 mM 
NaCl      138 mM 
KCl      2.7 mM 
Tween-20     0.1% (v/v) 
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2.2. Animals 
 
2.2.1. #-synuclein null mutant mice 
Generation of mice with a targeted deletion of the Sncg gene ($-synuclein null 
mutant) on a C57Bl6J background was described previously (Ninkina et al., 2003).  
 
2.2.2. Genotyping by conventional PCR 
Genomic DNA (gDNA) was isolated and purified using a Wizard SV gDNA 
purification system (Promega) and 5 µl of gDNA mixed with 45 µl of an 
amplification mastermix yielding a 50 µl reaction with the following components: 
 
 Tris-HCl pH 9.0     10 mM 
 MgCl2      1.5 mM 
 KCl       50 mM 
 Triton X-100     0.1% (v/v) 
 Primers (fwd/rev)    0.25 µM 
 dNTP      0.2 mM 
 Taq Polymerase     5 units 
 
DNA was amplified by 40 cycles of conventional PCR with thermal cycling 
conditions set at: 
 
 Denaturation  94oC   15 seconds 
 Annealing   60oC   30 seconds 
 Extension   72oC   40 seconds 
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A common upstream primer (SAUP) as well as primers specific for the wild type 
allele (GDN) and the PGK-neo cassette (NeoB’) were used for amplification: 
 
 SAUP  5’-AGTCCTGGCACCTCTAAGCA-3’ 
 GDN   5’-GGGCTGATGTGTGGCTATCT-3’ 
 NeoB’  5’-CTGAAGAACGAGATCAGCAGC-3’ 
 
(all sequences produced by Sigma-Genosys)  
 
Amplified fragments were separated on 1.5% (w/v) agarose gels in Tris-borate-EDTA 
(TBE) buffer: 
 
 TBE       100 ml 
 Agarose      1.5 g 
 Ethidium Bromide    2 µl 
 
10 µl of PCR product was mixed with 10 µl DNA loading dye and loaded into each 
well along with 5 µl of DNA ladder (Hyperladder I, Bioline). The electrophoresis was 
run at 130V until sufficient separation had taken place. PCR using these primers 
generated a 490bp fragment from wild type DNA and a 397bp fragment from $-
synuclein knockout DNA. 
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2.2.3. Husbandry & Diets 
Mice were single housed in standard cages, in a temperature and humidity controlled 
environment, a 12 hour light/dark cycle, and with free access to water. From the age 
of 9 week animals were fed either a low fat diet (LFD, equivalent of 10% energy from 
fat) or a high fat diet (HFD, equivalent of 45% energy from fat) ((Van Heek et al., 
1997), both purchased from TestDiet). Dynamics of body mass changes and amount 
of food consumed were measured weekly. All animal work was carried out in 
accordance with the United Kingdom Animals (Scientific Procedures) Act (1986). 
 
2.2.4. Tissue Collection 
On the day of tissue collection, food was removed 4 hours prior to terminally 
anaesthetizing mice with barbiturate overdose via i.p. injection (Euthatal, from 
Merial). Blood was harvested via exsanguination from a cardiac puncture using a 
syringe presoaked in 1 mg/ml sodium heparin (Sigma-Aldrich), centrifuged at 2,100 x 
g for 5 minutes at room temperature in Microvette CB300 LH heparinated tubes 
(Sarstedt), and the plasma pipetted off and snap frozen in liquid nitrogen. Liver, 
brown adipose tissue (BAT) and also white adipose tissue (WAT) from visceral 
(epididymal and retroperitoneal) and subcutaneous (femoral) depots were dissected, 
weighted and processed for subsequent analysis. 
 
2.3. Magnetic resonance imaging (MRI) analysis 
MRI is able to provide scans with detailed contrast between various soft tissues of the 
body, for example the distribution of fat amongst the major organs. Mice were 
anaesthetised and scanned at 9, 15, 20 weeks of age using a highfield (9.4T) small 
bore (72mm) Bruker 94/20 MRI/MRS scanner.  Two whole-body 2D RARE scans 
(one with fat suppression on and one with fat suppression off) were acquired per time 
point (matrix 512 x 256 = 156µm in plane resolution, 64 x 0.5mm slices, TE 12ms, 
TR 3.9s, RARE factor 4). Fat only images were generated by the subtraction of the fat 
suppressed image from the non-suppressed image. This subtraction, the 3D image 
reconstruction and user directed fat pad volume measurement were carried out using 
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‘FAT’ (Fat Analysis Tool), a small GUI application custom written in IDL at Cardiff 
University Experimental MRI Centre. 
 
2.4. Whole-body metabolic analysis 
A comprehensive lab animal monitoring system (CLAMS) can be used to measure 
simple parameters such as body weight and water/food consumption, as well as other, 
more complex measurements, including free physical activity and respiration rates, all 
over a set period of time. Metabolic rate in mice in the 8th week of HFD feeding was 
determined by indirect calorimetry with the use of a CLAMS (Columbus Instruments) 
attached to a custom built O2 and CO2 monitoring system, based in the Institute of 
Metabolic Science, Cambridge University. Mice were single housed, and were 
acclimatised to the cages a few days before testing period. Cages were maintained at 
constant temperature, air-flow was set at 0.4 L/min, and the O2 and CO2 concentration 
in room air and air leaving each cage was measured every 18 minutes to determine 
respiratory exchange ratio (RER, vCO2/vO2) and also energy expenditure (using 
constants according to (Elia and Livesey, 1992)) over a 72-hour period. Data was 
averaged for 3-hour intervals.  
 
2.5. Glucose- / Insulin Tolerance Testing 
Glucose- (GTT) and insulin tolerance tests (ITT) were performed on non-
anaesthetised mice in the 9th and 10th week of HFD feeding, respectively. Mice were 
fasted overnight before GTT or for 4 hours before ITT. For GTT, glucose levels in tail 
vein blood were measured at baseline, and 30, 60, 90 and 120 minutes after a single 
i.p. injection of D-glucose (1 g/kg body weight, from Sigma-Aldrich) using an 
Accutrend Plus glucometer (Roche Diagnostics). For ITT, mice received an i.p. 
injection of human insulin (Sigma-Aldrich) in 0.9% (w/v) NaCl (0.75 U/kg body 
weight). The blood glucose levels were measured at baseline, and 15, 30, 45 and 60 
minutes after injection. Data was plotted on graphs of blood glucose concentration 
over time with the area under the curve calculated for each genotype, for both GTT 
and ITT to quantify clearance of glucose from the blood, and insulin sensitivity 
respectively. 
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2.6. Lentiviral expression of $-synuclein 
 
2.6.1. DNA fragment amplification 
A 414 bp fragment of human $-synuclein cDNA that included the coding region and 
20 nucleotides upstream of the start codon, including the Kozak sequence, was 
amplified from a previously obtained plasmid clone (Ninkina et al., 1998) by PCR 
using primers with BamHI restriction endonuclease recognition site added at their 5’ 
end: 
 
hgamma_for_Bam  5’-ggatccCACAACCCTGCACACCCACCATGGATG-3’ 
 
h_gamma_rev_Bam    5’-ggatccCTAGTCTCCCCCACTCTG-3’ 
 
 
This fragment was cloned into a pCR-Blunt II-TOPO vector using One Shot 
chemically competent cells according to manufactures protocol (Invitrogen). 
Transformants were grown on LB agar plates with 50 µg/ml of kanamycin overnight 
at 37oC. Individual bacteria colonies were inoculated into 5 ml of LB medium with 
kanamycin and grown overnight at 37oC with intensive shaking. Plasmid DNA was 
extracted from 4 ml of bacteria suspension using a NucleoSpin mini-prep kit 
according to the manufactures (Macherey-Nagel GmbH) instructions. The presence of 
eukaryotic insert was checked by digestion of each plasmid DNA with BamHI and 
analysis of digestion products by electrophoresis in 1.2% (w/v) agarose gels. Inserts 
of several individual clones were fully sequenced to select those with correct 
nucleotide sequence.  
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2.6.2. Purification of insert DNA, and ligation, transformation and plasmid analysis  
Selected recombinant TOPO plasmid DNA was digested with BamHI prior to 
purification by electrophoresis in 1.2% (w/v) agarose gels. Correct molecular weight 
bands representing insert DNA were excised and purified using a gel extraction kit 
according to manufacturers protocols (Qiagen). Ligations were performed using T4 
DNA ligase (Invitrogen), with the DNA insert containing the coding region of human 
$-synuclein subcloned into the unique BamHI site of the pRRLsin.cPPT.hPGK-eGFP 
lentiviral expression vector (Follenzi et al., 2000, see Appendix 1). Prior to ligation, 
this vector was digested, treated with alkaline phosphatase and purified in agarose 
gels as above. Plasmids were transformed into DH5# competent cells with growth of 
transformants on LB agar plates, inoculation of individual colonies and extraction of 
plasmid DNA performed as in section 2.6.1. Insertion of the DNA insert in the correct 
orientation was checked by digestion of plasmid DNA with NcoI and XhoI and 
analysis of the digestion products by electrophoresis in 1.2% (w/v) agarose gels as 
well as sequencing using an oligonucleotide primer ‘p305for’ located in the hPGK-1 
promoter, 88 bp upstream of the cloning BamHI site.  
 
p305for   5’-GTTCCGCATTCTGCAAGC-3’ 
 
 
2.6.3. Lentiviral production 
Selected plasmids were used for production of recombinant lentivirus particles. All 
work involving lentiviral production was performed in the laboratory of Dr Riccardo 
Brambilla in the Institute of Experimental Neurology, San Raffaele Foundation and 
University, Milano. Virus particles were produced and tittered according to the 
previously described protocols (Indrigo et al., 2010).  
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2.6.4. Lentiviral transduction of cells in vivo and in vitro 
For expression of $-synuclein in cultured cells, 1.5x106 virus transducing units in one 
millilitre of the full culture medium were incubated for 48 hours with cells growing 
on culture dishes or coverslips. For expression in mouse WAT adipocytes, 5 µl of F12 
medium containing 5x105 virus transducing units were injected into an exposed 
subcutaneous femoral WAT pad of anaesthetized 9-week-old male mouse. 3-5 
injections of $-synuclein expressing viruses were made per right fat pad and 3-5 
injections of GFP-only expressing viruses – per left fat pad. After HFD feeding 
protocol, these fat pads were dissected out, fixed and immunostained as described in 
‘histological techniques’. 
 
2.7. Blood chemistry 
Commercially available kits were used to measure plasma levels of glucose, insulin, 
leptin and adiponectin (Linco Research), as well as plasma ketone body levels by !-
hydroxybutyrate content (Cayman Chemicals), all according to manufacturers 
instructions.  
 
2.8. Isolation of cell populations from WAT 
Mature adipocytes as well as the preadipocyte-containing stromal cell fraction were 
isolated from epididymal fat depots based on the method of (Rodbell, 1964) as 
modified by (Honnor et al., 1985). All cell processing was performed in Krebs-Ringer 
bicarbonate medium (KRM) buffered with 25 mM HEPES at pH 7.4 containing 2.5 
mM CaCl2, 10 mM glucose and 200 nM adenosine (to suppress cAMP production 
during cell isolation). Briefly, WAT was incubated in KRM containing 1% (w/v) fatty 
acid free bovine serum albumin (BSA) and 1 mg/ml collagenase, for 45 minutes at 
37oC with gentle shaking. Cells were filtered through a nylon mesh and centrifuged 3 
times for 1 minute at 250 x g and room temperature to sediment stromal-vascular 
cells, each time with aspiration of infranate, and resuspension of the floating 
adipocytes in KRM without collagenase.  
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2.9. Adipocyte lipolysis 
Mature adipocytes (isolated from 500 mg of epididymal WAT) were suspended at 
approximately 20% (v/v) in KRM, aliquoted in triplicate, and lipolysis measured 
under basal (200 nM (R)-(-)-N6-(2-phenylisopropyl)adenosine, PIA) and 
catecholamine-stimulated (200 nM PIA + 10 µM isoproterenol) conditions. Lipolytic 
rate was quantified by glycerol release into the media over a 2-hour period at 37oC 
using a free glycerol determination kit (Sigma-Aldrich). Results were normalized to 
the level of endogenous GAPDH expression in each suspension measured using semi-
quantitative Western blotting. 
 
2.10. Semi Quantitative Western blotting 
Western blotting is an important tool used to measure the abundance of a certain 
protein with the use of a specific antibody. 
 
2.10.1. Protein extraction  
Total tissue proteins were extracted from cells cultured on tissue culture plates or 
isolated mouse cell populations by direct homogenisation in SDS-PAGE loading 
buffer using a pellet pestle and motor, followed by incubation at 100oC for 10 
minutes. For WAT depots, 50 mg of tissue was homogenized into 350 µl SDS-PAGE 
loading buffer, vortexed, incubated at 37oC for 5 minutes and finally centrifuged at 
6,000 x g. The infranate was removed from underneath the fat cake, and incubated at 
100oC for 10 minutes. 
To analyse separately nuclear, cytosolic and lipid droplet-associated proteins, purified 
WAT mature adipocytes were lysed in a hypotonic sucrose buffer at 4oC using a glass 
Porter homogeniser. Lysates were centrifuged at 1,000 x g for 10 minutes at 4oC, and 
the infranate removed. The pellet and fat cake were washed three times with fresh 
lysis buffer, each time with centrifugation as above. All fractions were diluted or re-
suspended in SDS-PAGE loading buffer followed by incubation at 100oC for 10 
minutes. 
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2.10.2. Total protein quantification 
Levels of total proteins in each sample were estimated prior to analysis, using a 
commercial kit (BioRad) based on the Bradford protein assay (Bradford, 1976) and 
measuring absorbance at 590 nm using a multiwell plate reader (BioTek). 
 
2.10.3. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) & protein transfer 
Proteins were separated by SDS-PAGE using resolving gels of various acrylamide 
concentration (8-18%, w/v) and a 6% (w/v) stacking gel cast into BioRad plates and 
moulds.  
 
Resolving gel 
 
Acrylamide/bis-acrylamide  8-18% (w/v) 
Tris-HCl pH 8.8   313 mM 
Sodium dodecyl sulphate (SDS) 0.1% (w/v) 
Ammonium persulphate (APS) 0.1% (w/v) 
Tetramethylethylenediamine   0.1% (v/v) 
(TEMED)     
 
Stacking gel 
 
Acrylamide/bis-acrylamide  6% (w/v) 
Tris-HCl pH 6.8   156 mM 
SDS     0.1% (w/v) 
APS     0.1% (w/v) 
TEMED    0.1% (v/v) 
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Loaded proteins, along with 5 µl protein ladder (10-250 kDa, PageRuler, Fermentas) 
were separated at 200V using a Tris-glycine SDS-PAGE running buffer and 
electrophoretically transferred to polyvinylidene difluoride (PVDF) using iBlot 
technology (Invitrogen) according to manufacturer’s protocol.  
 
2.10.4. Antibodies and detection 
Subsequent membranes were blocked in 4% (w/v) non-fat dry milk (Marvel) in Tris-
buffered saline with 0.1% Tween-20 (v/v, TBS-T) followed by incubation with 
specific primary antibodies and appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibodies (1:3000, Amersham), both diluted in 4% (w/v) non-fat dry milk 
in TBS-T. Membranes were washed for 20 minutes in TBS-T after both primary and 
secondary antibody incubation. All antibodies used in Western blotting experiments 
are listed below in table 2.1. Enhanced chemiluminescence (ECL) and ECL plus 
reagents (Amersham) were used for detection of protein bands. Membranes were 
exposed to X-ray film (Fuji). Band intensities were obtained using an AlphaImager™ 
2200 and quantified using AlphaEase 2200 software (both AlphaInnotec). After 
subtracting background values, intensities of bands were normalised relative to the 
levels of GAPDH on the same membrane, to control variations in loading and confirm 
uniform efficiency of transfer.  
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Antibodies used for Western blotting  
Target Type / Clone Source Dilution 
$-synuclein (mouse) Rabbit polyclonal (Buchman et al., 1998b) 1:1000 
$-synuclein (human) Rabbit polyclonal ,-./0./1!23!1456!"**)7 1:1000 
GAPDH Mouse monoclonal (6C5) Santa Cruz Biotechnology 1:3000 
HSL Rabbit polyclonal Cell Signaling 1:1000 
phospho-HSL Rabbit polyclonal Cell Signaling 1:1000 
perilipin A Rabbit polyclonal Cell Signaling 1:1000 
ATGL Rabbit monoclonal (30A4) Cell Signaling 1:1000 
histone 3 (H3) Rabbit polyclonal Abcam 1:5000 
phospho-AMPK#  Rabbit monoclonal (40H9) Cell Signaling 1:500 
Akt/PKB Rabbit polyclonal Cell Signaling 1:1000 
phospho-Akt/PKB Rabbit monoclonal (D9E) Cell Signaling 1:1000 
Phospho-p70 S6 kinase Rabbit polyclonal Cell Signaling 1:1000 
ERK Rabbit polyclonal Cell Signaling 1:1000 
Phospho-ERK Rabbit monoclonal (20G11) Cell Signaling 1:1000 
VAMP-4 Rabbit polyclonal Abcam 1:1000 
Syntaxin-5 Rabbit polyclonal Synaptic Systems 1:3000 
SNAP-23 Rabbit polyclonal Synaptic Systems 1:3000 
Anti-mouse IgG (produced in sheep) Amersham 1:3000 
Anti-rabbit IgG (produced in donkey) Amersham 1:3000 
Table 2.1. Antibodies used in Western blotting experiments. 
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2.11. RNA expression analysis  
mRNA levels of a particular gene can be measured by purification of total RNA from 
tissues or cells, synthesis of first strand cDNA and finally quantitative amplification 
using specific oligonucleotide primers and a DNA-binding fluorescent dye.  
 
2.11.1. RNA extraction and cDNA synthesis 
Total RNA was extracted from 50 mg of epididymal and subcutaneous white adipose 
tissue or directly from cells growing on a tissue culture plate using an RNeasy™ lipid 
tissue kit (Qiagen) according to manufacturer’s protocol. Levels of the resultant 
purified RNA was quantified using a Nanodrop ND-1000 spectrophotometer 
(Labtech). First-strand cDNA was synthesized from 0.3 µg of total RNA using 0.5 µg 
of random hexadeoxynucleotide primers (Promega) incubated at 68oC for 10 minutes 
to denature RNA secondary structure, followed by a 1 hour incubation at 39oC in a 20 
µl reverse transcription reaction containing: 
 
Tris-HCl pH 8.3    50 mM 
KCl      75 mM 
MgCl2      3 mM 
Dithiothreitol (DTT)    10 mM 
dNTPs      0.5 mM  
SuperScript™ III     200 units 
reverse transcriptase (Invitrogen)   
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2.11.2. Quantitative PCR 
Gene expression was analysed by quantitative PCR (qPCR) using a StepOne Real-
Time PCR System (Applied Biosystems). Quantitative amplification of 2 µl of 
reverse transcriptase product was carried out in a 20 µl reaction mixture using thin-
wall fast optical 48 well qPCR plates (Applied Biosystems) and a SYBR Green I 
based mastermix containing: 
 
 SYBR Green I     0.001% (v/v) 
Tris-HCl pH 8.3    20 mM 
KCl      20 mM 
(NH4)2SO4     5 mM 
MgCl2      2.5 mM 
dNTPs      0.25 mM 
Primers (fwd/rev)    0.5 µM 
ROX      0.1 µM 
TrueStart Taq Polymerase (Fermentas) 15 units 
  
ROX was used as a passive reference dye to control for non-specific fluorescent 
signal variations, and amplification of GAPDH cDNA used as an internal gene 
control. After an initial 95ºC hot start, cDNA underwent 40 cycles of amplification, 
with thermal reaction conditions set at 95oC for 15 seconds and 60oC for 60 seconds, 
followed by melt curve determination in increments of 0.3oC. Changes in 
fluorescence were plotted against reaction cycle using StepOne v2.0 software. Fold 
changes in gene expression were calculated using the 2-''CT method (Livak and 
Schmittgen, 2001) with the threshold cycle value (CT) taken from the mid-exponential 
phase of amplification. All primers were designed using Primer3 software 
(http://fokker.wi.mit.edu/primer3/input.htm) and mRNA sequences available through 
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NCBI. Primers in each pair used for qPCR were located in different exons separated 
by large intronic sequences to prevent the influence of potential gDNA 
contamination. gDNA sequences were first aligned to mRNA sequences using Spidey 
mRNA-to-genomic alignment program (http://www.ncbi.nlm.nih.gov/spidey). All 
primers were first checked by amplifying cDNA using standard PCR and checking for 
the presence of a single product on 1.5% (w/v) agarose gels. All primers were 
produced by Sigma-Genosys and a summary of the sequences used is shown in table 
2.2. below: 
Sequences of primers used for qPCR 
Target Forward Reverse 
$-synuclein 5’-CCATGGACGTCTTCAAGAAAGG-3’ 5’-CGTTCTCCTTGGTTTTGGTG-3’ 
GAPDH 5’-CACTGAGCATCTCCCTCACA-3’ 5’-GTGGGTGCAGCGAACTTTAT-3’ 
leptin 5’-TGACACCAAAACCCTCATCA-3’ 5’-TGAAGCCCAGGAATGAAGTC-3’ 
HSL 5’-ACGCTACACAAAGGCTGCTT-3’ 5’-TCGTTGCGTTTGTAGTGCTC-3’ 
perilipin A 5’-CACTCTCTGGCCATGTGGAT-3’ 5’-AGAGGCTGCCAGGTTGTG-3’ 
ATGL 5’-CAACGCCACTCACATCTACG-3’ 5’-ATGCAGAGGACCCAGGAAC-3’ 
aP2 5’-TCACCTGGAAGACAGCTCCT-3’ 5’-AATCCCCATTTACGCTGATG-3’ 
3-KAT 5’-GGTCTTATGACATTGGCATGG-3’ 5’-TCTCTGGCCTTCTCGTTCTC-3’ 
UCP-1 5’-GGCAAAAACAGAAGGATTGC-3’ 5’-TAAGCCGGCTGAGATCTTGT-3’ 
ACC-1 5’-TGGTATTGGGGCTTACCTTG-3’ 5’-AAGCTGGTTGTTGGAGGTGT-3’ 
C/EBP!  5’-CAAGCTGAGCGACGAGTACA-3’ 5’-AGCTGCTCCACCTTCTTCTG-3’ 
LPL 5’-CTCTGTGTCTAACTGCCACTTCA-3’ 5’-AGTTTGGGCACCCAACTCTC-3’ 
PPAR$  5’-TTCAGAAGTGCCTTGCTGTG-3’ 5’-TCAGCAGACTCTGGGTTCAG-3’ 
 
Table 2.2. Summary of primer sequences used in qPCR experiments. 
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For PCR analysis of $-synuclein mRNA transcripts in WAT and MEF, PCR reactions, 
cycling conditions and agarose gel analysis were all performed as in section 2.2.2. 
Primers specific for $-synuclein cDNA representing the entire coding region of the 
gene, as well as primers specific for GAPDH cDNA were used for amplification: 
 
 #-synuclein for 5’-CCATGGACGTCTTCAAGAAAGG-3’ 
 #-synuclein rev 5’-CTAGTCTTCTCAACTCTTGG-3’ 
 GAPDH for 5’-CACTGAGCATCTCCCTCACA-3’ 
 GAPDH rev 5’-GTGGGTGCAGCGAACTTTAT-3’ 
 
 
2.12. Co-immunoprecipitation 
Co-immunoprecipitation (coIP) can be used to determine whether or not two proteins 
permanently bind within the cell. Co-immunoprecipitation of SNARE proteins 
vesicle-associated membrane protein 4 (VAMP-4) and syntaxin-5 in WAT was 
performed according to a protocol described previously for synaptic SNARE 
complexes (Burre et al., 2010). Briefly, 150 mg WAT was homogenised in 0.6 ml of 
IP buffer and lysates cleared by centrifugation at 16,000 x g for 10 minutes at 4oC. 
250 µl of supernatant was incubated with 5 µl of rabbit polyclonal anti-syntaxin-5 
antibody (Synaptic Systems) and 50 µl of Protein G Sepharose (Amersham). This 
suspension was rotated for 2 hours at 4oC after which Sepharose beads were 
sedimented by centrifugation for 1 minute at 500 x g and washed four times with IP 
buffer. Bound proteins were eluted by incubation at 100oC for 10 minutes in 50µl of 
SDS-PAGE loading buffer. 
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2.13. Histological techniques 
Dissected WAT, BAT and liver samples were fixed overnight in 10% (w/v) neutral 
buffered formalin (Sigma-Aldrich) at 4oC and dehydrated in a graded alcohol series: 
 
PBS      15 minutes (x3) 
95% ethanol      5 minutes (x3) 
100% ethanol      30 minutes 
1:1 ethanol:chloroform   30 minutes 
Chloroform     60 minutes 
Chloroform (4oC)    Overnight 
 
After dehydration, tissues were left in paraffin wax (RA Lamb) for 3 hours at 60oC 
before being embedded in fresh wax. 8 µm sections were cut using a HM 310 
microtome (Microm International) and mounted onto poly-L-lysine coated slides 
(Mendel Glazer) by floating cut sections onto the surface of dH2O heated in a 40
oC 
water bath. Slides were left to dry overnight at room temperature. 
 
2.13.1. Haematoxylin & Eosin (H&E) staining 
Paraffin sections were cleared in xylene, rehydrated, stained with Mayers 
haemotoxylin and 1% (w/v) aqueous eosin (both Leica) for 5 minutes each, both 
followed by washing with dH2O. Stained sections were brought to xylene through a 
graded alcohol series and mounted with di-n-butylphthalate in xylene (DPX, RA 
Lamb).  
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2.13.2. Immunohistochemistry 
Rehydrated tissues were subjected to an antigen retrieval process by microwaving for 
10 minutes at 750W in 10 mM sodium citrate pH 6.0. Endogenous peroxidase activity 
was quenched with 3% (v/v) hydrogen peroxide in methanol and slides washed three 
times with PBS. Tissues were blocked with 10% (v/v) horse serum in phosphate-
buffered saline (PBS) containing 0.4% (v/v) Triton X-100 (T-PBS) for 30 minutes 
before incubation with primary antibodies against GFP (1:1000, rabbit polyclonal, 
Living Colours from Clontech) in blocking solution for 2 hours at room temperature. 
Slides were washed with PBS before applying appropriate biotinylated secondary 
antibodies (Vector) diluted in T-PBS for 1 hour at room temperature. Slides were 
once again washed with PBS before incubation with Elite plus ABC solution (Avidin-
biotin HRP complex, Vector) for 30 minutes at room temperature. Detection of 
immune complexes was performed using 3,3’-diaminobenzidine (DAB, Sigma-
Aldrich) as a substrate until sufficient staining had taken place. Stained sections were 
brought to xylene through a graded alcohol series and mounted with DPX. 
 
2.13.3. Adipocyte size measurement 
Two different methods were used to estimate adipocyte cell size. Live images were 
obtained using an Olympus U-CMAD3 ColorView III camera fixed upon an Olympus 
BX41 microscope. Care was taken to choose fields of view that almost exclusively 
contained adipocytes to minimize stromal and vascular areas, and all counts and 
measurements were performed blindly. 
 
2.13.3.1. Using Image J 
White adipocyte area was measured from images of subcutaneous WAT loaded onto 
Image J software by using the ‘polygon selections’ tool and a calibrated 50 µm scale 
bar. Four randomly selected fields of view were used per section, with two sections 
taken at two different medial points through the embedded tissue. Data was averaged 
per medial point, in µm2.  
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2.13.3.2. According to Ashwell et al. (1976) 
This method estimates adipocyte diameter from the number of cells in a given area.  
Epididymal WAT images were loaded onto analySIS-3.2 software, and counts were 
performed on random fields of view (350 x 263 µm) using four different fields per 
section, with two sections taken from two different medial points through each fat 
pad. Cells were included if they crossed the top or left boundaries of the field of view 
and excluded if crossing the bottom or right boundaries. 
 
Cell counts were entered into the following formula: 
 
    d’ = (2 x !A) / (m x !(n) 
 
Where d’ = estimated cell diameter (µm); A = area of region from which cells are 
counted (µm2); m = magnification of section; n = number of cells counted in region. 
 
2.14. Lipid analysis 
 
2.14.1. Lipid extraction and separation 
Levels of lipids in biological samples were analysed using gas chromatography, in 
collaboration with the laboratory of Prof. John Harwood in the Cardiff University 
School of Biosciences, with assistance from Dr Irina Guschina. Lipids were extracted 
with 2.5 ml chloroform/methanol (2:1, v/v), before addition of 1.25 ml chloroform 
and 1.25 ml Garbus solution. Extracts were centrifuged at 250 x g, with the lower 
(organic) phase dried down under a stream of nitrogen and lipids reconstituted in 
chloroform. Non-polar (e.g. triacylglycerols) and polar lipids were separated by one-
dimensional and two-dimensional thin-layer chromatography on silica gel G plates 
(Merck) respectively. Individual lipids were scraped from TLC plates and fatty acid 
! '$!
methylation performed by incubation in 3 ml H2SO4 in methanol:toluene (2:1, v/v) for 
2 hours at 70oC.  
 
2.14.2. Gas chromatography 
Methylated fatty acids were extracted twice with hexane and fatty acid profiles 
determined using a Clarus 500 gas chromatograph with a flame ionising detector 
(Perkin-Elmer 8500) fitted with a 30 cm x 0.25 mm i.d. Elite 225 capillary column. 
The oven temperature was programmed: 170ºC for 3 minutes, heated to 220ºC at 
4ºC/minute, held at 220ºC for 15 minutes. Pentadecanoate (15:0) and heptadecenoate 
(17:1) were used as internal standards and fatty acids were identified using retention 
times of fatty acid standards (Nu-Chek-Pre. Inc.). 
 
2.15. In vitro experiments 
 
2.15.1. Cell culture 
 
2.15.1.1. Mouse embryonic fibroblasts 
Primary cultures of mouse embryonic fibroblasts (MEF) from E12.5 embryos were 
maintained and differentiated as described by (Soukas et al., 2001) with slight 
modifications. Briefly, embryos were removed from the uterine horn into PBS with 
the yolk sac, head, and internal organs discarded. Remaining tissue was sheared 
through the barrel of an 18-gauge needle attached to a 2 ml syringe into cell culture 
medium, a total of three times. These cell suspensions from each individual embryo 
were plated into separate wells on 6 well tissue culture plates (Nunclon), incubated 
for 24 hours (37oC, 5% CO2) and split (using 0.05% w/v trypsin/EDTA) onto 10 cm 
plates. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) and 
F12 (1:1) containing: 
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Fetal bovine serum (FBS)    10% (v/v) 
L-glutamine      1.8 mM 
Penicillin G      100 units/ml 
Streptomycin       100 µg/ml 
(all Gibco) 
 
At confluence cells were split onto 6 well tissue culture plates or poly-L-lysine coated 
13 mm coverslips. Two days post-confluence, media was changed to a pro-
differentiation media containing: 
 
Insulin      170 nM 
Dexamethasone    250 nM 
Isobutylmethylxanthine (IBMX)   0.5 mM 
(all Sigma-Aldrich)  
Rosiglitazone  (Axxora)   2.5 nM 
 
After 2 days, this media was removed and cells were fed media containing only 
insulin and rosiglitazone for a further 6 days. Cells were fixed, or harvested for RNA 
on day 0, 2, 5 and 8 respective to addition of the first differentiation regimen.  
 
2.15.1.2. Stable cell lines 
3T3-L1 preadipocytes were a kind gift from Dr Justin Rochford, Institute of 
Metabolic Science, Cambridge University. Both 3T3-L1 preadipocytes and 3T3 
fibroblasts were maintained in DMEM containing: 
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Newborn calf serum (Sigma-Aldrich) 10% (v/v) 
L-glutamine     1.8 mM 
Penicillin G     100 units/ml 
Streptomycin      100 µg/ml 
 
3T3-L1 preadipocytes were always passaged before they reached 70% confluence. 
For differentiation of 3T3-L1 preadipocytes, 2 day post confluent cells were switched 
to media containing 10% FBS rather than new born calf serum, and also: 
 
Insulin      1 µM 
Dexamethasone    1 µM 
Isobutylmethylxanthine (IBMX)   0.5 mM 
 
Cells were incubated in this pro-differentiation media for 2 days and then switched to 
the same differentiation media but without dexamethasone or IBMX for 2 further 
days. After this point cells were fed media containing FBS but with no pro-
differentiation agents for 6 more days, with media changed every 2 days.  
 
MG1361 cells were cultured in Williams E media containing:  
 
FBS      10% (v/v) 
L-glutamine     1.8 mM 
Penicillin G     100 units/ml 
Streptomycin      100 µg/ml 
Non essential amino acids   0.1 mM 
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For experiments involving expression analysis in response to IBMX treatment, 
subconfluent cultures of 3T3, 3T3-L1 and MG1361 cells were fed respective passage 
media plus 0.5 mM IBMX, with cells harvested for RNA after 2, 12 and 48 hours 
after introduction of IBMX. 
 
2.15.2. ERK activation assay 
3T3 cells were incubated with lentivirus particles for 48 hours at approximately 40% 
confluence as described in section 2.6.4. Subconfluent cultures were serum-starved 
overnight for 16 hours and cells harvested for protein analysis prior to re-feeding, and 
15, 30, 60 and 120 minutes after re-feeding with serum-containing passage media.  
 
2.15.3. Immunocytochemistry 
Cells growing on 13 mm coverslips were fixed with 4% (w/v) paraformaldehyde 
(Sigma-Aldrich) in PBS for 10 minutes at 4oC, washed twice with PBS, and blocked 
in 10% (v/v) goat serum and 0.1% (v/v) Triton X-100 in PBS for 1 hour at room 
temperature. After blocking, coverslips were incubated with primary antibodies 
against mouse $-synuclein (1:100, SK23, (Buchman et al., 1998b)) for 2 hours at 
room temperature, followed by washing twice with PBS. Appropriate AlexaFluor 
fluorescent secondary antibodies were then applied including counterstaining with 1 
µM Bodipy 493/505 (both Molecular Probes). Coverslips were subsequently washed 
with PBS, and mounted using Immu-mount aqueous mounting media (Thermo 
Scientific), and left to dry overnight in the dark. Fluorescent images were captured on 
a Leica TCS SP2 laser scanning confocal microscope.  
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2.16. Statistical analysis 
One Way Analysis of Variance tests (ANOVA) were employed to test for statistical 
differences between data sets, with data checked for normal distribution and equal 
variance using Anderson-Darling and Bartlett’s tests respectively. Data sets meeting 
both these criteria were considered to be parametric, and so ANOVA used in these 
cases. Where data was non-parametric, a Kruskal-Wallis test was used on 
untransformed data, with post hoc pair wise comparison made using a Fisher’s a 
priori test. Differences between pairs of data were analysed using two-sample Student 
t-tests or the Mann-Whitney U-test as the non-parametric equivalent. In these cases, 
distribution of normality and equality of variance were tested by Anderson-Darling 
and an F-test respectively. As previously, data that did not conform to these 
parameters were considered non-parametric. All calculations were made using 
Minitab 15, with a probability of error less than 5% considered significant (p<0.05).  
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Chapter 3 - WAT expression of $-synuclein 
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3.1. Overview 
Previous studies have demonstrated significant levels of $-synuclein in white adipose 
tissue (Frandsen et al., 2009; Oort et al., 2008). Moreover, the expression of $-
synuclein in WAT of obese humans is increased, and this upregulation is reversed 
upon calorific restriction (Oort et al., 2008). We have demonstrated high levels of 
both $-synuclein RNA and proteins in epididymal and subcutaneous fat depots in 
mice using Northern blotting, quantitative RT-PCR and Western blotting (Fig. 1.5-
1.7). To determine whether $-synuclein expression in murine WAT is nutritionally 
regulated, as is the case in human WAT, we employed a mouse model of diet-induced 
obesity, using a high fat diet known to cause obesity in wild type mice (Van Heek et 
al., 1997). This chapter discusses both the cell-type specific expression of $-synuclein 
in WAT and its subcellular localization, followed by the dynamics of $-synuclein 
expression in response to high fat diet feeding and calorific restriction in wild type 
mice. 
 
3.2.1. Results: Cell-specificity and subcellular localisation of $-synuclein in 
murine WAT 
WAT is made up of a number of cell types, including mature adipocytes, 
preadipocytes, vascular cells and immune cells. To determine whether expression of 
$-synuclein is restricted to the mature adipocytes or could also be found in WAT 
stromal cells, we obtained fractions enriched in these cell populations. Epididymal 
WAT from wild type mice was digested with collagenase in Krebs-Ringer 
bicarbonate medium and stromal cells pelleted by centrifugation, whilst mature 
adipocytes floated to the top of the buffer. These cell fractions were homogenized 
directly in SDS-PAGE loading buffer and proteins analysed by semi-quantitative 
Western blotting using antibodies against mouse $-synuclein (Buchman et al., 1998b). 
This work demonstrated that $-synuclein is expressed in the mature adipocyte but not 
the preadipocyte-containing stromal cell fraction of this tissue, with levels of GAPDH 
protein used to confirm similar levels of total protein in each lane (Fig. 3.1). 
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Fig. 3.1. Cell-specific expression of $-synuclein in murine WAT. Western blot 
analysis of $-synuclein expression in the total cell lysates of stromal-vascular (SV) 
and mature adipocyte fractions from epididymal WAT of wild type mice. A lysate of 
epididymal WAT of a $-synuclein-/- mouse ($-/- WAT) was included as control for 
specificity of antibodies. GAPDH was used as a loading control. 
 
*  *  * 
 
Subcellular fractionation was employed to reveal compartmentalisation of $-synuclein 
in murine white adipocytes. Isolated mature adipocytes from epididymal WAT of 
wild type mice were subjected to subcellular fractionation, first by lysis in a 
hypotonic sucrose buffer followed by centrifugation to pellet nuclei, whilst the lipid 
droplet-containing fat cake fraction rose to the top of the buffer. Both these fractions, 
as well as the supernatant beneath the fat cake (infranate), were diluted or re-
suspended in SDS-PAGE loading buffer and the proteins contained within each 
fraction were analysed by semi-quantitative Western blotting. Presence of marker 
proteins histone 3 and perilipin A were used to demonstrate efficient fractionation of 
nuclear and lipid-droplet fractions respectively (Fig. 3.2A). $-synuclein was recovered 
in the infranatant containing cytosol and membranes and was absent from the nuclear 
fraction (Fig. 3.2A). No $-synuclein was detected in the fraction containing lipid 
droplet-associated proteins either in the presence or absence of lipolytic stimulation, 
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achieved by incubation of purified mature adipocytes with the non-specific !-
adrenergic agonist, isoproterenol prior to cell lysis. This stimulation was sufficient to 
induce the translocation of hormone sensitive lipase (HSL) and phosphorylation at its 
catecholamine-sensitive regulatory phosphorylation site, serine 563 (Garton et al., 
1988; Stralfors et al., 1984) (Fig. 3.2A). Immunofluorescent staining of adipocytes 
differentiated from MEFs in vitro, using antibodies against mouse $-synuclein 
(Buchman et al., 1998b) also did not suggest an association of $-synuclein with lipid 
droplets, which were revealed by staining with the fluorescent neutral lipid stain, 
Bodipy 493/505. Instead, $-synuclein immunostaining revealed a diffuse, partly 
punctuate pattern throughout the cell cytoplasm (Fig. 3.2B). 
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Fig. 3.2. Subcellular localization of $-synuclein in WAT and MEF adipocytes. (A) 
Subcellular localization of $-synuclein in mature white adipocytes isolated from 
epididymal WAT of wild type mice and incubated for 30 minutes in the presence or 
absence of 10 µM isoproterenol. Proteins in the pellet (P), supernatant (SN) and fat 
cake (FC) fractions obtained after cell lysis in a hypotonic sucrose buffer were 
analysed by Western blotting using antibodies against $-synuclein and protein 
markers for each fraction. (B) Immunofluorescent staining of MEF differentiated into 
adipocytes in culture with antibodies against $-synuclein (red) and counterstained 
with the neutral lipid stain, Bodipy 493/505 (green). Scale bar = 20 µm. 
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3.2.2. Results: Nutritional regulation of $-synuclein in murine WAT 
To determine whether $-synuclein expression in murine WAT is nutritionally 
regulated we used a mouse model of high fat diet (HFD)-induced obesity. From the 
age of 9 weeks wild type mice were fed either a low fat (LFD) or HFD for 11 weeks 
(Van Heek et al., 1997) and expression of $-synuclein mRNA in WAT depots was 
measured by quantitative RT-PCR. Consistent with what was found in human adipose 
tissue, the level of $-synuclein mRNA was dramatically increased in both epididymal 
and subcutaneous adipose tissue (approximately 3 and 4-fold respectively) of mice 
fed a high fat diet for 11 weeks comparing with mice fed a control LFD for 11 weeks 
(Fig. 3.3A). This upregulation was also reversible upon calorific restriction. Levels of 
$-synuclein mRNA in both epididymal and subcutaneous WAT depots were 
decreased by approximately 50% after mice fed a HFD for 10 days were switched to a 
low fat diet (LFD) for 36 hours. When mice fed HFD for 10 days were switched to a 
LFD for 1 week or fasted for 36 hours, this reduction was more prominent, with levels 
of $-synuclein mRNA decreased by approximately 80% and 65% in epididymal and 
subcutaneous WAT depots respectively (Fig. 3.3B). Using semi-quantitative Western 
blotting and antibodies against mouse $-synuclein (Buchman et al., 1998b), levels of 
$-synuclein protein in epididymal WAT depots from these mice were also measured. 
Generally, changes in $-synuclein protein abundance following dietary manipulation 
were congruent with the changes in mRNA expression in this depot, with a similar 3-
fold increase of $-synuclein protein levels in mice fed a HFD for 11 weeks comparing 
with mice fed a control LFD for 11 weeks (Fig. 3.3C and Appendix 2). Consistently 
with results of mRNA expression analysis, we observed a similar (~75%) reduction in 
$-synuclein protein abundance when mice fed HFD for 10 days were switched to a 
LFD for 1 week or fasted for 36 hours (Fig. 3.3C and Appendix 2). The only obvious 
disparity between changes in mRNA and protein abundance observed in these 
experiments was for a group of mice switched from a 10 day HFD feed to a LFD for 
36 hours. The ~50% decrease in mRNA levels in epididymal WAT of this group was 
not followed by similar decrease at the protein level (Fig. 3.3C and Appendix 2). 
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Fig. 3.3. WAT expression of $-synuclein in response to changes in nutritional 
status in mice – previous page. (A) Quantitative RT-PCR analysis of $-synuclein 
mRNA expression in epididymal (ED, n=8) and subcutaneous (SC, n=4) WAT of 
wild type mice fed a low fat (LFD) or high fat diet (HFD) for 11 weeks. Results are 
shown as mean±SEM of fold change compared with LFD fed mice. (B) Quantitative 
RT-PCR analysis of changes $-synuclein mRNA expression in epididymal and 
subcutaneous WAT of mice fed a HFD for 10 days and then given LFD for 36 hours, 
1 week, fasted for 36 hours or maintained on HFD as controls. Results are shown as 
mean±SEM fold change compared with HFD fed controls (n=3-5).  (C) Western blot 
analysis of $-synuclein expression in epididymal WAT of the same wild type mice 
that were used for RT-PCR analysis shown in panels D and E. GAPDH was used as a 
loading control. Non-parametric Mann-Whitney U-test analysis demonstrated 
statistically significant differences between groups (* p < 0.05, ** p < 0.01, *** p < 
0.001). 
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3.3. Summary of results and discussion 
To assess whether expression of $-synuclein in murine WAT is nutritionally 
regulated, as is the case in human WAT (Oort et al., 2008), we employed a mouse 
model of HFD-induced obesity and measured dynamics of $-synuclein expression. 
Similar to the upregulation seen in obese humans, wild type mice fed HFD showed 
increased expression of $-synuclein compared to wild type mice fed a control LFD, 
both at the RNA and protein level. (Oort et al., 2008) also demonstrated that this 
upregulation could be reversed upon calorific restriction of obese patients. In wild 
type mice fed HFD, we have shown rapid reduction of $-synuclein mRNA and protein 
levels upon introduction of feeding with LFD or fasting. Overall, expression 
dynamics of $-synuclein in WAT appear to be under similar nutritional regulation in 
both humans and mice. 
In this section we have also demonstrated that $-synuclein expression is restricted to 
the mature adipocyte fraction of WAT, with no expression detected in the 
preadipocyte-containing stromal fraction. In addition we have shown that $-synuclein 
is localized exclusively to the cytosol of adipocytes both in vivo and in vitro, and no 
apparent association with lipid droplets. 
Overall, results in this section suggest that the high levels of $-synuclein in WAT may 
play a role in lipid metabolism in mature white adipocytes, but probably not by direct 
influence on TAG storage at the lipid droplet surface. This data also indicates a 
possible role for $-synuclein in the development of certain forms of obesity. To 
address this possibility, we investigated the effect of $-synuclein deficiency in a 
mouse model of HFD-induced obesity and these findings are discussed in the next 
chapter. 
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Chapter 4 – Effect of $-synuclein-/- 
in a mouse model of HFD-induced obesity 
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4.1. Overview 
The previous chapter described nutritional regulation of $-synuclein expression in 
mature white adipocytes, with upregulation both at the RNA and protein level upon 
introduction of HFD feeding in mice. This led us to investigate whether $-synuclein 
plays a role in the development of certain forms of obesity. To achieve this, we used 
mice with targeted inactivation of the $-synuclein gene ($-synuclein-/- mice), which 
have been previously created and characterised in our laboratory (Ninkina et al., 
2003). These animals do not show any obvious neuronal phenotype, even in neuronal 
populations where $-synuclein is most highly expressed (Ninkina et al., 2003; 
Papachroni et al., 2005). Moreover they do not display any sign of metabolic 
abnormalities when kept in conventional husbandry and diet conditions (our 
unpublished observations). We challenged these $-synuclein-/- mice and their wild type 
littermates with the same HFD as discussed in the previous chapter, to determine 
whether deficiency of $-synuclein affects HFD-induced WAT accumulation and 
overall body weight gain. Mouse weights and food consumption during the HFD 
feeding protocol were recorded, with MRI employed to monitor body fat composition. 
This chapter discusses the effect of $-synuclein deficiency in a mouse model of HFD-
induced obesity, as well as the analysis of obesity-related metabolic disorders in these 
mice.  
 
4.2.1. Results: $-synuclein-/- mice are resistant to diet-induced obesity  
9-week old $-synuclein-/- and wild type male mice were fed a HFD or a control LFD 
for a period of 11 weeks. Mice were single caged and both body weights and food 
consumption were measured weekly. At the beginning of the feeding protocol, no 
statistically significant differences in animal weight existed between any of the four 
groups. Mice of both genotypes fed LFD did not show any differences in weight gain 
throughout the duration of the 11 weeks, and indeed, at the end of the LFD-feeding 
protocol, there was no statistically significant difference in weights between wild type 
and $-synuclein-/- mice (Fig. 4.1). As expected, HFD feeding caused weight gain in 
both HFD-fed groups. However, HFD-feeding caused only modest gradual weight 
gain in $-synuclein-/- mice and they remained substantially leaner than their HFD-fed 
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wild type counterparts throughout the duration of the feeding protocol (Fig. 4.1). This 
difference was already statistically significant after 1 week of HFD feeding (p < 0.01). 
After 11 weeks of HFD feeding, wild type mice gained on average 53% of their 
original weight, compared to 34% in $-synuclein-/- mice. Further calculations showed 
that at the end of the study, $-synuclein-/- mice were on average only 16% heavier on 
HFD compared to LFD, compared to an average of 33% in wild type mice. 
Quantitative MRI analysis of body fat volume was performed on at the start of the 
dietary intervention or after 6 or 11 weeks on LFD or HFD. MRI scans of 
anaesthetized mice were uploaded onto custom written software ‘FAT’ which was 
provided for us by Stephen Paisey and Pavel Tokarchuk of the Experimental MRI 
Centre, Cardiff University. This software enabled generation of fat only images as 
well as user directed fat pad volume measurement. This analysis firstly revealed no 
differences in total body fat pad volume between all four experimental groups at the 
beginning of the experiment (Fig. 4.2). In addition to this, we observed a similar total 
fat pad volume between mice of both genotypes on LFD throughout the feeding 
protocol. As expected, HFD feeding caused substantial WAT accumulation, however 
this increase was attenuated in HFD-fed $-synuclein-/- mice compared to HFD-fed 
wild type mice (~8 fold increase in wild type and ~6 fold in $-synuclein-/- mice) (Fig. 
4.2). This attenuation was statistically significant after 11 weeks of HFD feeding (p < 
0.05) and was consistent with overall changes in total mouse body weight between the 
two HFD-fed groups. The reduced WAT accumulation seen in HFD-fed $-synuclein-/- 
compared to HFD-fed wild type mice was confirmed at the end of the feeding 
protocol following Schedule 1 sacrificing of experimental mice, and determining 
whole fat pad mass of dissected epididymal, subcutaneous and retroperitoneal depots, 
as well as fat pad mass to body mass ratios for all three depots (Fig. 4.3 and Appendix 
3). These data also demonstrated the increase in both fat pad mass and fat pad mass to 
body mass ratio of these three major depots upon HFD feeding in both genotypes 
(Fig. 4.3 and Appendix 3). 
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Fig. 4.1. Raw weights of wild type and $-synuclein-/- mice fed LFD or HFD. 
Dynamics of total body weight changes of wild type (+/+) and $-synuclein-/- mice (-/-) 
fed a LFD or HFD for 11 weeks. Results are shown as mean weight±SEM (n=12-15). 
Non-parametric Mann-Whitney U-test analysis demonstrated a statistically significant 
difference between wild type and $-synuclein-/- mice on HFD (** p < 0.01). 
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Fig. 4.2. Quantification of body fat volume by MRI. (A) MRI scans of wild type 
and $-synuclein-/- mice at the beginning (9w), middle (15w) and end (20w) of an 11 
week feed with either LFD or HFD. Two whole-body 2D RARE scans were used to 
generate fat only images (fat shown in white) by the subtraction of the fat suppressed 
image from the non-suppressed image. (B) MRI scans were used to quantify fat 
volume using custom written software ‘FAT’ (n=4 animals). Non-parametric Mann-
Whitney U-test analysis demonstrated a statistically significant difference between 
wild type and $-synuclein-/- mice on HFD (* p < 0.05). 
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Fig. 4.3. WAT mass to body mass ratios. Total epididymal (ED), subcutaneous (SC) 
and retroperitoneal (RP) WAT mass to body mass ratios of wild type (+/+) and $-
synuclein-/- (-/-) mice fed a LFD or HFD for 11 weeks (n=12-14). Bar charts represent 
mean±SEM. Non-parametric Mann-Whitney U-test analysis demonstrated statistically 
significant differences between groups (* p < 0.05, *** p < 0.001). 
 
To check whether or not the observed differences in WAT accumulation between 
HFD-fed wild type and $-synuclein-/- mice were due to any differences in calorific 
intake or absorption of lipids from the diet, we assessed both, by measuring food 
consumption as well as faecal lipid content. Taking into consideration the calorific 
value of each diet, we did not observe any statistically significant differences in 
calorific intake between all four experimental groups (Fig. 4.4A). To measure 
absorption of lipids from the diet, 3-4 faecel pellets were collected per day from each 
mouse cage over week 8 of the HFD feeding protocol, and following extraction the 
total lipid content was assessed using gas chromatography. We did not observe any 
difference between the levels of total lipids in faecel pellets from HFD-fed wild type 
and $-synuclein-/- mice, suggesting that lipid absorption from the diet is similar in both 
groups of mice (Fig. 4.4B). 
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To determine whether reduced WAT accumulation on HFD in $-synuclein-/- mice is 
due to reduced adipocyte size or number, we measured the area (using ImageJ, see 
Experimental Procedures) of individual white adipocytes in H&E stained histological 
sections of subcutaneous WAT, taken from wild type or $-synuclein-/- mice fed LFD 
or HFD for 11 weeks. White adipocytes were of similar size in LFD-fed mice of both 
genotypes (Fig. 4.5A, B). However, upon HFD-feeding the average adipocyte size 
increased by ~4.5 fold in subcutaneous WAT of wild type mice compared to an 
increase of ~2.4 fold in $-synuclein-/- mice (Fig. 4.5A, B). Similar differences between 
the four experimental groups were observed when cell diameter was quantified using 
H&E stained sections through epididymal WAT, using a different quantification 
method (according to (Ashwell et al., 1976), see Experimental Procedures) (Fig. 
4.5C). Using this method, we observed a ~2.2 fold increase in cell diameter upon 
HFD-feeding in epididymal WAT of wild type mice compared to an increase of ~1.8 
fold in $-synuclein-/- mice (Fig. 4.5C). To investigate whether the lack of $-synuclein 
affected adipocyte size in a cell-autonomous manner we performed localised rescue of 
$-synuclein expression by local injection of $-synuclein-expressing lentivirus in the 
subcutaneous adipose tissue of $-synuclein-/- mice prior to the 11-week HFD feeding 
protocol. We employed a recombinant lentivirus expressing a single mRNA that 
translated into both $-synuclein and GFP due to the presence of an internal ribosome 
binding site (IRES) upstream of the GFP open reading frame. Each animal also 
received injections of control lentivirus expressing only GFP into their contralateral 
subcutaneous WAT depot. Thus, we were able to identify transduced adipocytes in 
both ipsilateral and contralateral subcutaneous fat depots by immunostaining with the 
same anti-GFP antibody. Lentivirus particles were produced in collaboration with the 
laboratory of Dr Riccardo Brambilla based in the Institute of Experimental 
Neurology, San Raffaele Foundation and University, Milano. At the end of the 
feeding protocol we dissected out parts of the ipsilateral and contralateral 
subcutaneous WAT depots surrounding the injection site under a fluorescent 
dissecting microscope (Fig. 4.6Ai). Fixed WAT was then sectioned and 
immunostained with antibodies against GFP to identify transduced and non-
transduced cells in both subcutaneous WAT depots. Light microscope images were 
uploaded onto Image J to quantify cell area (Fig. 4.6Aii). Following 11 weeks on 
HFD we observed a statistically significant increase in size of adipocytes transduced 
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with $-synuclein-expressing lentivirus when compared either to adjacent non-
transduced cells (~27% increase) or to cells transduced with a control lentivirus 
expressing only GFP in the contralateral WAT depot of the same animal (~21% 
increase) (Fig. 4.6B). Overall this data strongly suggests that regulation of $-synuclein 
within the fat cell specifically and cell-autonomously affects adipocyte size in vivo.  
 
 
 
 
 
Fig. 4.4. Calorific intake and faecal lipid content. (A) Calorific intake of wild type 
(+/+) and $-synuclein-/- (-/-) mice fed either LFD or HFD for 11 weeks (n=12-15). (B) 
Faecal lipid content of wild type and $-synuclein-/- mice fed HFD. Samples were 
collected over the 8th week of an 11-week HFD feed (n=3 animals). Bar charts 
represent mean±SEM. 
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Fig. 4.5. Adipocyte size quantification in epididymal and subcutaneous WAT. (A) 
H&E stained sections through subcutaneous WAT taken from wild type ($ +/+) and $-
synuclein-/- ($ -/-) mice fed a LFD or HFD for 11 weeks, scale bar = 50 µm. (B) Using 
these images, average white adipocyte area for these groups was quantified using 
ImageJ (n=3 animals/12 sections, per group). (C) White adipocyte diameter was also 
quantified using H&E stained sections through epididymal WAT of wild type and $-
synuclein-/- mice fed a LFD or HFD for 11 weeks (n=3 animals/12 sections, per 
group). Bar charts represent mean±SEM. Non-parametric Mann-Whitney U-test 
analysis demonstrated statistically significant differences between groups (** p < 
0.01). 
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Fig. 4.6. Size of adipocytes from $-synuclein-/- mice with local re-expression of $-
synuclein by lentivirus delivery. (A) (i) Fluorescent microscope image of a whole 
subcutaneous fat pad from a $-synuclein-/- mouse showing adipocytes transduced with 
GFP-expressing lentivirus (inset). (ii) Histological sections through these 
subcutaneous fat pads were immunostained with antibodies against GFP to identify 
transduced (*) and non-transduced (#) cells (see Experimental Procedures). Scale bar 
= 50 µm. (B) Average adipocyte area was quantified using ImageJ on anti-GFP 
antibody-stained sections of subcutaneous WAT of $-synuclein-/- mice that received 
local injection of either $-synuclein-expressing lentivirus ($) or control GFP-only-
expressing lentivirus (GFP) into subcutaneous WAT followed by feeding HFD for 11 
weeks (see Experimental Procedures for details, n=3 animals/12 sections per group, 
minimum of 600 adipocytes). Bar chart shows means±SEM (** p < 0.01, Mann-
Whitney U-test). 
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WAT depots expand by hypertrophy of mature adipocytes, but also by hyperplasia 
and terminal differentiation of preadipocytes. We planned to determine whether 
adipocyte development might also contribute to differences in WAT accumulation 
between HFD-fed $-synuclein-/- and wild type mice. To do this we used mouse 
embryonic fibroblasts (MEFs) isolated from E12.5 embryos of wild type or $-
synuclein-/- mice and differentiated these cells into adipocytes in culture. cDNA 
synthesized using total RNA extracted from these cells was first used to identify if the 
same $-synuclein mRNA transcript found in WAT was present in MEFs from wild 
type mice. Indeed, primers specific for amplification of regions representing either a 
5’ or 3’ region of the mouse $-synuclein mRNA transcript produced the same (126 
and 112 bp respectively) fragment using cDNA from MEFs as was seen using cDNA 
from WAT (Fig. 4.7). Following differentiation, MEF adipocytes were harvested for 
total RNA with subsequent cDNA synthesis. Quantitative PCR analysis revealed the 
appearance of adipocyte-specific transcripts over the differentiation period, including 
the fatty acid transporter aP2, the critical adipogenic transcription factor peroxisome 
proliferator-activated receptor-$ (PPAR$) and the lipid droplet protein perilipin A. 
However, no differences were observed in the induction of these adipocyte genes 
during cell differentiation between $-synuclein-/- and wild type MEFs (Fig. 4.8). These 
data suggest that loss of $-synuclein does not affect the adipogenic capacity of 
precursor cells. 
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Fig. 4.7. PCR analysis of the $-synuclein mRNA transcript using cDNA from 
WAT and MEFs. (A) cDNA was synthesized using total RNA from wild type adult 
mouse epididymal white adipose tissue (WAT cDNA) and mouse embryonic 
fibroblasts (MEF cDNA) from E12.5 embryos. Specific primers were used to amplify 
fragments at the 5’ (5’, 126 bp) or 3’ (3’, 112 bp) end of the mouse $-synuclein 
mRNA transcript. Amplification of GAPDH cDNA was used as a control. (B) 
Structure of the mouse $-synuclein locus with 5 exons (black boxes, numbered with 
roman numerals). Two pairs of primers were used to amplify fragments at either the 
5’ end (between the ATG site and the start of exon II) or the 3’ end (between the end 
of exon III and the start of exon V). 
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Fig. 4.8. Adipocyte differentiation of mouse embryonic fibroblasts (MEFs) in 
culture. (A-C) MEFs were isolated from E12.5 embryos of wild type (+/+) and $-
synuclein-/- (-/-) mice and exposed to a pro-differentiation regimen in culture for 8 
days. mRNA expression of adipocyte-specific transcripts during MEF differentiation 
was analysed by quantitative RT-PCR. Results are shown as mean fold change 
compared with transcript levels at day 0 of wild type MEFs (n=6). In all graphs, 
means±SEM is shown. 
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4.2.2. Results: Loss of $-synuclein rescues mice from HFD-induced 
hyperinsulinaemia and hepatosteatosis 
We next assessed the effect of $-synuclein deficiency on whole-body metabolism. 
Restricting adiposity in the face of nutrient excess may lead to an increase in 
circulating lipids and ectopic lipid accumulation in non-adipose tissues, causing or 
exacerbating insulin resistance and metabolic disorders. Therefore, we determined 
triacylglycerol (TAG) levels in the liver and plasma of wild type and $-synuclein-/- 
mice fed LFD or HFD for 11 weeks. To do this, total lipids were extracted from either 
liver tissue or plasma and TAG separated by thin-layer chromatography (TLC). TAG 
levels were measured using gas chromatography, by quantifying total fatty acid 
methyl esters (see Experimental Procedures). No differences were observed in the 
levels of hepatic or plasma TAG in wild type and $-synuclein-/- mice fed a LFD (Fig. 
4.9A, B). In contrast, whilst HFD feeding resulted in an approximately two-fold 
increase in both hepatic and plasma TAG levels in wild type mice, no increase in liver 
or plasma TAG was observed in $-synuclein-/- mice (Fig. 4.9A, B). We also performed 
histological examination of H&E stained sections through fixed liver and BAT. This 
analysis revealed that the absence of $-synuclein protected the liver from the 
development of extensive hepatosteatosis, which was a characteristic feature of HFD-
fed wild type mice (Fig. 4.9C). Similarly, whilst HFD-feeding dramatically altered the 
morphology of BAT in wild type mice with the appearance of much larger lipid 
droplets, this was significantly attenuated in $-synuclein-/- mice (Fig. 4.9C). 
We also measured the levels of plasma non-esterified fatty acids (NEFA), ketone 
bodies and adiponectin in all four experimental groups of mice. Plasma NEFA levels 
were determined by extraction of total lipids from plasma, separation of NEFA from 
other lipid species by TLC and quantification by gas chromatography. Plasma levels 
of ketone bodies and adiponectin were measured using commercially available kits. 
Overall, the absence of $-synuclein had no effect on the levels of plasma NEFA, 
ketone bodies or adiponectin on LFD or HFD for 11 weeks (Table 4.1). We also 
performed i.p. glucose and insulin tolerance tests to determine whether $-synuclein 
deficient mice on HFD displayed any differences in the ability to clear glucose from 
the blood, or any differences in insulin sensitivity, respectively, compared to HFD-fed 
wild type control mice. GTT and ITT were performed on fasted mice during the 9th 
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and 10th week of an 11-week HFD feed respectively. GTT involved initial injection of 
D-glucose i.p. and measurement of blood glucose levels over the 2-hour period that 
followed. For ITT, mice received i.p. injection of human insulin with measurement of 
blood glucose levels over the following 1-hour period. GTT and ITT data were used 
to create curves representing blood glucose levels over time, from which the area 
under the curve (AUC) was calculated for each genotype to represent a value of 
glucose and insulin tolerance. This analysis revealed no significant differences 
between HFD-fed $-synuclein-/- and wild type mice for either GTT or ITT (Table 4.1). 
Next we assessed plasma leptin and insulin levels in wild type and $-synuclein-/- mice 
fed LFD or HFD for 11 weeks using commercially available kits. This analysis was 
performed by Dr Pieter Oort in the laboratory of Dr Sean Adams based in the 
USDA/Agricultural Research Service Western Human Nutrition Research Centre, 
California. No differences were observed in the levels of plasma leptin or insulin in 
wild type and $-synuclein-/- mice fed a LFD (Fig. 4.10A and B). Plasma leptin levels 
increased substantially in both genotypes upon HFD-feeding. However this increase 
was substantially attenuated in $-synuclein-/- mice (~5.5 fold increase in wild type 
compared to ~2.9 fold in $-synuclein-/- mice), consistent with the observed decrease in 
adiposity in these mice (Fig. 4.10A). Fasting plasma insulin levels were increased 
almost 3-fold following HFD-feeding of wild-type mice but were not raised in HFD-
fed $-synuclein-/- mice (Fig. 4.10B). Taken together, these data suggest that the 
reduced adiposity observed in $-synuclein-/- mice is associated with an improved 
metabolic profile compared with wild type mice when both are fed a HFD. 
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Fig. 4.9. Effect of $-synuclein-/- on lipid accumulation outside WAT. (A, B) Levels 
of triacylglycerols (TAG) in liver (n=5-8) and plasma (n=5-7) of wild type (+/+) and 
$-synuclein-/- mice (-/-) fed a LFD or HFD for 11 weeks. Bar charts represent 
mean±SEM. Non-parametric Mann-Whitney U-test analysis demonstrated statistically 
significant differences between groups (* p < 0.05). (C) H&E stained sections through 
brown adipose tissue (BAT) and liver taken from wild type and $-synuclein-/- mice fed 
a LFD or HFD for 11 weeks. Scale bar = 50 µm. 
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Genotype +/+ -/- +/+ -/- 
Diet 11 week LFD 11 week HFD 
     
pl. NEFA (µg/100µ l, n=6) 15.9 ± 3.5 19.5 ± 3.3 16.0 ± 2.0 20.5 ± 3.7 
pl. adiponectin (µg/ml, n=12) 77.1 ± 8.7 68.7 ± 7.6 58.3 ± 5.6 62.5 ± 3.2 
pl. ketone bodies (mM, n=6-9) 0.27 ± 0.05 0.31 ± 0.03 0.27 ± 0.04 0.24 ± 0.03 
 GTT (area under curve, n=7) - - 588 ± 107 532 ± 52 
ITT (area under curve, n=7) - - 224 ± 39 263 ± 37 
 
Table 4.1. Analysis of various metabolic markers in plasma and glucose/insulin 
tolerance testing. Levels of non-esterified fatty acids (NEFA), adiponectin and 
ketone bodies in plasma (pl.) of wild type (+/+) and $-synuclein-/- mice (-/-) fed a LFD 
or HFD for 11 weeks (GTT glucose tolerance test, ITT insulin tolerance test). 
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Fig. 4.10. Plasma levels of leptin and insulin. (A, B) Levels of leptin and insulin in 
plasma of wild type (+/+) and $-synuclein-/- (-/-) mice fed a LFD or HFD for 11 weeks 
(n=11-14). Bar charts represent mean±SEM (* p < 0.05, ** p < 0.01, Mann-Whitney 
U-test). 
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4.2.3. Results: Increased whole-body lipid utilisation and energy expenditure in 
$-synuclein-/- mice 
Given that the observed decreases both in adipose and ectopic lipid storage are not 
attributed to decreased caloric intake in the absence of $-synuclein we next examined 
substrate utilisation and energy expenditure in these mice.  During week 8 of the 11-
week HFD-feeding protocol, wild type and $-synuclein-/- mice were housed for 72 
hours in metabolic cages as part of a Comprehensive Lab Animal Monitoring System 
(CLAMS), based in the Institute of Metabolic Science, Cambridge University. Mice 
were given an acclimatisation period in these cages prior to the testing period.  
Exchange of CO2 and O2 in and out of individual cages was used to evaluate CO2 
production and O2 consumption by individual mice, which were in turn used to 
calculate respiratory exchange ratio (RER) and energy expenditure by indirect 
calorimetry. Over this 72-hour testing period, $-synuclein-/- mice had a significantly 
lower average RER (0.779 compared with 0.807 in wild type mice, Fig. 4.11A). A 
RER closer to 1.0 is indicative of carbohydrate usage as the main fuel source, whereas 
a RER nearer to 0.7 indicates that fat is being used primarily. HFD-fed $-synuclein-/- 
mice also exhibited increased energy expenditure, during the light cycles (Fig. 4.11B). 
Consistent with this difference in RER between genotypes, further analysis to 
calculate both lipid and carbohydrate oxidation (again using VCO2 and VO2, as well 
as known constants, see Experimental Procedures) demonstrated both increased lipid 
oxidation and reduced carbohydrate oxidation in $-synuclein-/- compared to wild type 
mice (Fig. 4.12A, B). During the 72-hour testing period, the physical activity of 
individual mice was also measured using the number of horizontal beam breaks. 
Analysis of this data showed that, surprisingly, the increased energy expenditure 
observed in $-synuclein-/- mice was despite lower levels of physical activity, mainly 
during the dark cycles (Fig. 4.13). 
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Fig. 4.11. Whole-body metabolic analysis. (A) Respiratory exchange ratio (RER) 
calculated by indirect calorimetry using CLAMS over a period of 72 hours in wild 
type (+/+) and $-synuclein-/- (-/-) mice fed a HFD for 8 weeks at time of trial (n=8 per 
genotype). (B) Energy expenditure by these animals over the same period. Black bars 
indicate periods of dark cycles. In both panels, individual values represent 
mean±SEM (* p < 0.05, ** p < 0.01, Student’s t-test). 
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Fig. 4.12. Substrate utilization during CLAMS analysis. (A, B) Fatty acid (NEFA) 
and carbohydrate (CHO) oxidation calculated by indirect calorimetry using CLAMS 
over a period of 72 hours in wild type (+/+) and $-synuclein-/- (-/-) mice fed a HFD for 
8 weeks at time of trial (n=8 per genotype). Black bars indicate periods of dark cycles. 
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Fig. 4.13. Physical activity during CLAMS analysis. Physical activity during 72-
hour CLAMS analysis of wild type (+/+) and $-synuclein-/- (-/-) mice fed a HFD for 8 
weeks at time of trial (n=8 per genotype). Black bars indicate periods of dark cycles. 
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4.3. Summary of results and discussion 
With the observed nutritional regulation of $-synuclein in murine and human WAT, 
we hypothesized that expression of $-synuclein may be required for the development 
of at least certain forms of obesity. To test this we used $-synuclein-/- mice that had 
previously been produced and characterized in our laboratory. Under conventional 
husbandry and diet conditions, these animals do not show any obvious neuronal 
(Ninkina et al., 2003; Papachroni et al., 2005) or metabolic abnormalities (our 
unpublished observations). These $-synuclein-/- mice were challenged with a HFD 
known to cause diet-induced obesity in wild type mice. 
Following the control LFD-feeding protocol, wild type and $-synuclein-/- mice showed 
no differences in weight gain, consistent with the lack of any difference in animal 
weight that we have previously observed in our cohorts of $-synuclein-/- mice 
compared with their wild type littermates. In contrast to this, HFD-fed $-synuclein-/- 
mice were substantially leaner than their HFD-fed wild type counterparts throughout 
the duration of the feeding protocol. This difference was mirrored by a reduction in 
the amount of WAT accumulated by $-synuclein-/- compared to wild type mice on 
HFD. Reduced WAT accumulation in $-synuclein-/- mice was not due to reductions in 
either food intake or absorption of lipids from the diet. At the cellular level, 
measuring the size of white adipocytes from epididymal and subcutaneous WAT 
revealed that the increase of adipocyte size upon HFD-feeding in wild type mice was 
attenuated in $-synuclein-/- mice. Moreover, injection of $-synuclein-expressing 
lentiviral particles into the fat pads of $-synuclein-/- mice before challenging them with 
HFD partially reversed this observed decrease in adipocyte size. Critically, this was 
only seen in those adipocytes re-expressing $-synuclein and not in non-transduced 
cells in the same depot, nor cells transduced with a control lentivirus expressing only 
GFP. This data suggests that regulation of $-synuclein within the fat cell specifically 
and cell-autonomously affects adipocyte size in vivo. As expression of $-synuclein is 
not restricted to white adipocytes, but is also found within various regions of the 
central and peripheral nervous system, we cannot exclude that the absence of $-
synuclein in non-WAT tissues also contributes to observed differences between wild 
type and $-synuclein-/- mice on HFD described in this chapter, such as the increased 
energy expenditure or decreased hepatic steatosis. However this finding demonstrates 
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the importance of WAT $-synuclein expression on expansion of this tissue during 
periods of increased intake of lipids from the diet. 
As well as hypertrophy of mature adipocytes, expansion of WAT depots occurs by 
hyperplasia and terminal differentiation of preadipocytes. We have observed that 
reduced adiposity between $-synuclein-/- and wild type mice on HFD is due to 
differences in mature adipocyte hypertrophy, however our data suggests that $-
synuclein does not appear to play a major role in adipocyte differentiation from 
precursor cells. We have demonstrated that $-synuclein-/- mouse embryonic fibroblasts 
(MEFs) differentiated into adipocytes as efficiently and with the same kinetics as wild 
type MEFs. Hence it seems that the decreased WAT accumulation in $-synuclein-/- 
mice on HFD is not caused by a reduced capacity to expand adipose depots when 
required, but that lipid storage in individual adipocytes is reduced. This is important 
as human syndromes of lipodystrophy as well as mouse models of limited WAT 
expansion, demonstrate that restricting adipose mass leads to dyslipidaemia, insulin 
resistance and metabolic disease (Schweiger et al., 2009; Moitra et al., 1998). 
Therefore, if modification of $-synuclein expression was to be employed as a 
therapeutic intervention aimed at improving obesity related metabolic disease; it is 
important to note that this method would not affect adipocyte formation. 
Reduced adiposity does not always coincide with an improvement in whole-body 
metabolic function. Moreover these alterations in fat metabolism can result in 
aberrant increase of lipids in the circulation and their deposition in non-adipose 
tissues, which are metabolically vulnerable. This however was not the case in HFD-
fed $-synuclein-/- mice. Instead we found that $-synuclein ablation rescues mice from 
HFD-induced metabolic disturbances, with protection from hypertriglyceridaemia, 
hepatic steatosis, hyperinsulinaemia and hyperleptinaemia. All of these signs of a 
metabolic disorder were a characteristic feature of HFD-fed wild type mice. Similar 
food intake between HFD-fed wild type and $-synuclein-/- mice despite significantly 
reduced plasma leptin levels in $-synuclein-/- mice, suggests that $-synuclein-/- mice 
are more leptin sensitive than their wild type counterparts on HFD. Although fasting 
plasma insulin levels in HFD-fed groups suggest that unlike their wild type 
counterparts, $-synuclein-/- mice do not display insulin resistance, we saw no 
improvement in glucose or insulin tolerance in these $-synuclein-/- mice. Overall, 
! "+"!
although deficiency of $-synuclein may render mice resistant to HFD-induced obesity, 
and rescue them from obesity-related hyperinsulinaemia, it does not cause these mice 
to be any more insulin-sensitive on HFD. Upon metabolic analysis of HFD-fed mice, 
we have also revealed that reduced adiposity in $-synuclein-/- mice was associated with 
increased whole-body lipid oxidation and energy expenditure, despite reduced levels 
of physical activity, all compared to HFD-fed wild type mice. A number of other 
mouse models, reported to be lean compared to control animals, also have elevated 
WAT NEFA oxidation with no increase in plasma NEFA (Martinez-Botas et al., 
2000; Nishino et al., 2008; Puri et al., 2007; Tansey et al., 2001). Although NEFA 
oxidation is not commonly considered to be a major metabolic pathway in WAT, 
these findings have led to speculation that increased adipocyte NEFA oxidation may 
play a significant role in energy metabolism and adiposity (discussed in (Lafontan, 
2008)). It is feasible to hypothesise that increased lipid utilisation and energy 
expenditure in these $-synuclein-/- mice may therefore be a compensatory mechanism 
in response to reduced lipid storage in adipocytes, to prevent increased levels of 
circulating lipids and their deposition in non-adipose tissues, factors that are thought 
to cause or worsen metabolic disease. 
In conclusion, knockout of $-synuclein leads to decreased weight gain and WAT 
accumulation in mice fed a HFD and this is associated with increased energy 
expenditure and lipid oxidation. These alterations in lipid/energy metabolism rescued 
$-synuclein-/- mice from various HFD-induced metabolic disturbances commonly 
associated with obesity. In the next chapter we will describe in more detail the 
changes in WAT of $-synuclein-/- mice. 
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Chapter 5 – $-synuclein and lipid  
metabolism in in vivo and in vitro fat cells  
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5.1. Overview 
In the previous chapter we demonstrated that $-synuclein deficiency in mice results in 
resistance to HFD-induced obesity, with reduced WAT accumulation, smaller 
adipocytes and increased lipid utilisation, all compared to HFD-fed wild type mice. 
To determine whether this reduction in adipocyte lipid storage was due to any specific 
alterations in $-synuclein deficient fat cells, we analysed lipid metabolism in WAT 
from $-synuclein-/- and wild type mice fed LFD or HFD. Furthermore, this chapter 
discusses findings concerning the expression of $-synuclein in differentiating 3T3-L1 
cells, a stable cell line frequently used to study gene function during and following 
adipocyte differentiation. 
 
5.2.1. Results: Increased adipocyte lipolysis in $-synuclein-/- mice 
We first investigated whether differences in lipid storage and lipid utilisation in $-
synuclein-/- mice fed HFD could be associated with alterations in adipocyte lipolysis. 
To do this, epididymal WAT from $-synuclein-/- and wild type mice fed HFD for 11 
weeks was dissected out, and mature white adipocytes were isolated. The procedure 
included collagenase digestion of WAT in Krebs-Ringer bicarbonate medium 
followed by centrifugation to pellet stromal cells, whilst mature adipocytes floated to 
the top of the buffer. Purified mature white adipocytes were incubated in the presence 
or absence of lipolytic stimulation using the non-specific !-adrenergic agonist, 
isoproterenol. Following this incubation period, media was collected from each 
suspension with subsequent determination of glycerol content. This was used as an 
index of lipolysis, with values normalized to the endogenous protein content of each 
suspension (see Experimental Procedures). The ex vivo glycerol release was 
approximately 3-fold higher in adipocytes isolated from HFD-fed $-synuclein-/- mice 
compared to adipocytes from HFD-fed wild type mice under basal (no lipolytic 
stimulation) conditions (Fig. 5.1A). Moreover, whilst isoproterenol dramatically 
stimulated glycerol release in adipocytes of both genotypes, this remained 
significantly higher (~2-fold) in adipocytes from $-synuclein-/- mice (Fig. 5.1A). These 
results suggest that the intracellular lipolytic capacity of adipocytes is greater in the 
absence of $-synuclein. We also looked at levels of NEFA in WAT from $-synuclein-/- 
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and wild type mice fed HFD for 11 weeks. This involved extraction of total lipids 
from epididymal WAT, separation of NEFA from other lipid species by TLC and 
quantification using gas chromatography. Interestingly, and consistent with our 
observations of increased adipocyte lipolysis, we observed increased levels of NEFA 
in WAT of HFD-fed $-synuclein-/- compared with wild type mice (Fig. 5.1B). 
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Fig. 5.1.  Lipolysis and NEFA levels in epididymal WAT. (A) Measurement of 
cellular lipolysis in white adipocytes isolated from epididymal WAT of wild type 
(+/+) and $-synuclein-/- (-/-) mice fed a HFD for 11 weeks. White adipocytes were 
incubated for 2 hours under basal or catecholamine-stimulated (stim) conditions (in 
the absence or presence of 10µM isoproterenol, correspondingly) and the lipolytic 
index was determined by measuring glycerol released from cells (n=8 animals per 
genotype/condition). Values obtained were normalized against levels of endogenous 
GAPDH protein expression (see Experimental Procedures). (B) Levels of non-
esterified fatty acids (NEFA) in epididymal WAT depots of wild type and $-
synuclein-/- mice fed a HFD for 11 weeks (n=5). Bar charts represent mean±SEM (* p 
< 0.05, ** p < 0.01, Mann-Whitney U-test). 
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5.2.2. Results: The expression of proteins involved in lipid metabolism is not 
altered in WAT of $-synuclein-/- mice 
We next determined the effect of $-synuclein loss on the expression of genes known 
to play a role in adipocyte lipid storage and metabolism. For this we used epididymal 
WAT from $-synuclein-/- and wild type mice fed either LFD or HFD for 11 weeks. For 
mRNA expression studies, total RNA was extracted from WAT with subsequent 
cDNA synthesis. Relative abundance of adipocyte transcripts was measured by 
quantitative PCR. For protein expression, total proteins were extracted by direct 
homogenization of WAT into SDS-PAGE loading buffer and analysed by semi-
quantitative Western blotting. At the RNA level we found that, consistent with the 
circulating leptin levels observed in these mice (Fig. 4.10A), leptin mRNA was 
increased by HFD-feeding in wild type animals and was blunted in $-synuclein-/- mice 
(Fig. 5.2A). We observed no effect of either $-synuclein loss or HFD-feeding on the 
mRNA expression of perilipin A, hormone sensitive lipase (HSL), adipose-
triglyceride lipase (ATGL) and lipoprotein lipase (LPL), nor the genes encoding aP2, 
or the transcription factors peroxisome proliferator-activated receptor-$ (PPAR$) and 
CCAAT-enhancer binding protein-! (C/EBP!) (Fig. 5.2B). The only statistically 
significant differences in this mRNA expression study were the similar (~1.5-fold) 
increases of aP2 mRNA levels in both $-synuclein-/- and wild type mice following 
HFD feeding (Fig. 5.2B). Further mRNA expression studies included other factors 
known to affect lipid metabolism, including enzymes involved in lipid oxidation (3-
ketoacyl-CoA thiolase B, 3-KAT), lipid synthesis (acetyl-CoA carboxylase, ACC-1) 
and mitochondrial uncoupling (uncoupling protein-1, UCP-1). This analysis revealed 
that the majority of these genes showed similar changes, with a similar 2-fold increase 
in WAT mRNA levels of 3-KAT in both wild type and $-synuclein-/- mice following 
HFD feeding (Fig. 5.3A). UCP-1 mRNA expression was unaltered by both $-
synuclein deficiency and HFD (Fig. 5.3A). However, whilst ACC-1 expression was 
significantly reduced following HFD-feeding in WAT of wild-type mice, this 
reduction was not significant in mice lacking $-synuclein (Fig. 5.3A). In BAT and 
liver, mRNA expression of 3-KAT was not affected by $-synuclein loss in HFD-fed 
mice, nor was the expression of uncoupling protein UCP-1 in BAT of HFD-fed mice 
(Fig. 5.3B-D). 
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At the protein level, there were no alterations in expression of perilipin A or HSL 
between all four experimental groups, nor any evidence of altered phosphorylation of 
HSL at its catecholamine-sensitive regulatory phosphorylation site, serine 563 
(Garton et al., 1988; Stralfors et al., 1984). There was however, a significant (~1.8-
fold) increase in the level of ATGL in epididymal WAT of HFD-fed $-synuclein-/- 
mice compared to HFD-fed wild type mice (Fig. 5.4, Appendix 4). 
We also investigated whether $-synuclein loss affected any major intracellular 
signaling pathways that might contribute to the protective phenotype in the null mice. 
As described above, total proteins were extracted from epididymal WAT of $-
synuclein-/- and wild type mice fed HFD for 11 weeks, and analysed by semi-
quantitative Western blotting. We found no differences in phosphorylation of AMP-
activated protein kinase (AMPK#, Thr172) or Akt/PKB (Ser473), nor any alteration 
in mTOR signaling as measured by phosphorylation of p70 S6 kinase 
(Thr421/Ser424) (Fig. 5.5). However we did observe a 1.9-fold increase in 
phosphorylation of extracellular signal-regulated kinase (ERK, Thr202/Tyr204) in 
epididymal WAT of HFD-fed $-synuclein-/- compared to HFD-fed wild type mice 
(Fig. 5.5). 
To determine whether $-synuclein is able to directly affect the phosphorylation of 
ERK, we employed an ERK phosphorylation response to serum-starvation and re-
feeding in cultured 3T3 fibroblasts. Dividing cells were transduced with the same $-
synuclein- or GFP-expressing lentivirus particles as discussed in the in vivo 
experiments in section 4.2.1 (for details about transduction see Experimental 
Procedures). Cells were serum-starved overnight and proteins harvested for analysis 
prior to re-feeding, and at various intervals up to 2 hours after re-feeding with serum. 
Analysis of proteins by semi-quantitative Western blotting firstly revealed that cells 
transduced with $-synuclein-expressing lentivirus particles showed significant 
overexpression of $-synuclein protein (Fig. 5.6A). Serum re-feeding caused rapid 
ERK phosphorylation within 15 minutes in cells transduced with either $-synuclein- 
or GFP-expressing lentivirus particles, with levels of phosphorylated ERK starting to 
diminish around an hour following serum re-feeding (Fig. 5.6B, C). However, the 
lentivirus-mediated overexpression of $-synuclein caused no difference in the 
dynamics of this ERK phosphorylation over the 2-hour period following serum re-
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feeding, as compared with cells transduced with GFP-only expressing lentivirus (Fig. 
5.5B, C). 
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Fig. 5.2. mRNA expression analysis of genes known to affect fat storage. (A, B) 
Bar charts show mean fold change (±SEM) of mRNA expression levels in epididymal 
WAT of wild type (+/+) and $-synuclein-/- (-/-) mice fed a LFD or HFD for 11 weeks, 
measured by quantitative RT-PCR and normalised to the mean level of each mRNA 
expression in wild type mice fed a LFD (n=5-9; * p < 0.05, Mann-Whitney U-test). 
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Fig. 5.3. Quantitative RT-PCR analysis of mRNA encoding proteins involved in 
lipid metabolism in WAT, BAT and liver. (A) Levels of 3-KAT, ACC-1 and UCP-
1 mRNA in epididymal WAT of wild type (+/+) and $-synuclein-/- (-/-) mice fed a 
LFD or HFD for 11 weeks (n=5-9). Results are shown as average fold change±SEM 
(* p < 0.05, ** p < 0.01, Mann-Whitney U-test) compared with LFD-fed wild type 
mice. (B-D) mRNA expression of 3-KAT and UCP-1 in BAT and liver of wild type 
and $-synuclein-/- mice fed a HFD for 11 weeks (n=4). Results are shown as average 
fold change±SEM compared with wild type mice. 
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Fig. 5.4. Protein expression analysis of genes known to affect fat storage. A 
representative Western blot of total proteins samples extracted from the epididymal 
WAT of wild type and $-synuclein-/- mice fed a LFD or HFD for 11 weeks. GAPDH 
was used as a loading control. 
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Fig. 5.5. Expression analysis of proteins involved in nutrient sensing and cell 
growth. A representative Western blot of total proteins samples extracted from the 
epididymal WAT of wild type and $-synuclein-/- mice fed HFD for 11 weeks. GAPDH 
was used as a loading control. 
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Fig. 5.6. Dynamics of ERK phosphorylation following lentivirus-mediated 
overexpression of $-synuclein. (A) Western blot analysis of $-synuclein expression 
in 3T3 cells transduced with $-synuclein- ($-syn) or GFP- (GFP) expressing 
lentivirus. GAPDH was used as a loading control. (B, C) ERK phosphorylation in 
3T3 cells was analysed by measuring abundance of phosphorylated and non-
phosphorylated ERK by semi-quantitative Western blotting. Subconfluent 3T3 
fibroblasts were transduced with $-synuclein- ($-syn) or GFP- (GFP) expressing 
lentivirus particles as described in Experimental Procedures. Cells were then serum-
starved for 16 hours and total proteins extracted prior to re-feeding and 15, 30, 60 and 
120 minutes after re-feeding with serum-containing media (n=6).  
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5.2.3. Results: $-synuclein mRNA expression is not altered during differentiation 
of 3T3-L1 cells, nor is there any detectable level of $-synuclein proteins from 
these cells 
The 3T3-L1 stable cell line is a useful tool for studying gene function during and 
following adipocyte differentiation in vitro. Upon the addition of certain pro-
differentiation factors in culture, 3T3-L1 fibroblasts begin to accumulate and store 
neutral lipids, along with the parallel induction of the expression of a number of 
adipocyte-specific transcripts. It has previously been demonstrated that $-synuclein 
mRNA levels increase from their relatively low abundance in 3T3-L1 fibroblasts to 
considerably higher levels (~25 fold increase by the time of full maturation) during 
their differentiation into mature 3T3-L1 adipocytes (Oort et al., 2008). We decided to 
also look at the dynamics of $-synuclein mRNA abundance during differentiation of 
3T3-L1 cells in culture, as well as levels of $-synuclein protein in both 3T3-L1 
fibroblasts and mature 3T3-L1 adipocytes. To do this, we harvested cells for total 
RNA and protein at various stages throughout the differentiation process, and 
measured mRNA and protein levels of $-synuclein using RT-PCR and semi-
quantitative Western blotting respectively. However, unlike what was found by (Oort 
et al., 2008), when measuring dynamics of $-synuclein expression during 3T3-L1 
adipocyte differentiation in our laboratory, we found that abundance of $-synuclein 
mRNA was low and did not alter significantly during any stage of the differentiation 
process (Fig. 5.7A). This was alongside the appearance, and a subsequent large 
increase, of perilipin A mRNA expression in the same cultures over this period (Fig. 
5.7A). We also observed the appearance of multiple intracellular lipid droplets when 
cells were viewed under a light microscope during the differentiation procedure. Both 
the increase in abundance of perilipin A mRNA and appearance of visible lipid 
droplets prove that adipocyte differentiation did indeed occur in these cultures. When 
analysing protein expression in 3T3-L1 cells, either as fibroblasts or mature 
adipocytes, we did not observe any detectable level of $-synuclein (Fig. 5.7B). We did 
however observe the appearance of perilipin A protein expression in the same cultures 
of mature 3T3-L1 adipocytes (Fig. 5.7B). 
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Fig. 5.7. $-synuclein mRNA expression during differentiation of 3T3-L1 cells.  
(A) Expression of $-synuclein and perilipin A mRNA in 3T3-L1 cells during their 
differentiation, measured by quantitative RT-PCR. 2-day post-confluent monolayers 
of 3T3-L1 fibroblasts (day 0) were exposed to a pro-differentiation medium as 
described in Experimental Procedures. Values are normalised to the mean level of 
mRNA expression at day -2 with individual values representing mean±SEM (n=4). 
(B) Western blot analysis of $-synuclein and perilipin A protein expression in 3T3-L1 
fibroblasts (3T3-L1 fib), mature 3T3-L1 adipocytes (mat 3T3-L1 adip) and white 
adipose tissue (WAT). GAPDH was used as a loading control. 
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5.2.4. Results: $-synuclein mRNA expression is downregulated by 
isobutylmethylxanthine (IBMX) in certain cell lines in culture 
Whilst performing experiments regarding adipocyte differentiation of precursor cells 
in culture, we noticed that 48 hours after introduction of the pro-differentiation 
regimen, there was a rapid and significant downregulation of $-synuclein mRNA in 
MEFs, as analysed by RT-PCR (20±8% of levels detected before induction of 
differentiation, p < 0.05, Mann-Whitney U-test). We decided to check if one or more 
agents included in this pro-differentiation medium were responsible for this 
downregulation. To do this we cultured MEFs in growth medium including only one 
of insulin, dexamethasone, rosiglitazone or isobutylmethylxanthine (IBMX), all at the 
same concentration as in the pro-differentiation cocktail. After 48 hours, total RNA 
was extracted from these cells, followed by synthesis of cDNA and determination of 
$-synuclein mRNA levels by quantitative PCR. This analysis showed no changes in 
abundance of $-synuclein mRNA following exposure to insulin, dexamethasone or 
rosiglitazone (104±21%, 82±32%, 92±18% all compared to parallel cultures treated 
with DMSO, respectively). However, cultures treated with IBMX showed a 
significant downregulation of $-synuclein mRNA compared to DMSO-treated 
cultures, which was of similar magnitude to what was seen when all four pro-
differentiation agents were used in cocktail (23±8%, p < 0.05, Mann-Whitney U-test). 
We repeated this experiment with the same IBMX treatment in three stable cell lines, 
namely 3T3 fibroblasts, mature 3T3-L1 adipocytes and MG1361 cells (a murine cell 
line established from mammary adenocarcinomas, (Sacco et al., 1998)). During 
studies involving mammary tumourigenesis in our laboratory, we had previously seen 
that this breast cancer cell line expresses relatively high levels of $-synuclein mRNA. 
These three cell lines were grown in their respective culture media, with total RNA 
extracted 2, 12 and 48 hours following exposure to IBMX. RT-PCR analysis showed 
that 2 hours after addition of IBMX to the culture media, there were no differences in 
the levels of $-synuclein mRNA in any of the three cell lines when compared to 
DMSO-treated control cultures (Fig. 5.8). In contrast to this, we observed a 
considerable downregulation (~85% reduction) of $-synuclein mRNA in 3T3 
fibroblasts and mature 3T3-L1 adipocytes 12 hours following exposure to IBMX, 
again compared to DMSO-treated cultures (Fig. 5.8). However, this downregulation 
was not present in MG1361 cells after either 12 or indeed 48 hours after addition of 
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IBMX. In 3T3 fibroblasts and mature 3T3-L1 adipocytes, the substantial 
downregulation of $-synuclein mRNA was still present 48 hours after the introduction 
of IBMX (Fig. 5.8). 
 
*  *  * 
 
 
 
Fig. 5.8. Effect of IBMX on $-synuclein mRNA expression in various cell types in 
culture. Levels of $-synuclein mRNA in MG1361 cells, 3T3 fibroblasts and mature 
3T3-L1 adipocytes upon exposure to IBMX, measured by quantitative RT-PCR. 
Values are compared to $-synuclein mRNA in parallel cultures treated with DMSO 
for each time point, with individual values representing mean±SEM (n=4-5 cultures 
per cell type/treatment, * p < 0.05 for both 3T3 fibroblasts and mature 3T3-L1 
adipocytes, Mann-Whitney U-test). 
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5.3. Summary of results and discussion 
The finding that deficiency of $-synuclein in mice confers resistance to HFD-induced 
obesity, with knockout mice displaying reduced WAT accumulation and adipocyte 
lipid storage, it was logical to look more closely at lipid metabolism in $-synuclein 
deficient white adipocytes. We also looked at expression of $-synuclein mRNA and 
protein in 3T3-L1 fibroblasts, a stable cell line capable of differentiating into mature 
adipocytes in culture.  
In isolated white adipocytes, we demonstrated that the absence of $-synuclein leads to 
increased basal and isoproterenol-stimulated lipolysis, suggesting a larger intracellular 
lipolytic capacity of $-synuclein-/- adipocytes. In addition to this, in HFD-fed mice we 
also found increased NEFA levels in WAT from $-synuclein-/- mice. It is possible that 
in $-synuclein-/- adipocytes, reduced intracellular lipid storage is primarily due to 
increased lipolysis, represented by increased WAT NEFA levels and efflux of these 
NEFA from this tissue. Consistent with this idea, we also observed increased levels of 
ATGL in WAT, the key triglyceride lipase in this tissue, in HFD-fed $-synuclein-/- 
compared to HFD-fed wild type mice. Similar to our $-synuclein-/- mice, transgenic 
mice that overexpress ATGL specifically in adipose tissue are also resistant to obesity 
and have smaller white adipocytes compared to wild type mice following high fat diet 
feeding (Ahmadian et al., 2009). The overlap of the phenotypes between these two 
mutant strains of mice suggest that the increased WAT ATGL expression in $-
synuclein-/- mice at least contributes to the decreased WAT accumulation in mice 
lacking $-synuclein. We observed no effect of $-synuclein loss on the expression of a 
number of genes known to play a role in adipocyte lipid storage and metabolism in 
WAT, BAT or liver, either at the RNA or protein level. Exceptions to this were 
changes to levels of leptin and acetyl-CoA carboxylase (ACC-1) mRNA in WAT. 
Changes in leptin mRNA abundance were consistent with both adipocyte size and 
circulating leptin levels in all four groups of experimental mice. Significant reduction 
of ACC-1 mRNA expression after HFD feeding in wild type mice was not found in $-
synuclein-/- mice, possibly representing that downregulation of the lipid synthesis 
pathway in WAT of wild type mice was not necessary in $-synuclein-/- mice. 
In mouse WAT, $-synuclein loss did not affect major intracellular signaling pathways 
involved in nutrient signaling (AMPK), cell growth (mTOR) or insulin signaling 
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(Akt/PKB). These data suggest that in adipocytes, $-synuclein functions independent 
or downstream of these pathways. Interestingly, in WAT of HFD-fed mice, $-
synuclein loss resulted in a significant increase in the phosphorylation of ERK, 
suggesting that ERK activity in this tissue is increased. However overexpression of $-
synuclein in cultured non-adipose cells did not affect the ERK phosphorylation 
response to serum-starvation and re-feeding, suggesting modulation of ERK 
phosphorylation by $-synuclein is cell-type specific. Although it is possible that this 
increased ERK activity is a compensatory mechanism in response to restricted 
adipocyte size in HFD-fed $-synuclein-/- mice, it is unclear at this time the exact 
reason for this observed increase. 
Previous work performed in another laboratory demonstrated a considerable increase 
of $-synuclein mRNA levels during the differentiation of 3T3-L1 fibroblasts into 
mature 3T3-L1 adipocytes (Oort et al., 2008). However, when performing a similar 
experiment in our laboratory, we found that abundance of $-synuclein mRNA was low 
and did not change significantly during any stage of the differentiation process. 
Moreover, we did not observe a detectable level of $-synuclein proteins in either 3T3-
L1 fibroblasts or mature 3T3-L1 adipocytes, probably reflecting the relatively low 
expression of $-synuclein mRNA and, consequently, $-synuclein protein expression. 
These experiments were performed using the same methods for determining 
expression at both the RNA and protein level that were carried out during work in 
previous chapters, and so it appears unlikely that these observations are false. 
Although there is no obvious reason for the disparity between findings in different 
laboratories concerning $-synuclein mRNA expression during 3T3-L1 differentiation, 
it is possible that the various sub-lines of 3T3-L1 cells propagated for a long time in 
different laboratories acquire different properties. If this is the case, then upregulation 
of $-synuclein expression during the differentiation procedure is an example of this. 
Regardless, these findings do further demonstrate (alongside our studies involving 
adipocyte differentiation of $-synuclein-/- MEFs – section 4.2.1) that $-synuclein is not 
required for adipocyte differentiation, and also that this cell line is not an ideal model 
for the study of $-synuclein function in cultured adipocytes.  
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During these in vitro experiments we also performed a small separate study that does 
not have direct link with the function of $-synuclein in white adipocytes, but might 
have potential implications for any, possibly therapeutic, reason to regulate 
expression of $-synuclein. We noticed that cultured undifferentiated MEFs express 
relatively high levels of $-synuclein mRNA but introduction of the pro-differentiation 
regimen used for their differentiation into adipocytes, induced a substantial 
downregulation of its expression. Functional dissection of components in the 
differentiation medium revealed that the isobutylmethylxanthine (IBMX) present in 
this differentiation cocktail was responsible for the downregulation of $-synuclein 
mRNA. IBMX is a non-specific cyclic nucleotide phosphodiesterase inhibitor capable 
of drastically elevating intracellular cAMP levels. In adipocytes, IBMX treatment 
promotes a lipolytic response, due to inhibition of phosphodiesterase 3B, raised 
intracellular cAMP levels and activation of protein kinase A (PKA). Downregulation 
of $-synuclein mRNA was highly pronounced in both 3T3 fibroblasts and mature 
3T3-L1 adipocytes, but absent in a breast cancer cell line known to express $-
synuclein mRNA, MG1361. Further investigation is required to determine whether 
this downregulation is a direct cellular response to increased cAMP levels, or via an 
independent pathway. It is possible that these different cell-types, each with their own 
properties and gene expression profile, respond differently to IBMX in terms of $-
synuclein expression. To better understand the regulation of $-synuclein expression 
by IBMX in various cell types, further analysis is required into the precise mechanism 
of this regulation, and the cellular pathways/molecules involved. 
Experimental results described in this chapter demonstrate that the intracellular 
lipolytic capacity of white adipocytes is greater in the absence of $-synuclein. We 
have also shown that a number of genes known to play a role in adipocyte lipid 
storage and metabolism are unaltered by loss of $-synuclein. However we did observe 
a significant increase in protein levels of the lipase ATGL in WAT between HFD-fed 
$-synuclein-/- and wild type mice, consistent with increases in adipocyte lipolysis in 
WAT of these mice. Interestingly, although not fully understood, $-synuclein loss in 
HFD-fed mice caused increased phosphorylation of ERK in WAT. Analysis of $-
synuclein expression in 3T3-L1 cells demonstrated that unlike documented in 
previous reports (Oort et al., 2008), $-synuclein mRNA levels did not alter 
significantly during differentiation of 3T3-L1 cells. In addition to this, we did not see 
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any detectable level of $-synuclein protein in either immature 3T3-L1 fibroblasts or 
fully mature 3T3-L1 adipocytes. In a separate experiment we demonstrate that 
treatment of certain cultured cells (3T3 fibroblasts, 3T3-L1 mature adipocytes) but 
not all (MG1361), with the non-specific phosphodiesterase inhibitor IBMX 
significantly downregulates mRNA expression of $-synuclein, although the precise 
mechanism involved requires further investigation. In the following chapter we look 
at an intriguing link between the functions of #-synuclein in neuronal synapses and $-
synuclein in adipocytes that may help to explain how the latter protein affects 
lipolysis and the size of mature adipocytes in conditions of nutrient excess. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! "#"!
 
 
 
 
 
 
 
 
Chapter 6 - Effect of $-synuclein-/- on 
SNARE complex formation in white adipocytes 
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6.1. Overview. 
In the previous chapters we have shown that in HFD-fed mice, loss of $-synuclein 
leads to reduced WAT accumulation and smaller adipocytes, with increases in WAT 
lipolysis, whole-body lipid utilisation and energy expenditure. Recently, (Burre et al., 
2010) published work concerning the role of another member of the synuclein family 
#-synuclein, in the assembly of SNARE complexes in neurons. This chapter discusses 
a possible role for $-synuclein involving the assembly of SNARE complexes in 
adipocytes, and a suggested mechanism for the reduced lipid storage seen in $-
synuclein-/- white adipocytes. 
 
6.2. Results: $-synuclein promotes assembly of SNARE complexes in WAT 
#- and $-synuclein are closely related proteins, with potential functional redundancy 
(Robertson et al., 2004; Senior et al., 2008). In neuronal synapses, #-synuclein is 
involved in regulation of synaptic vesicle fusion with the cell membrane by 
promoting the assembly of SNARE complexes from its subunits, namely vesicular 
SNARE (vSNARE) protein VAMP-2 and two target membrane-associated SNARE 
(tSNARE) proteins, syntaxin-1 and SNAP-25 (Burre et al., 2010). In adipocytes, 
SNARE complexes comprise of different, although structurally and functionally 
related SNARE proteins. Adipocyte SNARE complexes have been implicated in lipid 
droplet formation and growth by fusion between neutral TAG packaged within 
amphipathic lipoproteins and the lipid droplet phospholipid monolayer (Andersson et 
al., 2006; Bostrom et al., 2007; Bostrom et al., 2005; Olofsson et al., 2009). We 
hypothesised that in adipocytes, $-synuclein plays a similar role to that of #-synuclein 
in neurons. To determine whether $-synuclein functions as a regulator for the 
efficiency of SNARE complex formation in WAT, we quantified the assembled 
SNARE complexes in WAT lysates by measuring the amount of VAMP-4 (vSNARE) 
that co-immunoprecipitated with syntaxin-5 (tSNARE). To do this we used 
epididymal WAT from $-synuclein-/- and wild type mice fed LFD or HFD for 11 
weeks. WAT lysates were used for co-immunoprecipitation reactions, and VAMP-4 
and syntaxin-5 protein levels pulled down during immunoprecipitation were analysed 
by semi-quantitative Western blotting. Amounts of co-immunoprecipitated VAMP-4 
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were normalised per lysate by the amount of immunoprecipitated syntaxin-5. 
Although we found no differences in the number of assembled SNARE complexes 
between genotypes for LFD-fed mice, the number of SNARE complexes was reduced 
by approximately 35% in $-synuclein-/- mice fed HFD compared with HFD-fed wild 
type mice (Fig. 6.1A, B). To test whether this difference was caused by reduced 
expression of either VAMP-4, syntaxin-5 or SNAP-23 in WAT of $-synuclein-/- mice 
we measured levels of these proteins in lysates of epididymal WAT from HFD-fed 
mice of both genotypes. Levels of these proteins were analysed by semi-quantitative 
Western blotting using the same VAMP-4 and syntaxin-5 antibodies as in co-
immunoprecipitation experiments. This analysis showed that the decreased number of 
SNARE complexes in $-synuclein-/- mice fed HFD compared with HFD-fed wild type 
mice was not due to any reduction in protein levels of VAMP-4, syntaxin-5 or SNAP-
23 (Fig. 6.2). 
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Fig. 6.1. Quantification of SNARE complexes in WAT. (A) Representative 
Western blots showing co-immunoprecipitation of VAMP-4 with syntaxin-5 used to 
assess SNARE complex abundance in epididymal WAT of wild type (+/+) and $-
synuclein-/- (-/-) mice fed a LFD or HFD for 11 weeks. (B) Bar chart shows amount of 
VAMP-4 in syntaxin-5 immunoprecipitates normalized to the amount of 
immunoprecipitated syntaxin-5 and expressed as a percentage of wild type samples in 
each experiment (±SEM, total of 5 independent experiments). No changes were found 
in $-synuclein-/- mice fed LFD but the difference between values for wild type and $-
synuclein-/- mice fed HFD was statistically significant (p < 0.05, Mann-Whitney U-
test).  
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Fig. 6.2. Analysis of SNARE protein expression in WAT. Western blot analysis of 
VAMP-4, syntaxin-5 and SNAP-23 protein expression in epididymal WAT of wild 
type (+/+) and $-synuclein-/- (-/-) mice fed a HFD for 11 weeks. GAPDH was used as 
a loading control (n=4). (A) Bar charts show means±SEM compared with wild type 
mice fed HFD. (B) A representative Western blot is shown in the bottom panel.  
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6.3. Summary of results and discussion. 
Recently (Burre et al., 2010) published work on #-synuclein, a closely related protein 
to $-synuclein, showing that in neuronal synapses, #-synuclein enhances 
neurotransmitter exocytosis by promoting the assembly of SNARE complexes. These 
complexes play a crucial role in synaptic vesicle docking and fusion pore formation at 
the plasma membrane, and this group demonstrated how this function of #-synuclein 
becomes particularly important during periods of increased synaptic activity. In 
presynaptic terminals, the vSNARE protein VAMP-2/synaptobrevin and two tSNARE 
proteins, syntaxin-1 and SNAP-25 are the subunits that make up SNARE complexes 
in these neurons (summarised in (Rizo and Rosenmund, 2008; Sudhof and Rothman, 
2009)). In adipocytes, the functional homologs of these proteins are the vSNARE 
protein VAMP-4 and tSNARE proteins syntaxin-5 and SNAP-23. These adipocyte 
SNARE complexes are involved in fusion between neutral TAG packaged within 
amphipathic lipoproteins and the lipid droplet phospholipid monolayer, a process 
responsible for adipocyte lipid accumulation and subsequent lipid droplet growth 
(Andersson et al., 2006; Bostrom et al., 2007; Bostrom et al., 2005; Olofsson et al., 
2009). 
Work in this chapter has demonstrated that in conditions of increased lipid supply, i.e. 
in HFD-fed mice, SNARE complex formation in WAT is substantially attenuated in 
the absence of $-synuclein. This difference was not due to decreased expression and 
therefore availability of individual SNARE complex subunits in WAT. Our findings 
suggest that in HFD-fed mice, the decreased SNARE complex formation seen in $-
synuclein-/- adipocytes reduces incorporation of excess TAG (from increased dietary 
NEFA) into the lipid droplet, which contributes to the decreased adipocyte size (and 
WAT accumulation) in $-synuclein-/- mice. Overall, this suggests that both #-
synuclein and $-synuclein have the ability to potentiate SNARE complex-mediated 
fusion in two different cell types. Both neurons and adipocytes require this process for 
increased efficiency of cellular mechanisms that depend on this fusion, #-synuclein-
potentiated synaptic transmission in neuronal synapses and similarly $-synuclein-
potentiated lipid droplet formation in adipocytes. In the next chapter we will switch 
focus from WAT, and look at the effect of $-synuclein deficiency on lipid classes and 
fatty acid composition in the brain. 
! "#(!
 
 
 
 
 
 
 
 
 
Chapter 7 – Lipid classes and fatty acid patterns 
in the brains of $-synuclein-/- mice 
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7.1. Overview 
Alterations in brain lipid biochemistry have been previously linked to deficiency of !-
synuclein (Barcelo-Coblijn et al., 2007; Rappley et al., 2009). Since $-synuclein and 
#-synuclein are closely related proteins, whose functions are potentially redundant 
(Robertson et al., 2004; Senior et al., 2008), it was clearly important to evaluate if $-
synuclein might also play a role in brain lipid homeostasis. In chapters 5 and 6, we 
focused on $-synuclein expression in WAT, and the effect of loss of expression on 
lipid metabolism in this tissue. In this chapter, we look at the effect of $-synuclein 
deficiency on the lipid composition and fatty acid patterns of individual lipids from 
two different brain regions, the cerebral cortex and the midbrain. The midbrain 
exhibits relatively high levels of $-synuclein expression, whereas in the cerebral 
cortex, the expression level of this protein is substantially lower (Abeliovich et al., 
2000; Ninkina et al., 2003).! 
 
7.2.1. Results: Increased oleic acid levels in plasma of $-synuclein-/- mice 
For analysis of the effect of $-synuclein deficiency on lipid composition in the brain, 
we fed 9-week old male $-synuclein-/- and wild type mice low fat diet (LFD) for 11 
weeks. Subsequently, tissues of young but mature (20 week old) adult mice with a 
fully developed nervous system were analysed. We began by looking at the effect, if 
any, that loss of $-synuclein had on lipid composition in blood plasma of these mice. 
To do this, whole blood was taken immediately after sacrificing experimental 
animals, and plasma collected by centrifugation. Total lipids were extracted from 
samples of plasma with NEFA separated by TLC and the relative amount of each 
fatty acid determined by gas chromatography. Palmitic, stearic, oleic, linoleic and 
arachidonic acids were the major fatty acids in plasma together with a moderate 
amount of docosahexaenoic acid (DHA) in both wild type and $-synuclein-/- mice. The 
relative amount of oleic acid was increased significantly in the plasma of $-synuclein-/- 
compared to wild type mice (Table 7.1). 
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Fatty acids (% of total 
fatty acids) 
Plasma 
 wild type "-synuclein-/- 
C16:0 17.8 ± 4.7 19.8 ± 2.6 
C16:1 (n-7) 2.0 ± 0.7 3.1 ± 0.8 
C18:0 13.0 ± 2.2 13.0 ± 4.8 
C18:1 (n-9) 16.0 ± 1.9 20.5 ± 2.8* 
C18:1 (n-7) 2.2 ± 0.2 3.0 ± 0.8 
C18:2 (n-6) 17.3 ± 1.8 15.1 ± 1.8 
C18:3 (n-3) 0.5 ± 0.2 0.5 ± 0.3 
C20:3 (n-6) 1.6 ± 0.8 2.0 ± 0.7 
C20:4 (n-6) 20.3 ± 4.5 15.9 ± 4.4 
C22:6 (n-3) 7.3 ± 2.4 5.2 ± 1.9 
 
Table 7.1. Fatty acid composition in the plasma of wild type and $-synuclein-/- 
mice. Data as means ± S.D (number of mice = 5, * p < 0.05) as a % of total fatty 
acids. Fatty acids are indicated with the number before the colon showing the number 
of carbon atoms, the figure afterwards denoting the number of double bonds. The 
position of the first double bond is shown in brackets. 
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7.2.2. Results: Increased proportion of phosphatidylserine in midbrain polar 
lipids of $-synuclein-/- mice 
Table 7.2 below shows the fatty acid profile of the total polar lipid fraction from 
cortex or midbrain in wild type and $-synuclein-/- mice. Total lipids were extracted 
from dissected cerebral cortex or midbrain samples with polar lipids separated from 
other lipid species by TLC, and the fatty acid composition of total polar lipids 
determined by gas chromatography. Palmitic and stearic acids were the dominant 
fatty acids in cortex followed by DHA, oleic acid and arachidonic acid (ARA). In 
midbrain, stearic and oleic acids were the major compounds followed by palmitic, 
DHA and ARA. The percentages of palmitic, ARA and DHA in total polar lipids 
were significantly higher in the cortex region compared to midbrain in both wild type 
and $-synuclein-/- mice, whereas proportions of oleic and nervonic (C24:1) acids were 
higher in this lipid fraction from midbrain. There were no statistically significant 
differences in the relative proportions of fatty acids from the total polar lipid fraction 
between wild type and $-synuclein-/- mice in either brain region. 
The relative proportions of different polar lipids in the two brain regions are shown 
below in Fig. 7.1. Extraction of total lipids from either brain region was followed by 
separation of polar lipids by two-dimensional TLC. Three phospholipids, namely 
phosphatidylcholine (PtdCho), ethanolamine phospholipids (PtdEtn) and 
phosphatidylserine (PtdSer), were the major polar lipids in both brain regions 
(accounting for about 70-80% of the total polar lipids). Phosphatidylinositol (PtdIns), 
sphingomyelin (CerPCho), diphosphatidylglycerol (Ptd2Gro, cardiolipin) as well as 
sulfatide and cerebroside were present in smaller proportions and were each less than 
5% of the total polar lipids. The relative amounts of polar lipids did not vary 
substantially between midbrain and cortex samples from wild type animals, although 
the levels of sulfatides and PtdCho showed a statistically significant increase and 
decrease, respectively, in the midbrain region (Fig. 7.1). In this brain region, $-
synuclein deficiency resulted in a statistically significant (~40%) increase in the 
relative proportion of PtdSer compared to wild type mice, whereas the proportions of 
other lipids were not altered significantly (Fig. 7.1). No differences in the polar lipid 
composition were found in the cortex of wild type compared to $-synuclein-/- mice 
(Fig. 7.1). Also, no differences in the concentrations of total polar lipids and 
! "$"!
triacylglycerol (TAG) were observed for these brain regions as a result of $-synuclein 
deficiency (data not shown). 
 
*  *  * 
 
Fatty acid (% of 
total fatty acids 
Cortex Midbrain 
 wild type $-synuclein-/- wild type $-synuclein-/- 
C16:0 22.2 ± 0.5 22.6 ± 0.8 16.8 ± 0.2# 17.5 ± 0.8 
C16:1 (n-7) 1.3 ± 0.2 1.4 ± 0.2 0.1 ± 0.0# 0.2 ± 0.0 
C18:0 22.6 ± 0.4 22.8 ± 0.4 21.8 ± 2.3 21.6 ± 2.4 
C18:1 (n-9) 15.9 ± 0.2 15.6 ± 0.3 21.7 ± 0.6# 21.1 ± 1.1 
C18:1 (n-7) 3.8 ± 0.4 4.0 ± 0.3 4.7 ± 1.3 5.0 ± 0.5 
C18:2 (n-6) 0.9 ± 0.1 0.8 ± 0.1 2.8 ± 0.9# 2.8 ± 0.8 
C18:3 (n-3) 10.4 ± 0.5 10.5 ± 0.3 7.7 ± 0.9# 7.4 ± 1.2 
C20:3 (n-6) 2.4 ± 0.1 2.4 ± 0.1 3.0 ± 0.9 3.7 ± 2.0 
C20:4 (n-6) 16.5 ± 2.0 16.0 ± 0.6 12.1 ± 1.7# 11.5 ± 1.0 
C22:6 (n-3) 0.8 ± 0.2 0.8 ± 0.2 2.5 ± 0.6# 2.6 ± 0.6 
 
Table 7.2. Fatty acid composition of the total polar lipid fraction from cortex or 
midbrain of wild type and $-synuclein-/- mice. Data as means ± S.D (number of 
mice = 6-8, # p < 0.05 between midbrain and cortex in wild type animals) as a % of 
total fatty acids. Fatty acids are indicated with the number before colon showing the 
number of carbon atoms, the figure afterwards denoting the number of double bonds. 
The position of the first double bond is shown in brackets. 
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Fig. 7.1. Midbrain and cortex polar lipid composition (% of total polar lipids) 
from wild type and $-synuclein-/- mice. Values represent means ± SD (number of 
mice = 5, * effect of $-synuclein deficiency (-/-) when compared with wild type (+/+), 
# differences between midbrain (top panel) and cortex (bottom panel) in wild type 
animals, p < 0.05 for both). CerPCho, sphingomyelin; PtdCho, phosphatidylcholine; 
PtdEtn, phosphatidylethanolamine; Ptd2Gro, cardiolipin; PtdIns, phosphatidylinositol; 
PtdSer, phosphatidylserine; ST, sulfatide; Cer, cerebroside. 
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7.2.3. Results: Alterations in fatty acid patterns of phosphatidylserine and 
ethanolamine phospholipids in cortex of $-synuclein-/- mice 
The fatty acid composition of PtdSer and PtdEtn, which in brain tissues represent two 
lipid classes significantly enriched with the n-3 polyunsaturated fatty acid (PUFA) 
DHA, are shown in Fig. 7.2 and 7.3, respectively. Total lipids were extracted from 
dissected cerebral cortex or midbrain samples with both PtdSer and PtdEtn separated 
from other lipid species by two-dimensional TLC and the fatty acid composition of 
each determined by gas chromatography. For PtdSer, the levels of both C18:0 and 
DHA were higher in cortex compared to midbrain while oleate was reduced (Fig. 
7.2). Moreover, the level of DHA in PtdSer was significantly increased in the cortex 
of $-synuclein-/- mice compared to wild type animals (30.0% and 25.8% of total fatty 
acids, respectively) with a concomitant decrease in the proportion of stearate (C18:0) 
(Fig. 7.2). PtdEtn contained both ARA and DHA as major fatty acids and, similar to 
PtdSer, the proportion of DHA was enhanced significantly in cortex tissue in $-
synuclein-/- mice as compared to control wild type mice (25.4% and 21.4% 
respectively, Fig. 7.3). The proportions of ARA were unaffected by $-synuclein 
deficiency in PtdEtn from both cortex and midbrain tissues (Fig. 7.3). In addition to 
fatty acids from the diacyl form of PtdEtn, we also analysed the profile of 
dimethylacetal (DMA) derivatives that represent aliphatic chains from ether 
derivatives (mainly plasmalogens) of PtdEtn (Fig. 7.3). Four DMA were identified 
with a domination of C18:0-DMA, but no significant changes in the relative 
proportion of these compounds in cortex and midbrain were found between wild type 
and $-synuclein-/- mice. 
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Fig. 7.2. Fatty acid composition of phosphatidylserine from midbrain or cortex 
in wild type and $-synuclein-/- mice. Values represent means ± SD (number of mice 
= 5, * effect of $-synuclein-/- when compared with wild type, # differences between 
midbrain (top panel) and cortex (bottom panel) in wild type animals, p < 0.05 for 
both) as a % of total fatty acids. Fatty acids are indicated with the number before 
colon showing the number of carbon atoms, the figure afterwards denoting the 
number of double bonds. The position of the first double bond is shown in brackets. 
Only the major fatty acids ("0.5%) are listed. 
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Fig. 7.3. Fatty acid and dimethylacetal composition of ethanolamine 
phospholipids from midbrain and cortex of wild type and $-synuclein-/- mice. 
Values represent means ± SD (number of mice = 5, * effect of $-synuclein-/- when 
compared with wild type, # differences between midbrain (top panel) and cortex 
(bottom panel) in wild type animals, p < 0.05 for both) as a % of total fatty acids. 
Fatty acids are indicated with the number before colon showing the number of carbon 
atoms, the figure afterwards denoting the number of double bonds. The position of the 
first double bond is shown in brackets. Only the major fatty acids ("0.5%) are listed. 
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7.2.4. Results: Alterations in fatty acid patterns in various other major polar 
lipids in cortex and midbrain of $-synuclein-/- mice 
Table 7.3 below shows data on the fatty acid composition for other major polar lipids 
in cortex and midbrain from wild type and $-synuclein-/- mice. These data (including 
Figures 7.2 and 7.3 above) show a fatty acid distribution typical of that for murine 
brain tissues. Fatty acid composition of these polar lipids were measured in the same 
way as for PtdSer and PtdEtn in section 7.2.3, with extraction of total lipids from 
cerebral cortex or midbrain tissue, separation of these individual polar lipids by two-
dimensional TLC and the fatty acid composition for each polar lipid determined by 
gas chromatography. Phosphatidylcholine (PtdCho) in both cortex and midbrain is 
characterized by a domination of palmitate (approximately 48% and 40% in cortex 
and midbrain, respectively), stearate (14% and 16%) and oleate (21% and 24%) with 
much lower levels of the two major brain long-chain PUFAs, ARA and DHA (Table 
7.3). In the cortex, the relative concentrations of ARA and DHA in PtdCho were 
approximately 6% and 3%, respectively. In the midbrain, about 4% of each of ARA 
and DHA was found in PtdCho. The levels of all above-mentioned fatty acids were 
significantly different between the two brain regions. In contrast, there were no 
significant differences in these parameters between wild type and $-synuclein-/- mice. 
 
Phosphatidylinositol (PtdIns) is enriched with two fatty acids, stearic (around 44% in 
both cortex and midbrain) and ARA (37% and 34% in cortex and midbrain, 
respectively). DHA is a minor component in PtdIns and its relative concentration was 
about 2% in cortex and 4% in midbrain, these being significantly different. $-
synuclein-/-  resulted in an increased level of ARA in PtdIns in cortex tissue but did not 
affect the fatty acid profiles of this lipid in the midbrain (Table 7.3). 
 
Oleic acid and ARA were the major acids found in brain diphosphatidylglycerol 
(Ptd2Gro, cardiolipin). In this lipid, another C18:1 isomer, cis-vaccenic acid, was also 
present in appreciable amounts especially in the midbrain (around 11% versus 7% in 
cortex). The relative concentration of ARA was higher in Ptd2Gro from the cortex 
than in Ptd2Gro from the midbrain (18% and 13%, respectively). In comparison to 
other polar lipids isolated from the brain, Ptd2Gro contains higher levels of C16 and 
C18 monoenic acids, namely C16:1n-7 (up to 5%), C18:1n-9 (up to 38%) and 
C18:1n-7 (up to 15%). The proportion of the latter was significantly higher in the 
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midbrain than in cortex at the expense of arachidonic acid (Table 7.3). No statistically 
significant changes were found when comparing Ptd2Gro fatty acid profiles in the 
cortex between wild type and $-synuclein-/- animals, whereas in midbrain the 
proportion of C18:1n-7 was increased in $-synuclein-/- compared to wild type mice 
(Table 7.3).  
Sphingomyelin (CerPCho) from both cortex and midbrain contained stearic acid as its 
major fatty acid (up to 81% of total fatty acids in cortex, and up to 65% of that in 
midbrain). The presence of two very long chain acids, lignoceric (C24:0) and 
nervonic (C24:1n-6), is also characteristic for this lipid. Their levels were higher in 
midbrain than cortex. CerPCho fatty acids were unchanged as a response to $-
synuclein-/- in the cortex whereas in the midbrain a decreased percentage (~10%) of 
C18:0 was found.  
 
Fatty acids from both sulfatides and cerebrosides did not show any differences 
between cortex and midbrain. $-synuclein-/- resulted in a decreased proportion of 
lignoceric acid in sulfatides and cerebrosides in the cortex (Table 7.3). In the midbrain 
region, a reduced relative proportion of behenic acid (C22:0) was found in 
cerebrosides in $-synuclein-/- mice (Table 7.3).  
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Fatty acids          Cortex                                             Midbrain           
(% of total)       wild type        $-synuclein-/-      wild type      $-synuclein-/- 
 
Phosphatidylcholine
 
C16:0                                48.0 ± 2.7           45.2 ± 1.9               39.2 ± 3.5#          39.2 ± 2.6  
C16:1 (n-7)                       0.7 ± 0.1             0.8 ± 0.3                 0.7 ± 0.2              0.9 ± 0.2 
C18:0                                3.7 ± 0.7            13.0 ± 0.7               16.5 ± 1.2#           15.1 ± 1.6 
C18:1 (n-9)                      20.6 ± 0.8            20.9 ± 1.1               24.1 ± 1.6#           23.9 ± 1.1 
C18:1 (n-7)                       5.1 ± 2.0             6.8 ± 0.9                 7.2 ± 0.6               8.1 ± 1.6 
C20:1 (n-9)                       0.7 ± 0.1             0.7 ± 0.1                 1.7 ± 0.5#             1.6 ± 0.3 
C20:4 (n-6)                       5.7 ± 0.6             6.4 ± 0.5                 3.9 ± 0.7#             4.1 ± 0.6  
C22:6 (n-3)                       3.2 ± 0.5             3.8 ± 0.4                 3.7 ± 0.6               4.3 ± 0.6      
 
Phosphatidylinositol
 
C16:0                                8.2 ± 1.8             6.7 ± 1.9                 7.3 ± 1.8              9.4 ± 2.1 
C18:0                                44.1 ± 3.2           40.7 ± 1.1               44.9 ± 3.2            40.7 ± 2.1     
C18:1 (n-9)                       5.1 ± 0.8             5.1 ± 0.6                 5.5 ± 0.5              8.4 ± 2.4* 
C18:1 (n-7)                       2.2 ± 0.2             2.5 ± 0.4                 2.5 ± 0.4              3.4 ± 0.7 
C20:4 (n-6)                       36.8 ± 3.5           41.8 ± 2.4*             33.5 ± 3.6            32.4 ± 1.1 
C22:6 (n-3)                       2.0 ± 0.8             2.2 ± 0.5                 4.6 ± 1.7#             4.2 ± 1.3 
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Cardiolipin 
 
C16:0                                6.7 ± 2.2            6.1 ± 2.2                  7.8 ± 1.3              8.5 ± 1.9 
C16:1 (n-7)                       5.3 ± 1.1            5.1 ± 1.1                  4.1 ± 2.6              4.8 ± 1.6 
C18:0                                8.1 ± 3.4            8.2 ± 3.5                 10.6 ± 3.3             6.8 ± 2.9 
C18:1 (n-9)                       38.1 ± 2.2          36.4 ± 2.2               36.8 ± 2.3             33.9 ± 3.2  
C18:1 (n-7)                       6.9 ± 0.7            5.8 ± 0.9                 10.5 ± 2.3#           15.4 ± 3.0* 
C18:2 (n-6)                       5.7 ± 2.1            4.8 ± 0.4                 3.9 ± 0.6               4.2 ± 0.5 
C20:3 (n-6)                       1.9 ± 0.2            2.3 ± 0.4                 1.7 ± 0.2               1.8 ± 0.2 
C20:4 (n-6)                       17.7 ± 2.3          19.4 ± 2.1               13.1 ± 2.2#            13.4 ± 0.8 
C22:6 (n-3)      9.4 ± 2.3   11.5 ± 3.3    10.4 ± 2.9  10.7 ± 1.4 
 
Sphingomyelin
 
C16:0                                4.8 ± 2.1            5.2 ± 2.0                 5.2 ± 2.3               6.9 ± 4.0  
C16:1 (n-7)                       0.8 ± 0.2            0.7 ± 0.4                 1.2 ± 0.6               1.6 ± 0.6 
C18:0                                80.6 ± 3.4          77.8 ± 1.7               65.0 ± 8.4#           55.1 ± 5.8* 
C18:1 (n-9)                       0.5 ± 0.2            1.2 ± 0.5                 0.7 ± 0.3               1.7 ± 0.8 
C20:0                                2.3 ± 0.3            2.3 ± 0.3                 2.8 ± 0.4               2.4 ± 0.2 
C22:0                                2.7 ± 0.5            2.4 ± 0.5                 5.0 ± 2.1               4.6 ± 1.6 
C24:0                                2.1 ± 0.4            1.7 ± 0.4                 4.5 ± 2.5               3.9 ± 1.0 
C24:1 (n-6)                       4.1 ± 2.1            7.3 ± 1.9                11.1 ± 5.7              19.9 ± 9.3 
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Sulfatide 
 
C16:0                               6.9 ± 3.1              8.6 ± 1.8               7.9 ± 2.4                8.4 ± 2.4 
C16:1 (n-7)                      1.7 ±0.2               1.8 ± 0.5               1.7 ± 1.0               1.6 ± 0.9 
C18:0                               20.7 ± 2.9            23.6 ± 2.4             19.0 ± 2.8             16.5 ± 3.5 
C18:1 (n-9)                      11.5 ± 1.7            13.2 ± 3.6             13.3 ± 1.4             14.1 ± 2.8 
C18:1 (n-7)                      1.4 ± 0.4              1.7 ± 0.4               2.2 ± 0.7               1.5 ± 0.9 
C20:0                                1.6 ± 0.2              1.5 ± 0.3              1.5 ± 0.4               1.3 ± 0.2 
C20:1 (n-9)                      1.6 ± 0.5              1.5 ± 0.7               2.2 ± 0.7               1.9 ± 0.6 
C20:4 (n-6)                       2.1 ± 1.1             2.3 ± 1.3               2.0 ± 0.5               2.2 ± 0.6 
C22:0                                6.6 ± 1.1             5.8 ± 0.8               6.0 ± 0.8               5.4 ± 0.8 
C24:0                               14.4 ± 2.0           11.5 ± 2.1*            12.9 ± 2.6             11.7 ± 1.2   
C24:1 (n-6)                      28.8 ± 4.9            27.7 ± 4.3             29.2 ± 3.7             34.5 ± 5.2 
 
 
 
 
 
 
 
 
 
 
! "%"!
Cerebroside 
 
C16:0                                3.1 ± 0.7             5.3 ± 2.7                3.7 ± 1.3              5.0 ± 2.5 
C16:1 (n-7)                       1.7 ±0.2              1.7 ± 0.8                1.4 ± 0.7              0.8 ± 0.1 
C18:0                                11.4 ± 4.2           13.2 ± 4.4              12.1 ± 2.9            9.1 ± 3.0 
C18:1 (n-9)                       2.8 ± 1.1              4.6 ± 2.8               4.0 ± 0.7              7.0 ± 3.1 
C18:1 (n-7)                       0.4 ± 0.1              0.4 ± 0.2                0.8 ± 0.5             1.2 ± 0.5 
C20:0                                2.5 ± 0.1              2.0 ± 0.4               1.8 ± 0.5              1.6 ± 0.7 
C20:1 (n-9)                       0.4 ± 0.2              0.6 ± 0.3                0.8 ± 0.3             1.4 ± 0.5 
C20:4 (n-6)                       1.5 ± 0.9              2.3 ± 1.0               1.7 ± 1.0              2.2 ± 0.4  
C22:0                                12.0 ± 1.6            9.1 ± 1.7               10.2 ± 1.6            7.5 ± 0.8* 
C22:1                                1.9 ± 0.8              2.5 ± 0.2               2.0 ± 0.2              2.3 ± 0.3 
C24:0                                22.8 ± 4.0           15.7 ± 3.7*            21.4 ± 4.3            15.2 ± 2.8 
C24:1 (n-6)                       39.6 ± 6.5           42.4 ± 5.5              40.2 ± 6.3            46.9 ± 4.7 
 
 
Table 7.3. Fatty acid composition (% of total fatty acids) in individual polar lipid 
classes from cortex or midbrain of wild type and $-synuclein-/- mice. Data as 
means ± S.D (number of mice = 6-7). The asterisk (*) indicates a significant effect of 
$-synuclein-/- when compared with WT (p < 0.05). The hash (#) indicates significant 
differences between midbrain and cortex in WT animals (p < 0.05). Fatty acids are 
indicated with the number before colon showing the number of carbon atoms, the 
figure afterwards denoting the number of double bonds. The position of the first 
double bond is shown in brackets. 
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7.3. Summary of results and discussion 
$-synuclein-/- mice were used to determine the effects of $-synuclein-/- on lipid 
metabolism in the brain focusing on two different brain regions, the cerebral cortex 
and the midbrain. Using these mice, we found that the level of phosphatidylserine 
(PtdSer) was increased in the midbrain in response to loss of $-synuclein whereas no 
changes in the relative proportions of membrane polar lipids were observed in the 
cerebral cortex of $-synuclein-/- compared to wild type mice. In addition, higher levels 
of DHA were found in PtdSer and phosphatidylethanolamine (PtdEtn) from the 
cerebral cortex of $-synuclein-/- mice. These findings show that $-synuclein-/- leads to 
alterations in the lipid profile in specific brain tissues and suggest that this protein, 
like !-synuclein, might affect neuronal function via modulation of lipid metabolism. 
We saw no effect of $-synuclein-/- on the total polar lipid content and TAG 
accumulation in the cerebral cortex and midbrain, which contrasts to studies with !-
synuclein deficient mice where an increase in TAG content of the whole brain has 
previously been demonstrated (Barcelo-Coblijn et al., 2007). 
Neither the mitochondria-specific phospholipid Ptd2Gro (found in both brain regions 
studied, making up 4% of the total polar lipids), nor the fatty acid profile of Ptd2Gro 
was affected by $-synuclein-/-. This is in contrast to the findings reported for !-
synuclein deficient mice in which there was a reduction in total brain Ptd2Gro content 
with a strongly altered acyl chain composition, a mitochondrial lipid abnormality 
which may explain the electron transport chain impairment reported in the brain of 
Parkinson’s disease patients (Ellis et al., 2005). Our data suggest that deficiency of $-
synuclein is unlikely to affect mitochondrial function in the nervous system by 
altering lipid composition. 
Similar to !-synuclein deficiency (Barcelo-Coblijn et al., 2007), $-synuclein-/- did not 
change the level of ethanolamine phospholipids in the brain. The plasmenyl species of 
PtdEtn are important phospholipid components of most electro-active cellular 
membranes, such as cardiac sarcolemma and neuronal cell membranes. Between one-
half and two thirds of the ethanolamine phospholipids in the whole brain are in 
plasmalogen form and 11-12% of myelin phospholipids are plasmalogens (Nagan and 
Zoeller, 2001). A deficiency of ethanolamine plasmalogens has been shown to be 
associated with aging and some degenerative diseases, especially those associated 
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with peroxisomal disorders (Dragonas et al., 2009; Farooqui et al., 2000; Farooqui et 
al., 1997). The absence of ethanolamine plasmalogen alterations is consistent with 
only mild alterations in normal neural function in both !-synuclein and $-synuclein-/- 
mice. However, further comparative studies of aging mice would be important, due to 
various effects of aging on their nervous systems (Al-Wandi et al., 2010). 
 
Among the polar lipids studied, only the relative proportion of PtdSer was altered in 
$-synuclein-/- as compared to wild type mice. This change was evident only in the 
midbrain region where expression of $-synuclein is much higher than in the cerebral 
cortex (Ninkina et al., 2003). Although this increase was relatively minor in whole 
midbrain tissue, the changes in PtdSer content may more pronounced in specific 
neuronal populations since $-synuclein has been shown to be expressed only in a 
subset of midbrain neurons (Ninkina et al., 2003). Previously, increases in PtdSer 
have been noted in plasma membrane phospholipids from affected regions of 
Alzheimers disease brains, where they may induce formation of amyloid fibers 
(Farooqui et al., 1997; Zhao et al., 2004). It is also of note that PtdSer has roles in 
apoptosis, in the regulation of many enzymes and in control of the channel function of 
the acetylcholine receptor (Farooqui et al., 2000; Mozzi et al., 2003; Sunshine and 
McNamee, 1992). Thus, alteration in PtdSer may have implications for neuronal cell 
functions. However, the changes we observed were not sufficient for triggering overt 
pathological alterations in the nervous system of $-synuclein-/- mice (Ninkina et al., 
2003; Robertson et al., 2004; Senior et al., 2008).! 
Three lipid classes in brain contain high levels of PUFA. Whereas PtdSer and PtdEtn 
are enriched in DHA, PtdIns contains substantial amounts of ARA. In comparison to 
the midbrain region, the cortex region was enriched in ARA but has lower levels of 
DHA (Table 7.2). These differences may be partly explained by higher content of 
PtdCho (see Fig 7.1), which possesses elevated levels of ARA, in the cerebral cortex 
(see Table 7.3). Interestingly, statistically significant changes were found in the 
relative amount of PtdSer in the midbrain region of $-synuclein-/- mice and in the 
DHA content of both PtdSer and ethanolamine phospholipids in the cerebral cortex. 
Because only a limited number of cortical neurons normally express $-synuclein, 
changes of DHA levels in these cells might be much more profound than those 
revealed by analysis of total cortex phospholipids. It is noteworthy that although !-
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synuclein null mutant mice have slightly decreased levels of DHA in whole brain 
PtdEtn and PtdSer, an increased uptake of this fatty acid into brain phospholipids has 
also been reported (Golovko et al., 2007). It is well known that DHA is essential to 
perinatal neurological development during which it increases in the CNS. The high 
demand for DHA in the brain is maintained either by dietary supply or by 
biosynthesis from !-linolenate within the liver (Barcelo-Coblijn et al., 2007). Since 
no very long-chain PUFA were present in the diet, and no changes in the liver (data 
not shown) or plasma PUFA profiles (Table 7.1) were found in our study, we suggest 
that the differences in DHA levels likely relate to possible effects of $-synuclein 
deficiency on DHA metabolism in the developing brain. Alternatively, complete 
absence of $-synuclein might trigger systemic changes, including alterations in 
adipose and other tissues normally expressing this protein, that activate compensatory 
mechanisms during brain development. To address this question, a brain-specific, 
conditional knockout of $-synuclein may be required. 
There is a growing body of evidence regarding the importance of PUFA in brain 
function. Its deficiency is associated with cognitive decline during aging and with 
neurodegenerative diseases (Lukiw and Bazan, 2008). The beneficial 
neurophysiological role of DHA most probably relates to metabolites such as 
eicosanoids and other autacoids which are important as modulators of membrane 
microdomain composition, receptor signalling and gene expression (Kim, 2007). A 
recent study demonstrated a role for neuroprotectin D1 (NPD1) in the homeostatic 
regulation of brain cell survival and repair involving neurotrophic, anti-apoptotic and 
anti-inflammatory signalling in Alzheimer’s disease (Lukiw and Bazan, 2008). 
Unfortunately, there is no information about the possible involvement of such DHA 
metabolites in Parkinson’s disease, to which the synuclein family has been linked. $-
synuclein-/- mice, which exhibit higher levels of DHA accumulation in certain brain 
regions, may provide a useful model for future research in this area. 
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8. Final Discussion 
 
8.1. A possible role for $-synuclein in white adipose tissue 
In this study we made use of mice with a targeted deletion of the $-synuclein gene in 
order to determine the molecular and cellular consequences of $-synuclein-/- on lipid 
metabolism in adipose and brain tissues. Outside of the nervous system, $-synuclein 
expression is restricted to very few cell types but is particularly high in white adipose 
tissue, suggesting that it plays an important role in the adipocyte. Our major finding in 
this study was that $-synuclein is a novel regulator of adipocyte function in vivo that 
influences whole-body energy balance. Knockout of $-synuclein, which is highly 
expressed in WAT, led to decreased weight gain in mice fed a high fat diet, and this 
was associated with increased energy expenditure and lipid oxidation. In addition, we 
observed increased basal and isoproterenol-stimulated lipolysis in isolated adipocytes 
from these mice, increased NEFA levels in adipose tissue and decreased adipocyte 
size in vivo. Together these data suggests that $-synuclein loss may increase lipolysis 
in adipocytes and that this may lead to increased lipid oxidation in adipose, and 
potentially other tissues. In support of this hypothesis, we observed increased levels 
of ATGL, the key triglyceride lipase in WAT. It has previously been demonstrated 
that overexpression of ATGL specifically in adipose tissue, like $-synuclein loss, 
leads to obesity resistance with increased energy expenditure and lipid oxidation, 
decreased adipocyte size and reduced hepatic steatosis following high fat diet feeding 
without affecting food intake (Ahmadian et al., 2009). The significant overlap 
between the phenotypes of adipose specific ATGL transgenic and $-synuclein-/- mice 
suggests that increased ATGL expression has the potential to contribute to the 
decreased adiposity and improved metabolic health of mice lacking $-synuclein. We 
did not observe altered levels of perilipin A, HSL nor changes in HSL 
phosphorylation in these mice suggesting a selective effect on ATGL rather than a 
general increase in components of the lipolytic pathway. It is notable that ATGL 
mRNA expression was not altered in WAT of null mutant mice suggesting that $-
synuclein loss may affect ATGL accumulation. The exact mechanism of this effect is 
a key question for future studies. However, it is clear that the increased lipolysis 
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observed in $-synuclein-/- adipocytes could alone drive the obesity resistance and 
improved metabolic phenotype in these mice. 
Since $-synuclein expression is not exclusive to adipose tissue, it is possible that loss 
of $-synuclein expression in other tissues contributes to some aspects of the 
phenotypes we observed. However, we have shown that specifically re-expressing $-
synuclein in the fat pads of null mutant mice reverses the observed decrease in 
adipocyte size. Critically, this reversal was only seen in those adipocytes re-
expressing $-synuclein and not in non-transduced cells in the same depot, indicating 
that this aspect of the in vivo phenotype is cell-autonomous. Despite this, we cannot 
exclude a role for either an effect of $-synuclein-/- in the brain, or compensatory 
responses in non-adipose tissues to global $-synuclein-/-, that could contribute to other 
aspects of the phenotype such as the increased energy expenditure or decreased 
hepatic steatosis. Thus far we have not observed any significant changes in the 
expression of genes, such as those regulating !-oxidation and lipid metabolism in the 
liver to suggest this. In addition, other studies, such as those targeting ATGL or 
perilipin A, imply that altering lipolysis selectively in adipose tissue is capable of 
profoundly influencing lipid accumulation and metabolism in other tissues and organs 
(Ahmadian et al., 2009; Martinez-Botas et al., 2000; Miyoshi et al., 2010).  
An intriguing link between function of #-synuclein in neuronal synapses and $-
synuclein in adipocytes might also explain how $-synuclein affects lipolysis and the 
size of mature adipocytes in conditions of nutrient excess. In the presynaptic terminals 
#-synuclein enhances neurotransmitter exocytosis by promoting the assembly of 
SNARE complexes that play a pivotal role in the synaptic vesicle docking and fusion 
pore formation at the plasma membrane, and this function becomes particularly 
important during periods of increased synaptic activity (Burre et al., 2010). Synaptic 
SNARE complexes comprise of a vSNARE protein VAMP-2/synaptobrevin and two 
tSNARE proteins, syntaxin-1 and SNAP-25 (summarised in (Rizo and Rosenmund, 
2008; Sudhof and Rothman, 2009)). Their functional homologs, vSNARE protein 
VAMP-4 and tSNARE proteins syntaxin-5 and SNAP-23, form SNARE complexes in 
adipocytes. These complexes are involved in fusion between neutral TAG packaged 
within amphipathic lipoproteins and the lipid droplet phospholipid monolayer, the 
process underlying lipid accumulation in the adipocyte and consequent increase in its 
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size (Andersson et al., 2006; Bostrom et al., 2007; Bostrom et al., 2005; Olofsson et 
al., 2009). More broadly, recent screens of genes affecting lipid droplet formation, 
fusion and morphology in insect cells and yeast have revealed roles in these processes 
for several proteins involved in vesicle trafficking (Szymanski et al., 2007; Guo et al., 
2008). We have demonstrated that in conditions of increased lipid supply, i.e. in 
HFD-fed mice, the lack of $-synuclein substantially attenuates assembly of SNARE 
complexes in adipocytes. It is therefore possible that the decreased SNARE complex 
formation seen in $-synuclein-/- adipocytes reduces TAG incorporation into the lipid 
droplet contributing to the decreased adipocyte size. Indeed, one possibility is that the 
increased lipolysis and WAT NEFA levels we observe may partly reflect the 
increased availability of TAG, which has not been appropriately incorporated into the 
core of the lipid droplet. This TAG is subsequently hydrolysed, with this process 
requiring compensatory increases in ATGL protein levels (summarised in Fig. 
8.1). This could be particularly apparent in situations of increased turnover, for 
example when WAT is exposed to increased dietary lipids. Overall our data suggest 
that both #-synuclein and $-synuclein share the ability to potentiate SNARE-mediated 
fusion in physiological and/or environmental conditions requiring increased 
efficiency of cellular mechanisms that depend on this fusion, the former important for 
synaptic transmission in neuronal synapses and the latter important for lipid droplet 
maintenance and expansion in adipocytes. 
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Fig. 8.1. A proposed model for the role of $-synuclein in white adipocytes in 
times of energy surplus. When the NEFA supply to WAT is low (e.g. balanced or 
low fat diet) and the amount of newly synthesized TAG is limited, a basal level of 
SNARE complex assembly matches the demand for lipid droplet fusion. Therefore $-
synuclein has little effect on adipocyte physiology. In contrast, when adipocytes 
synthesize large quantities of TAG due to the increased supply of NEFA (e.g. in 
HFD-fed mice) the ability of $-synuclein to potentiate SNARE-mediated fusion of 
lipid droplets becomes critical for the efficient accumulation of these TAG (left 
panel). In $-synuclein-/- adipocytes (right panel) the un-potentiated rate of SNARE 
complex assembly holds up lipid droplet fusion creating a bottleneck. This leads to 
decreased availability of droplet coat components (e.g. PAT proteins perilipin, ADRP, 
TIP47) for sequestering large amounts of newly synthesizing TAGs, which as known 
from experiments with cells and animals deficient for these proteins, stimulates TAG 
hydrolysis that require compensatory increase of ATGL level.  
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In this study we also examined the ability of MEFs derived from $-synuclein-/- mice to 
differentiate into adipocytes in culture. Our data suggested that $-synuclein was not 
essential for adipocyte differentiation in this system as wild type and mutant MEFs 
differentiated into adipocytes with the same efficiency and kinetics as wild type 
MEFs. We interpret this to mean that the decreased adipose mass of $-synuclein-/- 
mice was not due to a reduced capacity of adipose depots to expand when required. 
This is an important observation as human syndromes of lipodystrophy and mouse 
models of restricted adipose expandability demonstrate that merely constraining 
adipose mass leads to dyslipidaemia, insulin resistance and metabolic disease 
(Schweiger et al., 2009; Moitra et al., 1998). As the loss of $-synuclein appears to 
selectively affect mature adipocytes without inhibiting their formation, it may prove a 
useful therapeutic target for improving obesity related metabolic disease. 
$-synuclein appears to play an important role in adipocyte lipid metabolism, 
particularly in conditions of nutrient excess. Our study suggests that increased $-
synuclein expression could contribute to the development of obesity-related metabolic 
disease but also that inhibiting $-synuclein expression or function may represent a 
novel potential therapeutic avenue for the treatment of this prevalent condition. 
 
8.2. A possible role for $-synuclein in brain lipid homeostasis 
As well as the effects of $-synuclein-/- on lipid metabolism in WAT, we have also 
identified changes in lipid handling in the CNS of mice lacking $-synuclein. We 
found that the level of phosphatidylserine was increased in the midbrain region but 
not in the cerebral cortex of $-synuclein-/- mice compared to wild type. In addition to 
this, higher levels of docosahexaenoic acid were found in phosphatidylserine and 
phosphatidylethanolamine from the cerebral cortex of $-synuclein-/- mice. These 
alterations in lipid handling resulting from deficiency of $-synuclein did not appear to 
cause overt pathological changes in the nervous system of $-synuclein-/- mice (Ninkina 
et al., 2003; Robertson et al., 2004; Senior et al., 2008). However, it may be that 
under certain conditions, the modified lipid metabolism induced by $-synuclein-/- will 
alter neuronal function. 
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8.3. Final comments 
$-synuclein is expressed at a high level in certain populations of neurons as well as 
white adipocytes, and we have shown that in both these cell types, $-synuclein has the 
ability to modulate lipid handling. The closely related protein, #-synuclein, has been 
heavily implicated in both lipid biochemistry and human neurodegeneration disease, a 
group of disorders where dysfunction of lipid homeostasis is known to play a role. 
There is currently no well-defined pathological role for $-synuclein in human 
neurodegenerative conditions. We have shown that loss of $-synuclein function in 
white adipocytes causes alterations in lipid handling, ultimately leading to changes in 
whole-body metabolic outcome, and so it is possible that $-synuclein plays a role in 
the development of human obesity and related disorders. Indeed it is also feasible that 
the modulation of lipid metabolism in the brain by $-synuclein might affect neuronal 
function in certain human neurodegenerative diseases. 
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Appendix 
 
Appendix 1. Map of the pRRLsin.cPPT.hPGK-eGFP lentiviral expression vector 
(Follenzi et al., 2000). The coding region of human $-synuclein was inserted into the 
unique BamHI site downstream of a human phosphoglycerate kinase-1 (PGK) 
promoter. 
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Appendix 2. Quantification of $-synuclein protein abundance in epididymal 
WAT of mice fed HFD or on calorific restriction. 
HFD feeding 
Diet 11 week LFD 11 week HFD   
$-synuclein 
(% of LFD) 100 ± 16 299 ± 20*   
Calorific restriction 
Diet HFD control 36 hour LFD 1 week LFD 36 hour fast 
$-synuclein 
(% of HFD 
control) 100 ± 19 88 ± 12 22 ± 9* 26 ± 11* 
(LFD low fat diet, HFD high fat diet, * p < 0.05, Mann-Whitney U-test, n=4). 
 
 
 
 
 
 
 
 
 
 
 
! ")(!
Appendix 3. Raw weights of major WAT depots from wild type and $-synuclein-/- 
mice fed a LFD or HFD for 11 weeks.  
Genotype +/+ -/- +/+ -/- 
Diet 11 week LFD 11 week HFD 
     
ED WAT (g) 0.58 ± 0.09 0.52 ± 0.06 2.07 ± 0.11 1.40 ± 0.14** 
SC WAT (g) 0.32 ± 0.05 0.31 ± 0.03 1.16 ± 0.07 0.72 ± 0.05** 
RP WAT (g) 0.12 ± 0.03 0.11 ± 0.02 0.52 ± 0.02 0.37 ± 0.03** 
(n=12-14, +/+ wild type, -/- $-synuclein-/-, ED epididymal, SC subcutaneous, RP 
retroperitoneal, LFD low fat diet, HFD high fat diet, ** p < 0.01, Mann-Whitney U-
test, n=12-14). 
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Appendix 4. Western blot quantification of protein marker expression in 
epididymal WAT. 
Genotype +/+ -/- +/+ -/- 
Diet 11 week LFD 11 week HFD 
% of +/+ LFD     
HSL 100 ± 5.0 94.2 ± 13.4 93.7 ± 9.7 108.5 ± 9.0 
perilipin A 100 ± 6.7 112.1 ± 17.7 75.9 ± 14.3 84.7 ± 12.4 
ATGL 100 ± 7.8 108.5 ± 13.5 82.2 ± 7.2 144.4 ± 14.5** 
(+/+ wild type, -/- $-synuclein-/-, LFD low fat diet, HFD high fat diet, HSL hormone-
sensitive lipase, ATGL adipose triglyceride lipase, ** p < 0.01, Mann-Whitney U-
test, n=6). 
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